Preventing Overdiagnosis by Moynihan, Raymond
Bond University
DOCTORAL THESIS
Preventing Overdiagnosis
Moynihan, Ray N
Award date:
2016
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 10. May. 2019
Preventing Overdiagnosis 
 
 
 
 
A thesis submitted in total fulfilment of the requirements of the degree of 
Doctor of Philosophy                                                                                         
 
 
 
Raymond Noel Moynihan 
Centre for Research in Evidence-Based Practice,  
Faculty of Health Sciences and Medicine,  
Bond University, Australia 
 
 
 
 
 
 
February 2015  
 
 
Preventing Overdiagnosis 
 
 
2 
 
  
Preventing Overdiagnosis 
 
 
3 
 
Summary                      
Background  
Medicine’s ability to help the sick is being challenged by its propensity to harm the healthy. 
As part of broader evidence and concern about too much medicine,[1] overdiagnosis is 
being increasingly recognised as a cause of harm and waste.[2] Overdiagnosis occurs when 
people are diagnosed with a disease that won’t harm them, commonly as a result of 
screening programmes detecting non-progressive diseases, such as indolent cancers. More 
broadly defined, overdiagnosis happens when expanding disease definitions label more 
people with milder symptoms or at lower risks, for whom a label and treatment may do 
more harm than good.  
Aims 
The thesis aimed to research the nature and causes of overdiagnosis, the mechanisms by 
which disease definitions are expanding, public awareness of overdiagnosis, and possible 
policy responses. 
Methods 
Several different methods were employed for a range of related research. An initial scoping 
of the literature was undertaken to prepare an overview. A cross-sectional study 
investigated how influential expert panels were changing definitions of common conditions. 
Arising from the scoping and the study, chronic kidney disease was selected and examined 
according to an explicit template, to learn more about how controversial definitions are 
expanded and defended. A questionnaire was developed and piloted, and a national 
quantitative survey conducted. A qualitative study analysed themes emerging from 
community responses to an open-ended question about the meaning of overdiagnosis.  
Results  
The initial literature scoping identified considerable evidence for overdiagnosis and 
potential drivers.[3] The cross-sectional study found among 16 expert panel publications, 10 
widened definitions, 1 narrowed, and for 5, it was unclear.[4] No panel reported on potential 
for overdiagnosis, and of those panels making disclosures, 75% of members had multiple 
financial ties to companies with direct interests in broadened patient populations, contrary 
to Institute of Medicine, IOM, recommendations.[5,6] The case study found against a 
backdrop of sustained criticism, the controversial expansion of chronic kidney disease was 
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repeatedly defended by conflicted experts.[7] The survey found a minority of respondents 
(10%) - including those screened for prostate,(18%) and breast cancer,(10%) - reported they’d 
been informed about overdiagnosis, and a majority(78%) felt it inappropriate disease-
defining panels had ties to companies.[8] A qualitative analysis of responses to “what do 
you think the term overdiagnosis means?” found 40% of participants had approximate 
understandings, 24% thought it meant overuse, and none mentioned screening.[9] 
Discussion and Implications  
A greater sensitivity to the problem of overdiagnosis is required in running and reporting 
on primary studies of tests and treatments, the production of systematic reviews, and 
proposals to change disease definitions.[10] Findings of endemic conflicts in panels setting 
diagnostic thresholds, in direct contrast to IOM and public antipathy, suggest a need for 
more independent and representative panels, informed by evidence about benefits and 
potential harms, including overdiagnosis. Survey findings reinforce the need for more 
information about overdiagnosis, particularly with screening. Recommendations include: (i) 
synthesising existing overdiagnosis evidence into an accessible repository; (ii) further 
investigating expanding disease definitions; (iii) reforming disease definition processes; (iv) 
initiating new international collaborations to further understand and combat overdiagnosis.  
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Summary 
 
This chapter introduces the problem of overdiagnosis, offers a brief description of the 
framework and approach for the thesis, provides a discursive review of the literature, 
outlines the thesis research aims and questions, and concludes with brief explanations of the 
thesis research projects, which feature in forthcoming chapters.  
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Background 
The problem of overdiagnosis has been the subject of growing attention in the medical 
literature over recent decades. Narrowly defined, overdiagnosis happens when someone is 
diagnosed with a disease that would not have caused them harm, often as a result of 
undertaking screening, and can lead to unnecessary treatments and wasted health resources. 
[1] As a result of a growing body of increasingly rigorous research, we now know 
overdiagnosis happens regularly as a by-product of certain cancer screening programmes 
which seek to detect early cancers in the healthy population, some of which would never go 
on to cause symptoms or premature death. 
Because there are on-going debates over how to precisely define overdiagnosis, and measure 
how often it occurs, there are wide variations in estimates of the magnitude of the problem. 
In addition there is a view that some degree of overdiagnosis is an inevitable risk of 
screening programmes which target the healthy,[2] and that attempts to reduce 
overdiagnosis should proceed with caution as they may come at the cost of increasing 
underdiagnosis. Notwithstanding these debates and views there is an established consensus 
within the literature that for cancer screening, overdiagnosis is a real risk, it is causing 
significant amounts of potentially avoidable harm, and requires much wider recognition and 
action from health professionals, policy-makers and the public.[3]  
The literature also includes much research and broader discussion on examples of 
overdiagnosis unrelated to cancer and screening.[1] More broadly defined, overdiagnosis 
happens when disease definitions are expanded, diagnostic thresholds lowered or 
diagnostic processes changed in ways that label more and more people at low risk of future 
illness or with milder symptoms, for whom a disease label and subsequent treatment may 
do more harm than good. While extensive, and covering many conditions, this literature on 
non-cancer overdiagnosis has not generally developed the same level of rigorous or 
consistent methods, though there are important exceptions.[4] In this broader definition, the 
literature on overdiagnosis intersects with Ivan Illich’s critique of the medicalisation of life,[5] 
more recent sociological research on medicalisation,[6] wider evidence and concern about 
overuse of tests and treatments,[7] and historical analysis of medical excess.[8] Counter-
balancing medicine’s many successes with the growing threat to human health posed by 
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that success, the celebrated medical historian Roy Porter noted in 1996 the problem of 
“diagnosis creep” and the “expansion of treatable illnesses.”  Describing the increasing 
medicalisation of normal life events and the transformation of risks into diseases, Porter 
observed that “Doctors and ‘consumers’ alike are becoming locked within a 
fantasy…everyone has something wrong with them, everyone can be cured.”[8] 
The literature featuring explicit concerns about the problem described as “overdiagnosis” 
dates back to at least the 1970s, though papers at this time were extremely rare.  Chapter 2 of 
this thesis - published in The BMJ in 2012 and the result of an initial scoping of the 
overdiagnosis literature at the commencement of my thesis[9] - offers an overview of 
contemporary understandings and examples of overdiagnosis.  It notes the different 
pathways to overdiagnosis, including via “incidentalomas”, explores several factors driving 
overdiagnosis and what responses might help prevent it. In this opening introductory 
chapter 1, I outline the framework and approach of the thesis, offer a comprehensive 
discursive review of the literature up until 2014, and close with my research aims and 
questions, and with brief explanations of the forthcoming chapters. 
Framework and approach 
Being based for the duration of my thesis as a senior research fellow at the Centre for 
Research in Evidence-Based Practice at Bond University in Australia, the thesis framework 
for understanding the problem of overdiagnosis and its literature is the evidence-based 
approach to medicine.  This approach explicitly involves a focus on rigorously discovering 
how well interventions work, for whom, and what harms they do, rather than relying on the 
opinions of experts.[10] A second key feature of the evidence-based approach is to 
summarise all the least-biased evidence, and then incorporate that evidence with clinical 
expertise and patient preferences and values in order to make more informed health care 
decisions.  
While the phrase “evidence-based medicine” arose in the 1990s, the roots of the approach 
date back deep into the history of attempts to empirically evaluate the effects of medical 
interventions. In 1753 James Lind famously wrote up his controlled experiments testing six 
different treatments for scurvy, together with a systematic summary of what had previously 
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been published on the subject.[11] Through the 20th century the science of evaluation and 
research synthesis continued to develop,[12] and by the 1970s epidemiologist Archie 
Cochrane, among others, was persuasively arguing for what many believed, mistakenly, 
was already common practice: routine rigorous evaluation of medical interventions, and 
accessible systematic summaries of the resulting evidence.[13] 
Another relevant milestone in the history of the evidence-based approach was the report 
from the 1979 Canadian Task Force on the Periodic Health Examination, which applied a 
then new, but now familiar system for rating the strength and quality of studies being 
summarised, using a hierarchy with randomised trials at the top and expert opinion at the 
bottom.[14] The value of expert opinion was further challenged by the presentation of a 
study at a landmark 1993 New York Academy of Sciences conference. The study by two 
leading advocates of the evidence-based approach, Andy Oxman and Gordon Guyatt, found 
review articles written by experts were generally of “inferior quality” and that “the greater 
the expertise the more likely the quality is to be poor.”[15] At the same 1993 conference the 
concept for the international Cochrane Collaboration was announced. Taking its name from 
Archie Cochrane, a new global not-for-profit organisation was launched, dedicated to 
producing accessible systematic reviews of the evidence for thousands of health care 
interventions.[16] 
It is not coincidental that the increasingly rigorous conceptualisation and measurement of 
overdiagnosis taking place in recent decades - particularly but not exclusively in relation to 
cancer screening - has run somewhat in parallel with the rise of the evidence-based 
approach to medicine. As per the examples below, what started as informed theoretical 
speculation about possible harm, has grown in a number of cases into reliable evidence 
about the existence of overdiagnosis and estimates of how often it occurs - particularly in 
relation to cancer screening - through the accumulated results of observational studies, 
randomised controlled trials and systematic reviews of those studies.  
The aim of this thesis is to contribute to our understanding about the problem of 
overdiagnosis, its nature, causes and consequences, and how we might start to prevent it. 
The literature review covers some key examples from the overdiagnosis research on cancer 
and non-cancer conditions, as flagged in Table 1, as well as key analysis of generic aspects of 
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the problem abstracted from overdiagnosis research on individual conditions. The review 
also explores related research on medicalisation, examines the issue of expanding disease 
definitions and closes by touching on research and debate about how guidelines may be 
contributing to the problem of medical excess.  
Table 1. Examples covered in literature review  
 
Examples covered in this 
review  
Importance  
 
Cancers  
Prostate and breast cancer 
screening 
Examples show how speculation about potential for 
overdiagnosis as a risk of screening programmes has moved 
to convincing evidence and estimates of magnitude of the 
problem 
Neuroblastoma screening  Historical example being increasingly cited in literature 
showing how tumours can regress, and treatment of 
indolent tumours can cause harm. Highlights need for 
caution about initial enthusiasm for interventions, rigorous 
evidence-based evaluation and analysis 
 
Risk-based conditions  
High blood pressure Examples of changing definitions of risk-based conditions, 
and lowering diagnostic thresholds which label more and 
more people at lower risks of future illness, some of whom 
will receive a diagnosis and treatment that will do more 
harm than good 
High cholesterol 
Osteoporosis 
Overweight 
 
Behavioural/mental disorders 
Attention Deficit 
Hyperactivity Disorder  
Example of a behaviour/symptom-based condition cited in 
overdiagnosis and medicalisation literature, where there is 
concern about expanding disease boundaries 
 
A review of the literature  
For more than 30 years the scientific literature has featured growing concern and evidence 
about “overdiagnosis”, both in relation to cancer and cancer screening, and non-cancer 
conditions.  Much of the literature is analysis or commentary, but there are also many 
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primary research studies employing a wide range of methods, including but not limited to: 
autopsy studies which demonstrate important reservoirs of indolent disease, for example for 
prostate cancer and ductal carcinoma in situ; observational studies including studies 
analysing incidence and mortality trends; studies that review patient records to check the 
veracity of existing diagnoses and uncover overdiagnosis; randomised controlled trials of 
screening programmes; systematic reviews of studies; and ultimately inquiries or other 
official reports which review and summarise all the evidence including where relevant 
multiple systematic reviews. As evidence for overdiagnosis is better established in relation 
to cancer screening, I will address that literature first.  
Prostate and breast cancer screening 
By the 1980s cancer screening activities were coming under increasing scientific scrutiny, 
facing specific questions about the risk that programmes could cause the overdiagnosis of 
non-progressive cancers, at a time well before important randomised controlled trials of 
screening had reported. For example in 1985 Love identified “overdiagnosis or diagnosis of 
‘pseudo-cancers’” as a potentially “major problem” with screening for prostate cancer.[17] 
Referring to screening using digital rectal examination, he pointed out that without 
randomised trial evidence it was impossible to know if early detection via screening 
improved prognosis, and that “interpreting the results of treatment for asymptomatic cases 
diagnosed by screening is difficult because of …..possible overdiagnosis of nonprogressive 
cancers.” Importantly Love’s 1985 article drew on evidence and analysis from the previous 
decade, including the 1979 report of the Canadian Task Force on the Periodic Health 
Examination,[14] highlighting the fact that awareness of the problem of unnecessary 
diagnoses, and concerns about the harms of screening pre-dated more common usage of the 
specific term “overdiagnosis”. Also in 1985 Chamberlain noted encouraging early evidence 
breast cancer screening could reduce cancer deaths, but speculated that mammography 
“may have the disadvantage of overdiagnosing cases of borderline non-invasive neoplasia 
which might not progress to invasive cancer within the woman's lifetime.”[18] 
As large trials were initiated and reported and systematic reviews summarised the resulting 
evidence through the intervening three decades, these early speculations about prostate and 
breast cancer screening have proved prophetic. In response to mounting scientific evidence 
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and concern over benefits and harms of breast screening, in the United Kingdom an 
independent inquiry was recently initiated by Cancer Research UK and the national 
department of health. An independent panel lead by epidemiologist Sir Michael Marmot 
was commissioned to investigate the current state of the evidence. Following a review of all 
the accumulated evidence, and hearing testimony from experts, the report concluded in 2012 
that along with screening benefits “the major harm of screening considered by the Panel was 
that of overdiagnosis”, defined as a cancer “diagnosed by screening that would not 
otherwise have come to attention in the woman‘s lifetime.”[19] 
The results of Marmot’s independent review, published simultaneously in The Lancet, 
estimated that 19% of the breast cancers diagnosed during the active mammography 
screening period are overdiagnosed cancers.[20] Reflecting on-going debate about the best 
ways to measure the occurrence of overdiagnosis, the authors stressed this was an estimate 
only, and included this important caveat: “Since the estimates provided are from studies 
with many limitations and whose relevance to present-day screening programmes can be 
questioned, they have substantial uncertainty and should be regarded only as an 
approximate guide.”[20] Complicating estimation of the magnitude of overdiagnosis 
resulting from screening programmes is a lack of research attention to the harms of 
screening, even in high quality evaluations.  As Heleno and colleagues found, only a small 
fraction of randomised trials of cancer screening have quantified rates of false positives and 
overdiagnosis.[21] 
Also in 2012, the influential United States Preventive Services Task Force handed down its 
evidence-based report on the accumulated evidence around prostate cancer screening, 
recommending against screening, and finding overdiagnosis to be a major potential harm of 
screening. The publicly funded independent Task Force concluded there was “convincing 
evidence that PSA-based [prostate-specific antigen] screening leads to substantial 
overdiagnosis of prostate tumors”, with estimates ranging from 17% to 50%.[22] While 
neither of these major reports is the last word on the magnitude of overdiagnosis for these 
screening activities, and debate about methods and the range of estimates continue,[23,24] 
they help mark a more formal official acceptance that the problem represents a significant 
public health challenge. Importantly, independent panels produced both of these landmark 
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reports. One initial implication of this evidence is the clear need to routinely inform people 
invited to undergo screening about the risk of overdiagnosis.  
Neuroblastoma screening 
One valuable case study which emerges from a long-term review of the overdiagnosis 
literature is screening for the potentially fatal childhood cancer called neuroblastoma. 
Because the presence of neuroblastoma could be detected with a urine test, there was great 
hope in some nations in the 1970s and 1980s that mass screening of young infants could 
identify and treat early neuroblastoma tumours, and prevent premature death. Again, as 
with prostate and breast cancer, looking back over the literature, we see increasingly 
rigorous evidence-based scrutiny of the risks and benefits of neuroblastoma screening 
programmes, and over time and with the accumulation of evidence and its critical appraisal, 
we see initial enthusiasm turn give way to doubt and finally concern that screening was 
doing more harm than good, chiefly because of overdiagnosis and subsequent 
overtreatment of benign tumours.   
Extensive neuroblastoma screening programmes were set up in Japan in the 1970s, and by 
the early 1980s enthusiastic reports on the benefits of screening were appearing in the 
medical literature, inspiring screening programmes elsewhere around the world. In 1991 an 
epidemiological analysis of those earlier enthusiastic reports found “the data needed to 
definitively assess the value of screening were not a part of those reports and that the 
benefits claimed from the reported data could be due to overdiagnosis.”[25]  Screening was 
certainly finding early tumours in infants, but it was unclear how many of those newly 
discovered tumours would have ever gone on to cause harm if they hadn’t been detected via 
screening. By 1994, another analysis of the existing literature on neuroblastoma screening 
was raising even more serious doubts.[26] While noting that many child cancer experts were 
still advocating for screening, according to the 1994 analysis of the data “screening is 
differentially picking up the tumours that are least likely to progress” and that screening 
“ ‘overdiagnoses’ many non-progressive cases, with consequent physical and psychological 
morbidity.” In other words many infants were undergoing invasive treatment unnecessarily. 
The paper concluded that “on balance present evidence suggests that the number of deaths 
that could be prevented by screening is small and the potential for overdiagnosis is great.”  
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By 1998 Ajiki and colleagues published research in Cancer Causes and Control, analysing the 
population-based cancer registry in Osaka in Japan, showing that the introduction of 
neuroblastoma screening corresponded with a massive increase in incidence of the disease, 
but with no corresponding change in the rate of death.[27] They found the “annual age-
standardized incidence rate per million children increased from 7.5 in 1970-84 to 20.5 in 
1985-94, while the mortality rates did not differ between these two periods.”  The authors 
concluded “mass screening for neuroblastoma causes harm because of overdiagnosis, and it 
has little effect on decreasing the incidence and the mortality of neuroblastoma at 1-4 years 
of age.”  Four years later, in 2002, a controlled study was published in the New England 
Journal of Medicine.[28] That study compared the outcomes for one and a half million 
children in German states who underwent screening, and over two million children in other 
states which didn’t have screening. Schilling and colleagues found “substantial” 
overdiagnois of children diagnosed by screening – children who would not benefit from 
earlier diagnosis and treatment - and the authors concluded the evidence did not support 
the continuation of screening.  
 
Neuroblastoma now appears in the overdiagnosis literature as a powerful example of the 
need to rigorously assess screening programmes for risk of overdiagnosis.[29-31]  In the 
Archives of Internal Medicine Lauer has made the point, which has a much wider resonance 
across the literature on overdiagnosis, “while our diagnostic technologies were good enough 
to detect early disease, they were not able to distinguish between those tumors that 
represented a genuine threat to a child’s life and those that did not.”[30] And in The Lancet 
Oncology Esserman and colleagues have recently highlighted that much harm was done 
because a “spontaneously regressing type” of cancer, which had not been previously 
recognised, was detected and treated with surgery and chemotherapy: “This example draws 
attention to two important principles: tumours can regress, and treatment of indolent 
tumours can often cause harm.”[31] 
Abstracting the problem from the examples  
Alongside many papers in the literature that concern specific diseases, there are a small 
number which offer an analysis of the nature of overdiagnosis, largely with the focus on 
cancer screening, where evidence is strongest.  While not the only institution in the world 
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offering this kind of analysis, much work stands out in this regard from the community of 
researchers based at the university at Dartmouth College in New England in the United 
States. Dartmouth has emerged as a highly influential centre bringing rigorous evidence-
based scrutiny to both the benefits and harms of medical interventions, for understanding 
overdiagnosis, and communicating about the problem.   
In 1993, clinician-researchers Black and Welch published an analysis article in the New 
England Journal of Medicine, showing how general advances in diagnostic imaging were 
causing overestimations of disease prevalence and therapy benefits.[32] The article drew on 
emerging evidence related to several cancers, including thyroid, prostate, lung and breast 
cancer and one non-cancer condition, abdominal aortic aneurysm. The article also cited an 
evaluation of screening dating back to 1969, which noted that screening would detect cases 
“which may never go on to clinically recognizable disease”.[33] The 1993 analysis showed 
how new technologies like CT scanning enabled detection of smaller and smaller 
“abnormalities”, often of uncertain prognosis, but which were nevertheless classified as 
disease and routinely treated. This, authors argued, was leading to overestimates of the 
prevalence of genuine disease and exaggerations of the effectiveness of treatments, as 
clinicians treated more and more “disease” that would never have caused harm if it 
remained undetected. This in turn was fuelling an increasingly intense cycle, where 
misplaced assumptions about the benefits of detecting and treating tinier abnormalities were 
driving more potentially unnecessary diagnosis and treatment, causing harm and waste.  
The 1993 New England Journal of Medicine article did not use the term “overdiagnosis” but 
did describe “large reservoirs of clinically occult disease” and diagnosis and treatment that 
was conferring “little or no benefit”. Issuing a prescient warning the authors speculated 
that, ”despite clinicians best intentions, many patients may have been labelled with diseases 
they do not really have, and many may have been given therapy they do not really need.” 
The article concluded with a range of recommendations, particularly for more precision in 
research and clinical practice about the exact size of “abnormalities” and more rigorous 
research on the risks and benefits of treating symptomless or subclinical problems.  
Five years later in 1998, Black published a paper titled “Advances in radiology and the real 
versus apparent effects of early diagnosis”, drawing from and developing ideas in the 1993 
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paper, but this time explicitly using the term “overdiagnosis”.[34] Black’s article discussed a 
range of biases relevant to the science around early diagnosis, including the problem of lead 
time bias in survival statistics, often misused by advocates of screening programmes to 
inflate benefits. As he explained, even if having an early diagnosis has no effect on 
extending the time at which symptoms ultimately emerge for a person, or death from 
disease happens, it will appear as if survival has been prolonged, if survival is measured 
from time of diagnosis. Getting an early diagnosis in this scenario could simply mean living 
with the diagnosis for longer, with no real benefit in terms of reducing suffering or 
extending life. Length bias pertains to comparisons “not adjusted for the rate of disease 
progression.” An awkward fact of screening is that it tends to more often detect disease 
which is slower growing and may never cause harm, rather than rapidly progressive disease. 
Changing disease definitions 
In 1999, another Dartmouth team, Schwartz and Woloshin, examined the issue of early 
diagnosis of disease from another perspective - the way in which disease definitions were 
expanding, catching more people at lower risk of actual illness.[35] They chose four well 
known “conditions” - high blood pressure, diabetes type 2, high cholesterol and being 
overweight - where professional societies had recently proposed lowered diagnostic 
thresholds.  They showed how the changes would dramatically increase the number of 
Americans labelled as having these conditions to almost 75% of the total adult population of 
the United States. The authors outlined several reasons for concern including: limited 
evidence that the newly described “patients” would benefit from treatment; the risk of 
drawing resources and attention from those with more serious conditions; and the harms of 
diagnosis and treatment for those who don’t benefit. Echoing alarm about the beguiling yet 
dangerous cycle of increasing intensity, as in the discussion above, they pointed out that 
“lower diagnostic thresholds will not only raise the prevalence of disease, they will appear 
to improve disease outcomes.” Because milder cases would now be included in population 
statistics on prevalence, the “average” blood pressure or blood sugar levels of all those 
labelled would appear to be improved, and treatments, now targeted at less severe cases, 
will appear to work more effectively.  
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In Europe around this time, Getz and colleagues were conducting similar research and 
raising related concerns, arguing that the issue of lowering diagnostic thresholds demanded 
much more critical scrutiny and may ultimately be causing more harm than good to many 
people.[36]Applying diagnostic thresholds embedded in professional society guidelines for 
high blood pressure and high cholesterol to over 60 000 Norwegians aged 20-79, Getz and 
colleagues found 76% of people had “unfavourable” risk profiles, despite Norway having 
one of the world’s longest living and healthiest populations. They found by age 24, 50% of 
people had blood pressure or cholesterol levels above recommended cut-off points, by age 
50, the figure was 90%. The authors explored ethical dilemmas around labelling and 
medicalising so many among the healthy population, and pointed to resulting problems of 
health system sustainability. Importantly they pointed to evidence that giving people 
information about risk of future disease “can cast shadows of doubt and insecurity over 
people’s lives”, which could potentially “undermine an individual’s subjective experience of 
integrity, well-being and health.” 
Growing evidence, growing recognition 
By 2010 Black and Welch published what would become one of the most highly cited articles 
within the overdiagnosis literature. It was titled “Overdiagnosis in Cancer” and was 
published in the journal of the National Cancer Institute, JNCI.[29] The authors described 
how sometimes large reservoirs of indolent cancer - as evidenced by autopsy studies - were 
being uncovered by screening programmes targeting the healthy.  This was then causing 
significant overdiagnosis, as demonstrated by both randomised controlled trials of screening 
programmes, and observational studies analysing big increases in disease incidence 
unaccompanied by increases in rates of premature death. Where data from randomised 
trials were available, Black and Welch offered worrying estimates of the magnitude of 
cancer overdiagnosis: about 25% of mammographically detected breast cancers: 50% of x-ray 
or sputum-detected lung cancers; and 60% of prostate-specific antigen detected prostate 
cancers. The article also articulated the complex “trade-off” for people making decisions 
about screening, “between the potential to avert a cancer death and the risk of 
overdiagnosis”. In conclusion the authors offered a range of suggestions for addressing the 
problem: more research on numerical estimates of overdiagnosis risk and patient 
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preferences; more information and education; and consideration of raising thresholds at 
which diagnoses are made.  
In 2011 the critically acclaimed book Overdiagnosis: making people sick in the pursuit of health 
was published.[1] Authored by Welch, Schwartz and Woloshin, the book offered an 
accessible summary of the problem for overdiagnosis, meticulously citing a range of 
evidence to challenge the pervasive myth that an early detection approach is always the best 
policy.  Examples of conditions where overdiagnosis was a potential harm for people 
covered both cancers and non-cancers. The non-cancer examples included several risk-based 
conditions where diagnostic thresholds have been lowered in recent decades - e.g. high 
cholesterol and low bone mineral density - as well as other conditions where diagnostic 
technology is enabling smaller and smaller potentially harmless “abnormalities” to be 
diagnosed - e.g. abdominal aortic aneurysm and pulmonary embolism. In each case, people 
at lower risks for health problems have become at higher risk of being overdiagnosed: given 
medical labels and treatments that might do them more harm than good. Determining the 
exact magnitude of those risks however remains challenging.    
Challenges in quantifying risk of overdiagnosis on non-cancer conditions 
The review of the literature conducted for this thesis demonstrates clearly that quantifying 
the risk of overdiagnosis for any given condition is highly complex and uncertain. While 
numerical estimates have emerged in recent years in relation to some cancer screening 
programmes, they are still commonly surrounded by wide confidence intervals of 
uncertainty, and on-going debate about methods.[37] Methods for quantifying the risks of 
overdiagnosis with non-cancer conditions are generally less well-developed, and made more 
complicated by uncertainty and controversy around the definitions of many conditions, and 
the thresholds or cut-points at which they are diagnosed. This is particularly the case when 
dealing with the wide range of common “conditions” which are essentially risk factors for 
future illness - including for example high blood pressure, high cholesterol, osteoporosis, 
and even diabetes type 2 - conditions which are diagnosed and treated using surrogate 
endpoints or biomarkers, where the focus is on numbers rather than the person’s symptoms.  
As part of broader concern about the risks of overdiagnosis and overtreatment, the 
importance and value of surrogates is under increasing scrutiny,[38] and the still well-
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established practice of diagnosing numerical risks as diseases is being challenged.[38] In 
2010 the United States Institute of Medicine, IOM, released a major report on biomarkers 
and surrogates.[40] While stressing their utility, the report raised many serious questions 
about how they were being used in medical practice. The report warned against a 
generalised over-reliance on intermediate end-points rather than clinically meaningful 
outcomes, and called for much more rigorous evaluation of how surrogates are used. In 2011, 
Ioannidis and Panagiotou found the importance of biomarkers tended to be overestimated 
in highly cited studies - often early enthusiastic reports -  as compared to subsequent meta-
analyses.[41]  Editorialising about that study in JAMA, Bossuyt outlined the hope that 
biomarkers could help deliver a more “personalised medicine” - better locating those people 
at risk of future illness, detecting early disease, and identifying those most likely to benefit 
from treatment - but argued ”most of these promises have yet to be fulfilled”.[42] Earlier, in 
an article entitled “Against Diagnosis”, Vickers and colleagues had advocated a dramatic 
shift away from diagnosing risk-based conditions in medicine, and urged a move towards 
risk-prediction rather than diagnostic approaches.[39] With such controversy and 
uncertainty over what constitutes a “condition” and whether to even diagnose it, attempts to 
identify where appropriate diagnosis ends and overdiagnosis begins is extremely 
challenging.  
As with cancer, studies in non-cancer conditions appearing in the literature have employed 
a variety of methods, sometimes enabling researchers to make tentative estimates of the 
magnitude of overdiagnosis.  For example in Denmark in 2013 researchers retrospectively 
reviewed the patient records of almost 900 people under the age of 65 diagnosed with 
dementia, finding only 60% met the diagnostic criteria.[43] In Tanzania, researchers 
prospectively observed the treatment and outcomes for over 4000 people diagnosed with 
severe malaria across 10 hospitals, finding almost half did not have malaria.[44] Writing in 
The BMJ in 2004 authors concluded “malaria is commonly overdiagnosed in people 
presenting with severe febrile illness” and that this is associated with “a failure to treat 
alternative causes of severe infection”,  though others will see this as an example of 
misdiagnosis, rather than overdiagnosis. Other studies analyse population statistics finding 
big increases in incidence but little change in mortality trends over time, as has occurred 
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with research suggesting widespread overdiagnosis and overtreatment of pulmonary 
embolism.[4] 
While many studies in the literature find evidence of overdiagnosis, others do not.  In one 
example Pohl and Welch documented a rapid rise in incidence of esophageal 
adenocarcinoma between 1975 and 2001, but because there was little change in the 
proportion of people found with in situ or localized disease at diagnosis, and because that 
rise was accompanied by a similar rise in mortality, overdiagnosis was excluded as an 
explanation for the increasing incidence.[45] In this case researchers concluded there was a 
genuine increase in disease burden.  In another example a review of the literature on 
Attention Deficit Hyperactivity Disorder, ADHD, found the criteria for diagnosing the 
condition had broadened, but little evidence of widespread overdiagnosis.[46]  
Estimating the nature and magnitude of overdiagnosis is made more complicated because 
different types of conditions are vulnerable to different drivers of potential excess.  For the 
risk-based conditions, exemplified by high blood pressure, expert panels changing 
diagnostic cut-points on the basis of new trial evidence is a key driver of expansion in the 
patient pool.  For physical but often asymptomatic conditions, exemplified by what has 
happened with the expansion in diagnosis of pulmonary embolism, a key driver has been a 
change in diagnostic technology: the advent of the CT scan which enables the identification, 
diagnosis and treatment of much smaller clots, many of which are likely to have a benign 
prognosis if left undetected.[4] For mental disorders, where there is often controversy over 
the appropriate boundary between the condition and normal life experience, a different set 
of factors, including changes in diagnostic thresholds, are driving expansions in the patient 
pool.   
Medicalisation 
Many papers in the overdiagnosis literature discuss mental disorders, dating back almost 40 
years to an article in 1978 examining the methodological difficulties facing epidemiological 
studies of what were then described as affective disorders, including bipolar disorder and 
depression.[47] Prefiguring much contemporary debate, Turns concluded that the label of 
“affective disorders” covered conditions of varying severity, that the most prevalent 
conditions had a “high rate of spontaneous recovery”, and that “mental health professionals 
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may, in fact, be overdiagnosing and overtreating”.[47] This debate about potential 
overdiagnosis of mental health disorders is perhaps best exemplified by debate around 
ADHD, which has also been used as an example in the related sociological literature on 
medicalisation.   
For more than four decades the leading medical sociologist Peter Conrad has been 
describing the process of medicalisation - widening medical boundaries - sometimes using 
ADHD as an example of broader trends. In 1975 Conrad described the medicalisation of 
deviant behaviour and medicine’s role in social control, using the example of “hyperkinesis”, 
a medical label for a suite of behaviours in children that would later be described as 
ADHD.[48] In 2000 Conrad published an article on the expansion of medical categories, this 
time using the example of the way criteria for ADHD were widening from children to 
include adults as well, and showing how lay people, lay-professional alliances and the 
media were all playing a role in this dramatic expansion.[49] “In the adult ADHD case the 
diagnosis is embraced and promoted by the people who receive it” wrote Conrad and Potter. 
“In this case, medication treatment may be seen as much as an enhancement as a form of 
social control.” In 2005, in an article titled “The Shifting Engines of Medicalization” Conrad 
described the rising influence of consumers, insurers and the biotechnology and the 
pharmaceutical industries, arguing that “medicalization is now more driven by commercial 
and market interests than by professional claims-makers”.[50] In light of this shift to the 
market place, the article also called for sociologists of medicine to more often consider 
political economy perspectives. Most recently in 2014, the sociologist described a coming 
“globalization of ADHD”, showing how the North American medical label was migrating to 
many nations, carried by a range of vehicles including global pharmaceutical companies, 
western psychiatry, highly accessible internet-based screening checklists and well-organised 
advocacy groups.[51] 
Others have described a move from what was previously understood as medicalisation to a 
more all-encompassing “biomedicalization”, occurring as a result of vast economic, political 
and social changes, from the transformation of the economy to changes in personal identify 
which are emerging from the interconnected rise of biomedicine and information 
technologies.[6] “In the biomedicalization era” wrote sociologists Clarke and colleagues in a 
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landmark 2003 article, “what is perhaps most radical is the biomedicalization of health 
itself”, an era when “it is no longer necessary to manifest symptoms to be considered ill or 
‘at risk’”. Similarly Armstrong has detailed the inexorable rise of what he calls “surveillance 
medicine”, which through the latter part of the 20th century reconstructed the nature of 
disease, to become “less the illness per se but rather the semi-pathological pre-illness at-risk 
state.”[52] 
A small literature also relevant to discussions of overdiagnosis addresses the problem 
known as “disease-mongering”, a phrase popularised by Payer,[53] but with an important 
debt to Illich’s influential work on the medicalisation of life.[5] Disease-mongering, also 
described as “selling sickness”,[54] is the process of portraying more and more ordinary life 
as the signs and symptoms of severe and treatable diseases and disorders, commonly 
motivated by a desire to build markets for those who sell or deliver treatments, and often 
driven explicitly by pharmaceutical industry funded “disease awareness” campaigns run in 
alliance with industry-linked health professionals and advocacy groups. A special collection 
of articles on disease-mongering was published in the open access journal PLOS Medicine in 
2006, [55] covering conditions including bipolar disorder,[56] erectile dysfunction,[57] 
female sexual dysfunction,[58] and restless legs syndrome.[59] The paper on restless legs 
syndrome from Dartmouth authors Woloshin and Schwartz analysed how pharmaceutical 
marketing helped to distort media coverage and blur the lines between common difficulties 
and a treatable syndrome. “The news coverage of restless legs syndrome is disturbing” they 
wrote. “It exaggerated the prevalence of disease and the need for treatment, and failed to 
consider the problems of overdiagnosis.” 
While overdiagnosis can lead to overtreatment - for example if someone was unnecessarily 
diagnosed with restless legs syndrome and then treated for it - problems of overuse more 
generally can also be unrelated to overdiagnosis, and driven by some different factors. 
While sitting under the wider umbrella of “too much medicine”,[60] the broad and extensive 
literature on waste and overuse [7, 61]- whether CT scans of children,[62] inappropriate 
polypharmacy among the elderly,[63] or poorly evaluated procedures like vertebroplasty[64] 
- is largely outside the scope of this thesis. 
Guidelines, Evidence and Overdiagnosis 
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A final part of the scientific literature relevant to this thesis pertains to clinical guidelines. 
While guidelines have been promoted as the way high quality evidence can be translated 
into clinical practice and produce improved patient care, there is increasing evidence and 
concern about flaws in both the way guidelines are produced and the constitution of panels 
which produce them, as well as their potential to drive overdiagnosis and overtreatment. In 
a 2012 review of 130 randomly selected guidelines,[65] Kung and colleagues found generally 
poor compliance with IOM standards for developing and reporting guidelines.[66] In 
relation to the composition of panels producing guidelines, Kung and colleagues found that 
independent “information scientists” and patient or public representatives were rarely 
included on panels, and that where financial conflicts of interest were reported, they were 
pervasive, including among panel chairs. A 2011 systematic review of studies of guidelines 
and financial ties similarly found conflicts of interest among clinical guideline panels were 
extremely common.[67] 
While no studies have systematically investigated links between guideline output and 
overdiagnosis, there is significant anecdotal concern about the connection. The former head 
of the task force which compiled the fourth edition of the influential Diagnostic and Statistical 
Manual of Mental Disorders, the DSM IV, psychiatrist Allen Frances, has expressed public 
concern that the DSM IV has unwittingly contributed to an explosion of unnecessary 
diagnoses in the areas of attention deficit, autism, and bipolar disorder.[68] Taking a broader 
interest in guidelines and disease definitions, Frances has raised doubts about many 
contemporary guidelines, observing that they are generally developed by experts with 
intellectual or financial conflicts that “biases them toward overdiagnosis and 
overtreatment.”[69] Former president of the Royal College of General Practitioners in the 
United Kingdom, Iona Heath, has gone further: “Whenever I see the sort of guidelines that 
are, right now, driving overdiagnosis and overtreatment, I think of this: our responsibility 
not to follow the rules.”[70] 
 
Part of the concern is about the proliferation of single-condition guidelines, and their 
distorted impact on the way care is delivered and the way quality of care is measured. In The 
BMJ in 2009 Heath and colleagues raised questions about the appropriateness of applying 
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narrow disease-specific specialist guidelines to the complexity of primary care, where 
people present with multiple co-morbidities and complex physical, psychological and social 
problems, and then measuring the quality of patient care based on the application of such 
narrow guidelines.[71] Similarly, in a provocative article in 2012 in The BMJ, titled Beyond 
Diagnosis, primary care clinician and researcher Mangin and colleagues pointed to the 
weakness of the single-condition evidence embedded in evidence-based guidelines, and 
called for a shift from thinking about individual abstract diagnoses, to thinking more 
holistically about the care of real people. Such a shift is necessary, the authors argued, in 
order to provide good care to people with multiple co-morbidities, and in particular to avoid 
poly-pharmacy that may result from adherence to multiple single-condition guidelines and 
their related quality measures.[72] 
 
The work of Heath, Mangin and others has helped expose the unintended consequences of 
the rise and rise of the evidence-based approach to medicine, a problem outlined in a 2014 
article by Greenhalgh and colleagues, titled “Evidence based medicine: a movement in 
crisis?”[73] Ironically the application of the evidence-based approach is increasingly 
revealing how “evidence” can be routinely distorted and even corrupted by vested interests 
both financial and professional, how an unmanageable proliferation of single condition 
“evidence-based” guidelines can cause overtreatment, and how “evidence” is increasingly 
harnessed to detect and intervene in “non-disease”, producing the real risk of 
overdiagnosis.[73] At the same time the systematic review methodology at the heart of the 
evidence-based approach has increasingly gained access to unpublished data, exposing the 
limited benefits and previously hidden harms of many common “evidence-based” 
interventions, a recent example being findings about widely used influenza treatments.[74] 
The broad movement behind the evidence-based approach appears to have entered 
something of a crisis and there are currently discussions of a possible renaissance, as I 
explore when discussing responses to the problem of overdiagnosis in chapter 8.   
Aims, research questions and subsequent chapters 
Following the initial scoping of the literature and the planning for the thesis, several areas of 
research interest emerged. In a broad sense, more work on the basic nature of the problem 
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was clearly required. While evidence about the risk of overdiagnosis was most mature in 
relation to cancer screening, more research was required on how and why disease 
definitions were expanding, and how those changes were helping drive the problem of 
overdiagnosis. Another gap in the literature was data on public knowledge and perceptions 
about overdiagnosis. And finally, a clear need existed to imagine, design and evaluate a 
range of potential responses to the problem, and to articulate how medical evidence, and its 
synthesis and use in guidelines, might be better marshalled to prevent rather than 
exacerbate overdiagnosis.      
In summary, the broad aims of the thesis were to answer the following research questions: 
1. What is overdiagnosis and what is driving it?                    
2. Who is defining diseases and with what financial ties to industry?               
3. How and why are disease-definitions expanding?                                                 
4. Awareness and views about overdiagnosis among the public: are people being 
informed about the overdiagnosis risk of screening and what does the public think 
about conflicted guideline panels which change disease definitions?  
5. How might “evidence” be produced and used in ways that better respond to the 
problem of overdiagnosis?          
     
The first aim of the thesis, arising from the scoping of the literature, was to produce an 
accessible overview article describing overdiagnosis, its drivers and possible responses, to 
help introduce the topic to a wider group of health professionals, policy-makers and the 
public. Chapter 2, published as a peer-reviewed paper in The BMJ in 2012 is the result of that 
initial scoping of the literature.[9] The paper uses a range of brief examples of cancer and 
non-cancer conditions where overdiagnosis has been identified as a risk, to help illustrate 
the problem. Since publication in 2012 the article has been well-cited in the scientific 
literature and helped bring public attention to the problem, through high profile domestic 
and global media coverage.[75, 76] The paper also introduced two important and related 
projects initiated as part of my work on overdiagnosis through the development of this 
thesis.  
 
Preventing Overdiagnosis 
 
 
40 
 
Arising from the discussions with colleagues at the inception of the thesis, and reinforced by 
the initial scoping of the overdiagnosis literature, it became clear it was time for an 
international multi-disciplinary scientific conference on overdiagnosis, to share the 
emerging science, bring researchers together and advance research and policy agendas. A 
small planning meeting took place in 2012, from which a global alliance of academic, journal 
and consumer partners emerged, to hold what has become a series of highly successful 
international scientific conferences called Preventing Overdiagnosis.[77] The first meeting took 
place in 2013 at Dartmouth, the second in 2014 at the University of Oxford, and the third is 
scheduled for September 2015 at the National Cancer Institute in the United States. The 
second project foreshadowed in the paper was the launch of a new series of peer-reviewed 
articles in The BMJ,[60] documenting, condition by condition, the problem of expanding 
disease definitions and risk of overdiagnosis.  
 
While there has a strong focus on cancer screening in the overdiagnosis literature, a key 
focus of the thesis is investigating the problem of expanding disease definitions, and how it 
might relate to the problem of overdiagnosis. While the literature had included several 
papers discussing different condition-specific examples, no study had systematically 
examined the expert guideline panels which review and change the definitions of common 
conditions. Chapter 3 is a peer-reviewed paper featuring the results of a major study of 
expert panels which review and change disease definitions, published in PLOS Medicine in 
2013.[78] Our study made valuable findings about the extent to which definitions are being 
expanded, the way they are being expanded, whether the risks of such expansion  - 
including overdiagnosis -  were being investigated, and the extent to which expert guideline 
panel members have financial ties to companies with an interest in the size of disease 
markets.  
 
To investigate more deeply how and why disease definitions are changing, the thesis used a 
case study involving a widened disease definition which was the subject of much scientific 
controversy. Chapter 4 is the result of investigating the case study of chronic kidney disease, 
CKD, which was published as a peer-reviewed article in The BMJ in 2013.[79] This chapter is 
a result of research into the controversy over the definition CKD, which labels around half of 
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all those over the age of 70 as diseased. Closely analysing a decade of literature from 
proponents and critics of the CKD definition, the chapter brings important insights into the 
way controversial decisions are promulgated and defended in the face of sustained scientific 
criticism. The chapter urges caution in applying the controversial CKD definition’s 
diagnostic thresholds and concludes the definition is so problematic that an independent 
review by an un-conflicted panel is required.  
As covered above in the review of the overdiagnosis literature, while there are varying and 
uncertain numerical estimates of magnitude, it has become clear that overdiagnosis is a 
genuine risk of some cancer screening activities, with evidence being well-established for 
breast and prostate cancer. However, there has been little investigation into how often 
people invited to screening are being informed about the risks. More broadly there are very 
few survey data in the literature about public awareness of and attitudes about 
overdiagnosis. As part of the thesis, with research colleagues and staff from a social research 
company experienced in health surveys, we designed and piloted a new questionnaire and 
ran a national community survey of 500 adult Australians investigating understanding of 
and attitudes about overdiagnosis.  The results appear in the submitted manuscript that is 
chapter 5 of the thesis.[80] Drawing from the results of my study of expert guideline panels 
covered in chapter 3, as part of the survey questionnaire, we included questions about 
attitudes to expert panels with financial ties.  
Chapter 6, a submitted manuscript, features the results of a qualitative analysis of public 
responses to our survey question “What do you think the term overdiagnosis means?”.[81] 
While growing evidence has brought recognition of the need to start communicating with 
people more effectively about the risk of overdiagosis, there was no survey data on what the 
general community understands the term overdiagnosis to mean. At a time when there is 
on-going scientific debate about how best to define overdiagnosis, and its relationships with 
overuse and the wider problem of too much medicine, our survey asked 500 Australians 
what they understood the term overdiagnosis to mean. The results, and our thematic 
analysis of responses, start to bring the voice of the community into the debate about 
overdiagnosis, and offer a rich data set for those designing communication strategies about 
overdiagnosis.  
Preventing Overdiagnosis 
 
 
42 
 
Possible responses to the problem of overdiagnosis are covered in chapters 7 and 8. 
Published as a peer-reviewed article in PLOS Medicine in 2014,[82] chapter 7 explores how 
evidence can be used more effectively to combat overdiagnosis and related overtreatment. 
The article looks at how the running of primary studies of tests and treatments, the 
production of systematic reviews and the reviewing and changing of disease definitions 
might all much more routinely include an explicit awareness of the risk of overdiagnosis. A 
key aim is to develop a more extensive evidence base on which to build disease definitions 
and diagnostic thresholds which reduce the risks of overdiagnosis and overtreatment, and 
which can be employed to better inform shared decision-making when there is controversy 
or uncertainty. These issues become part of a wider discussion in chapter 8 of the thesis 
findings and research and policy implications.  
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Medicine’s much hailed ability to help the sick is fast being challenged by its propensity to 
harm the healthy. A burgeoning scientific literature is fuelling public concerns that too many 
people are being overdosed,[1] overtreated,[2]and overdiagnosed.[3] Screening programmes 
are detecting early cancers that will never cause symptoms or death,[4] sensitive diagnostic 
technologies identify “abnormalities” so tiny they will remain benign,[5] while widening 
disease definitions mean people at ever lower risks receive permanent medical labels and 
lifelong treatments that will fail to benefit many of them.[3,6] With estimates that more than 
$200bn (£128bn; €160bn) may be wasted on unnecessary treatment every year in the United 
States,[7] the cumulative burden from overdiagnosis poses a significant threat to human 
health. 
Narrowly defined, overdiagnosis occurs when people without symptoms are diagnosed 
with a disease that ultimately will not cause them to experience symptoms or early death.[3] 
More broadly defined, overdiagnosis refers to the related problems of overmedicalisation 
and subsequent overtreatment, diagnosis creep, shifting thresholds, and disease mongering, 
all processes helping to reclassify healthy people with mild problems or at low risk as sick.[8]  
The downsides of overdiagnosis include the negative effects of unnecessary labelling, the 
harms of unneeded tests and therapies, and the opportunity cost of wasted resources that 
could be better used to treat or prevent genuine illness. The challenge is to articulate the 
nature and extent of the problem more widely, identify the patterns and drivers, and 
develop a suite of responses from the clinical to the cultural.  
At the clinical level, a key aim is to better discriminate between benign “abnormalities” and 
those that will go on to cause harm. In terms of education and raising awareness among 
both the public and professionals, more honest information is needed about the risk of 
overdiagnosis, particularly related to screening. More deeply, mounting evidence that we’re 
harming healthy people may force a questioning of our faith in ever-earlier detection, a 
renewal of the process of disease definition, and a fundamental shift in the systemic 
incentives driving dangerous excess. 
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Next year, an international scientific conference called Preventing Overdiagnosis aims to 
deepen understanding and awareness of the problem and its prevention. The conference 
will take place on 10-12 September 2013 in the United States, hosted by the Dartmouth 
Institute for Health Policy and Clinical Practice in partnership with The BMJ, the leading US 
consumer organisation Consumer Reports, and Bond University. The conference is timely, 
as growing concern about overdiagnosis is giving way to concerted action. The Archives of 
Internal Medicine’s feature “Less is More” now regularly augments the evidence base,[9] high 
level health policy groups in Europe are debating ways to tackle excess,[10] and the recently 
launched Choosing Wisely campaign warns about dozens of potentially unnecessary tests 
and treatments across nine specialties.[11] 
Many factors—including the best of intentions—are driving overdiagnosis, but a key 
contributor is advances in technology. The literature suggests several broad and related 
pathways to overdiagnosis: screening detected overdiagnosis in people without symptoms; 
overdiagnosis resulting from use of increasingly sensitive tests in those with symptoms; 
overdiagnosis made incidentally—“incidentalomas”; and overdiagnosis resulting from 
excessively widened disease definitions. These different pathways are not mutually 
exclusive, and a more rigorous classification of the different forms of overdiagnosis will be a 
focus of discussion at the 2013 scientific conference. 
Screening detected overdiagnosis 
This pathway to overdiagnosis occurs when a screening programme detects disease in a 
person without symptoms but the disease is in a form that will never cause that person 
symptoms or early death. Sometimes this form of disease is called pseudodisease. Contrary 
to popular notions that cancers are universally harmful and ultimately fatal, some cancers 
can regress, fail to progress, or grow so slowly that they will not cause harm before the 
individual dies from other causes.[5] As we will discuss below, there is now strong evidence 
from randomised trials and other studies comparing screened and unscreened populations 
that an important proportion of the cancer detected through some popular screening 
programmes may be pseudodisease.[4,12] Evidence from autopsy studies suggests a large 
reservoir of subclinical disease in the general population, including prostate, breast, and 
thyroid cancer, the bulk of which will never harm.[12] Similarly, screening the hearts of 
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people without symptoms or at low risk may also lead to overdiagnosis of coronary 
atherosclerosis and subsequent unnecessary interventions.[13] Our understanding of the 
nature and extent of overdiagnosis and the amount of pseudodisease detected by screening 
remains limited but is evolving, and as Woolfe and Harris observed recently in JAMA, 
“concern about overdiagnosis is justified.”[14] 
Increasingly sensitive tests 
People presenting to doctors with symptoms can also be overdiagnosed because changes in 
diagnostic technologies or methods have enabled the identification of less severe forms of 
diseases or disorders. It is becoming clearer that a substantial proportion of these earlier 
“abnormalities” will never progress, raising awkward questions about exactly when to use 
diagnostic labels and therapeutic approaches traditionally deployed against much more 
serious forms of disease. 
Incidentalomas 
Diagnostic scanning of the abdomen, pelvis, chest, head, and neck can reveal “incidental 
findings” in up to 40% of individuals being tested for other reasons.[15] Some of these are 
tumours, and most of these “incidentalomas” are benign. A very small number of people 
will benefit from early detection of an incidental malignant tumour, while others will suffer 
the anxiety and adverse effects of further investigation and treatment of an “abnormality” 
that would never have harmed them. As others have shown, the rapidly rising incidence for 
some cancers, set against relatively stable death rates, is a phenomenon suggestive of 
widespread overdiagnosis, whether from screening or the detection of incidentalomas.[12] 
Excessively widened definitions 
Another pathway to overdiagnosis is through disease boundaries being widened and 
treatment thresholds lowered to a point where a medical label and subsequent therapy may 
cause people more harm than good. Changing diagnostic criteria for many conditions are 
routinely increasing the numbers of people defined as sick,[16] causing virtually the entire 
older adult population to be classified as having at least one chronic condition.[17] This 
widening has happened both with asymptomatic conditions that carry a risk of an adverse 
event, such as osteoporosis, where treatments may do more harm than good for those at 
very low risk of fracture,[18] and for behavioural conditions such as female sexual 
dysfunction, where common difficulties have been reclassified as dysfunctions.[19]  
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Such changes in diagnostic criteria are commonly made by panels of health professionals 
with financial ties to companies that benefit directly from any expansion of the patient 
pool.[20] As definitions broaden and thresholds fall, people with smaller risks or milder 
problems are labelled, which means the potential benefits of treatment decline, raising the 
possibility that harms will outweigh benefits. As Welch and colleagues estimated in their 
2011 book Overdiagnosed,[3] many people diagnosed and treated long term for near-normal 
cholesterol concentration or near-normal osteoporosis may be “overdiagnosed,” in the sense 
that they would never have experienced the events their treatments are designed to prevent.  
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Figure 1. Rates of new diagnosis and death for five types of cancer in the US, 1975-2005. 
Adapted from Welch and Black, with permission.[12] 
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A related form of overdiagnosis occurs when people are diagnosed outside of already 
widened diagnostic criteria, as can occur when inappropriate manufacturers’ norms 
exaggerate the incidence of abnormality,[21] when diagnostic methods wrongly label 
random or normal fluctuations in biomarkers as true abnormalities,[22] or when important 
qualifiers are left out of the process of diagnosis.[23]  
Examples of overdiagnosis 
The growing evidence on overdiagnosis suggests the problem may exist to varying extents 
across many conditions, including those for which underdiagnosis may simultaneously be a 
feature. For some conditions, the evidence remains tentative and speculative, for others it 
has become much more robust.  
Breast cancer 
Arguably the strongest evidence of overdiagnosis comes from studies of screening detected 
breast cancers, though estimates of its extent are wide ranging. A 2007 systematic review in 
Lancet Oncology found the proportion of overdiagnosis of invasive breast cancer among 
women in their 50s ranged from 1.7% to 54%.[24] An Australian study estimated the rate 
was at least 30%,[25] while a Norwegian study calculated 15-25%.[26] A 2009 systematic 
review in The BMJ concluded up to one third of all screening detected cancers may be 
overdiagnosed.[4] However, even with strong evidence from population based studies, it is 
currently impossible to discriminate between cancers that will harm and those that will not. 
Thyroid cancer 
While the chances of tests detecting a thyroid “abnormality” are high, the risk it will ever 
cause harm is low.[3,27] Analysis of rising incidence shows many of the newly diagnosed 
thyroid cancers are the smaller and less aggressive forms not requiring treatment,[28] which 
itself carries the risk of damaged nerves and long term medication.[3] 
Gestational diabetes 
A 2010 revision of the criteria defining gestational diabetes recommended a dramatic 
lowering of the diagnostic threshold, more than doubling the number of pregnant woman 
classified to almost 18%.[29] Proponents argue universal screening with the new definition 
will reduce health problems, including babies being “large for gestational age.”[29 ] Critics, 
however, are calling for an urgent debate before the new expanded definition is more 
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widely adopted, because they fear many women may be overmedicalised and 
overdiagnosed, that the screening test has poor reproducibility for mild cases, the evidence 
of benefit for the newly diagnosed pregnant women is weak, and the benefit modest at 
best.[30, 31] 
Chronic kidney disease 
More than 10% of adults in the United States are now classified as having some form of 
chronic kidney disease.[32] A working definition launched as part of new clinical 
guidelines[33] asserts that an estimated glomerular filtration rate (eGFR) below 60 
ml/min/1.73m2 and sustained for three months or longer is deemed abnormal, a decision 
critics argue automatically creates the potential for overdiagnosis, particularly among 
elderly people.[34] 
According to Winearls and Glassock in an article last year the new classification system is 
“like a fishing trawler” and “captures many more innocent subjects than it should.”[23] 
They estimate that up to one third of people over 65 may meet the new criteria, yet of these, 
fewer than 1 in 1000 will develop end stage renal disease each year. They also point to major 
problems with the reliability and consistency of the eGFR test and express concern many 
older people are being labelled on the basis of a single and potentially inaccurate laboratory 
measure. Elsewhere they have argued that “the majority of those held to have CKD [chronic 
kidney disease] have no identifiable kidney disease” and they’ve highlighted attempts by 
some organisations to move away from the controversial new definition, raise the threshold 
for diagnosis, and dramatically reduce prevalence.[35] Responding to criticisms, proponents 
have defended the new definition as being “clear, simple, and useful.”[36] 
Asthma 
Although asthma can be severe and may be underdiagnosed and undertreated, some studies 
suggest that there may also be substantial overdiagnosis. One large study in 2008 found that 
almost 30% of people diagnosed as having asthma did not have the condition, and almost 66% 
of those did not need drugs or asthma care during six months of follow-up.[37] The authors 
concluded, “A substantial proportion of people . . . may be overdiagnosed with asthma and 
may be prescribed asthma medications unnecessarily.” In the same year a Dutch study 
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found that of 1100 patients using inhaled corticosteroids, 30% may have been using the 
drugs without any clear indications.[38] 
Pulmonary embolism 
Doctors think of pulmonary embolism as a “not to be missed” diagnosis, because failure to 
detect it can have catastrophic consequences. Historically it was diagnosed only when the 
blockage was large enough to cause infarction of part of the lung or haemodynamic 
instability. In such patients, treatment with an anticoagulant or a thrombolytic agent was 
considered mandatory. Now, however, computed tomography (CT) pulmonary 
angiography can detect smaller clots, and there is uncertainty about whether treatment is 
always necessary.[39] Analysing trends before and after the widespread introduction of CT 
pulmonary angiography, Weiner and colleagues suggested that the almost doubling in 
incidence “reflects an epidemic of diagnostic testing that has created overdiagnosis,” with 
much of the increase consisting of “clinically unimportant” cases that “would not have been 
fatal even if left undiagnosed and untreated.”[40] An observational study is investigating 
the safety of not treating people with very small blood clots.[41] 
Attention deficit hyperactivity disorder 
Much has been written about expanding diagnostic definitions within mental illness and 
concerns about the dangers of overtreatment.[42] Debate has intensified with suggestions 
that current processes for defining disease may be contributing to the widespread 
overdiagnosis of conditions such as bipolar, autistic disorder, and attention deficit 
hyperactivity disorders.[43,44] One focus of concern is the possible overdiagnosis of children, 
who have no say in the appropriateness of a label that can permanently change their lives. 
This is particularly salient with attention deficit hyperactivity disorder.[45] A recent study of 
almost a million Canadian children found boys born in December (typically the youngest in 
their year) had a 30% higher chance of diagnosis and 40% higher chance of receiving 
medication than those born in January, with the authors concluding their findings “raise 
concerns about the potential harms of overdiagnosis and overprescribing.”[46] 
Drivers of overdiagnosis 
The forces driving overdiagnosis are embedded deep within the culture of medicine and 
wider society, underscoring the challenges facing any attempt to combat them (box 1). A key 
driver is technological change itself. As Black described in 1998, the ability to detect smaller 
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abnormalities axiomatically tends to increase the prevalence of any given disease.[5] In turn 
this leads to overestimation of the benefits of therapies, as milder forms of the disease are 
treated and improvements in health are wrongly ascribed to treatment success, creating a 
“false feedback” loop fuelling a “cycle of increasing testing and treatment, which may 
eventually cause more harm than benefit.”[5] 
Box 1. Drivers of overdiagnosis 
Technological changes detecting ever smaller “abnormalities” 
Commercial and professional vested interests 
Conflicted panels producing expanded disease definitions and writing guidelines  
Legal incentives that punish underdiagnosis but not overdiagnosis 
Health system incentives favouring more tests and treatments 
Cultural beliefs that more is better; faith in early detection unmodified by its risks 
 
The industries that benefit from expanded markets for tests and treatments hold wide 
reaching influence within the medical profession and wider society, through financial ties 
with professional and patient groups and funding of direct-to-consumer advertising, 
research foundations, disease awareness campaigns, and medical education.[8] Most 
importantly, the members of panels that write disease definitions or treatment thresholds 
often have financial ties to companies that stand to gain from expanded markets.[20] 
Similarly, health professionals and their associations may have an interest in maximising the 
patient pool within their specialty, and self-referrals by clinicians to diagnostic or 
therapeutic technologies in which they have a commercial interest may also drive 
unnecessary diagnosis.  
Avoidance of litigation and the psychology of regret is another obvious driver as 
professionals can be punished for missing the early signs of disease yet don’t generally face 
sanctions for overdiagnosing. Quality measures focused on doing more may also encourage 
overdiagnosis in order to meet targets for remuneration incentives.[47] 
An intuitive belief in early detection, fed by deep faith in medical technology is arguably at 
the heart of the problem of overdiagnosis. Increasingly we’ve come to regard simply being 
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“at risk” of future disease as being a disease in its own right. Starting with treatment of high 
blood pressure in the middle of the 20th century,[48] increasing proportions of the healthy 
population have been medicalised and medicated for growing numbers of symptomless 
conditions, based solely on their estimated risk of future events. Although the approach has 
reduced suffering and extended life for many, for those overdiagnosed it has needlessly 
turned the experience of life into a tangled web of chronic conditions. The cultural norm that 
“more is better” is confirmed by recent evidence suggesting patient satisfaction flows from 
increased access to tests and treatments, even though more care may be associated with 
greater harm.[49,50] 
What can we do about overdiagnosis? 
Building on existing knowledge and activity, the 2013 conference on overdiagnosis will 
provide a forum for learning more, increasing awareness, and developing ways to prevent 
the problem (www.preventingoverdiagnosis.net). Research on overdiagnosis is now 
recognised as part of the future scientific direction of the National Cancer Institute’s division 
of cancer prevention in the United States.[51] The 2013 conference hopes to provide 
researchers working in this field with the chance to share and debate methods and further 
advance research agendas. As to education, the development of a range of curriculums and 
information packages could help raise awareness about the risks of overdiagnosis, 
particularly associated with screening.[52[ In association with The BMJ, a series of articles 
about the potential for overdiagnosis within specific conditions is being planned. And at the 
level of clinical practice new protocols are being developed to bring more caution in treating 
incidentalomas.[3] Similarly, some are urging that we consider raising the thresholds that 
define “abnormal”—in breast cancer screening, for example—and evaluate methods of 
observing changes to some suspected pathologies over time, rather than intervening 
immediately.[53] As we’ve seen, early studies of how to safely undiagnose or de-prescribe 
are starting to emerge. 
At a policy level, reform of the process of defining disease is urgently required, with one 
model coming from the National Institutes of Health in the United States, where people with 
financial or reputational conflicts of interest are disqualified from panel membership.[20] 
Dispassionate assessment of evidence may result in disease definitions being narrowed, as 
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has been seen with the recent tentative proposals to raise thresholds for high blood pressure 
that could demedicalise up to 100 million people.[54] Processes for defining disease may 
also benefit from an attempt to synthesise the evidence from clinical medicine with literature 
on the wider social and environmental determinants of health. Other policy reforms could 
review the permanency of some diagnostic labels, address calls for increased independence 
in the design and running of scientific studies,[55] and adjust the structural and legal 
incentives driving overdiagnosis. 
Concern about overdiagnosis does not preclude awareness that many people miss out on 
much needed healthcare. On the contrary, resources wasted on unnecessary care can be 
much better spent treating and preventing genuine illness. The challenge is to work out 
which is which, and to produce and disseminate evidence to help us all make more 
informed decisions about when a diagnosis might do us more good than harm. 
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Box 2. Examples of overdiagnosis 
Asthma—Canadian study suggests 30% of people with diagnosis may not have asthma, and 
66% of those may not require medications. [37] 
Attention deficit hyperactivity disorder—Widened definitions have led to concerns about 
overdiagnosis; boys born at the end of the school year have 30% higher chance of diagnosis 
and 40% higher chance of medication than those born at the beginning of the year[46] 
Breast cancer—Systematic review suggests up to a third of screening detected cancers may 
be overdiagnosed[4] 
Chronic kidney disease—Controversial definition classifies 1 in 10 as having disease; 
concerns about overdiagnosis of many elderly people [23] 
Gestational diabetes—Expanded definition classifies almost 1 in 5 pregnant women [31] 
High blood pressure—Systematic review suggests possibility of substantial 
overdiagnosis[22] 
High cholesterol—Estimates that up to 80% of people with near normal cholesterol treated 
for life may be overdiagnosed[3] 
Lung cancer—25% or more of screening detected lung cancers may be overdiagnosed[56] 
Osteoporosis—Expanded definitions may mean many treated low risk women experience 
net harm[18] 
Prostate cancer—Risk that a cancer detected by prostate specific antigen testing is 
overdiagnosed may be over 60%[12] 
Pulmonary embolism—Increased diagnostic sensitivity leads to detection of small emboli. 
Many may not require anticoagulant treatment [39] 
Thyroid cancer—Much of the observed increase in incidence may be overdiagnosis[28] 
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Abstract 
Background 
Financial ties between health professionals and industry may unduly influence professional 
judgments and some researchers have suggested that widening disease definitions may be 
one driver of overdiagnosis, bringing potentially unnecessary labelling and harm. We aimed 
to identify guidelines in which disease definitions were changed, to assess whether any 
proposed changes would increase the numbers of individuals considered to have the disease, 
whether potential harms of expanding disease definitions were investigated, and the extent 
of members' industry ties. 
Methods and Findings 
We undertook a cross-sectional study of the most recent publication between 2000 and 2013 
from national and international guideline panels making decisions about definitions or 
diagnostic criteria for common conditions in the United States. We assessed whether 
proposed changes widened or narrowed disease definitions, rationales offered, mention of 
potential harms of those changes, and the nature and extent of disclosed ties between 
members and pharmaceutical or device companies. 
Of 16 publications on 14 common conditions, ten proposed changes widening and one 
narrowing definitions. For five, impact was unclear. Widening fell into three categories: 
creating “pre-disease”; lowering diagnostic thresholds; and proposing earlier or different 
diagnostic methods. Rationales included standardising diagnostic criteria and new evidence 
about risks for people previously considered to not have the disease. No publication 
included rigorous assessment of potential harms of proposed changes. 
Among 14 panels with disclosures, the average proportion of members with industry ties 
was 75%. Twelve were chaired by people with ties. For members with ties, the median 
number of companies to which they had ties was seven. Companies with ties to the highest 
proportions of members were active in the relevant therapeutic area. Limitations arise from 
reliance on only disclosed ties, and exclusion of conditions too broad to enable analysis of 
single panel publications. 
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Conclusions 
For the common conditions studied, a majority of panels proposed changes to disease 
definitions that increased the number of individuals considered to have the disease, none 
reported rigorous assessment of potential harms of that widening, and most had a majority 
of members disclosing financial ties to pharmaceutical companies. 
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Introduction 
Changes in technologies, treatments, medical knowledge, and cultural norms provide cause 
to review and change disease definitions and diagnostic thresholds, a task that is commonly 
undertaken by expert panels, consensus meetings, or influential workgroups who publish 
findings as statements, special reports, or as part of clinical practice guidelines. While such 
changes can be beneficial, there is an increasing recognition that widening of disease 
definitions may be one factor contributing to the problem of overdiagnosis, occurring across 
a range of conditions including pulmonary embolism, breast and prostate cancers.[1,2] The 
concern expressed by some researchers is that for some people with milder symptoms, at 
lower risks, or in earlier stages of possible disease, the harms of a diagnostic label and 
treatment may outweigh benefits.[3,4] 
At the same time there is accumulating evidence about pervasive financial ties between 
pharmaceutical companies and health professionals,[5] including those writing guidelines,[6] 
and disease definitions.[7] While noting the value of professional–industry collaborations, a 
2009 Institute of Medicine (IOM) report found “widespread relationships with industry have 
created significant risks that individual and institutional financial interests may unduly 
influence professionals' judgments,” and that these “conflicts of interest” threaten the 
integrity of research, the objectivity of education, the quality of patient care, and public trust 
in medicine.[5] 
The 2009 report recommended professional societies and other organisations drafting 
clinical practice guidelines should “generally exclude as panel members individuals with 
conflicts of interest.” A subsequent 2011 IOM report on how to produce trustworthy 
guidelines included recommendations that “whenever possible,” guideline developers 
“should not have” conflicts of interest, that only a minority should have conflicts, and that 
chairs should be free of conflicts.[8] 
As both reports make clear, in addition to financial ties there are non-financial or intellectual 
conflicts such as academic advancement, and there should be no assumption that having a 
conflict is unethical, or “that any particular professional will necessarily let financial gain 
influence his or her judgment”.[5] 
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A 2011 systematic review found many clinical guideline panels have failed to disclose 
financial ties, and those that did disclose had a “high percentage” of individuals with 
financial conflicts of interest.[6] Studies analysing ties of working groups for the Diagnostic 
and Statistical Manual of Mental Disorders (DSM), which set definitions and diagnostic criteria, 
have also found a majority of members with ties.[7] Kung and colleagues recently found 
two-thirds of individuals chairing guideline committees had conflicts of interest.[9] 
Few studies[7] have examined the financial ties of members of panels reviewing and 
changing definitions of common conditions, whether as part of practice guideline 
development or other processes. Our aim was to identify guideline panels in the US setting 
that have most recently made decisions about definitions or diagnostic thresholds for 
common conditions, and to report on any proposed changes and their industry ties. 
Methods 
List of Conditions 
On the basis of the method previously used by Choudhry and colleagues,[10] we derived a 
list of common conditions in the United States, drawing from a list of the ten most costly 
adult diseases,[11] the top 20 therapeutic classes of drugs, and the top 25 individual drugs 
by expenditure.[12] Consistent with that method, drugs used to treat many non-specific 
conditions were excluded (e.g., pain killers). For situations in which a drug was approved 
for a number of conditions, we identified the most common condition for inclusion (e.g., 
etanercept ultimately mapped to rheumatoid arthritis, not psoriatic arthritis). If a condition 
in the top ten costly disease list was too broad or diffuse, or covered many specific 
conditions, it was excluded (e.g., back problems). A flowchart of the method appears in 
figure 2. 
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Figure 2. Flowchart identifying study conditions and panels reviewing definitions. 
 
 
 Note: bipolar/depression was one panel. 
 
  
We aimed to identify the most recent publication from panels making decisions about 
disease definition and diagnosis. A panel publication was eligible for inclusion if it was 
generated or supported by a widely recognised US-based organisation, published between 
2000 and April 2013, and included deliberations and decisions on disease definitions and/or 
diagnostic criteria, classification, or assessment. If the panel made decisions, but proposed 
no changes, our search would continue for the most recent publication proposing changes, 
to include as well. If the focus of the panel publication was limited to specific sub-groups of 
patients, (e.g., adolescents), specific sub-categories of the condition (e.g., work-related 
asthma), it came from a single entity (e.g., a health maintenance organisation), or it included 
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treatment recommendations but no review and deliberation on disease definition or 
diagnostic criteria, it was excluded. 
During a pilot phase, using the searches for the most recent hypertension and asthma panel 
publications, an explicit search strategy using standardized keywords was iteratively 
developed in order to maximise sensitivity. We searched Medline (Ovid) using terms for 
each disease/condition and combined these terms with a standardized search strategy 
consisting of a string of MeSH and keyword terms to identify panels and publications 
(example in Table S1). Searches were run over 26–31 July 2012, updated 17–18 April 2013, 
and limited to English language from 2000. 
To further improve sensitivity and try to ensure recent publications were not missed, two 
authors (RM, GC) independently analysed the results of the standardised Medline searches 
for all conditions, and supplemented this with independent individual searches of the 
websites of the relevant National Institutes of Health and the National Guideline Clearing 
House. For two conditions, minor discrepancies in independent suggestions were resolved 
by discussion and, in one case (diabetes II), by consultation with a third author (PPG). 
Because of their global prominence and influence, if a panel was constituted under the 
umbrella of the National Institutes of Health (NIH), or the American Psychiatric 
Association's DSM, and met our inclusion criteria, these panels were identified for inclusion 
in our study. If there was a more recent panel publication that also met the study's inclusion 
criteria, in addition to the NIH or DSM panel, we included the more recent publication as 
well. This occurred twice (asthma and high cholesterol), resulting in two publications being 
identified for each condition. 
Information on the Panels' Decisions 
For each publication we extracted information on key proposed changes to 
definitions/diagnostic criteria, the rationale offered, and any mention of potential harms 
associated with the proposed changes (e.g., overdiagnosis, overtreatment, medicalising 
normality, labelling asymptomatic people). All six authors then made an assessment of 
whether the panel's proposed key changes would tend to widen (e.g., earlier diagnosis, 
lower thresholds, adding symptoms, increasing numbers diagnosed) or narrow the disease 
definition, or whether it was unclear. 
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Information on Industry Ties 
Using published disclosure sections from the panel publications, duplicate independent 
extraction of data was conducted (RM and research assistant Peter Coxeter), with a third 
party resolving any disagreement (PG). Ties were categorized as speaker/honorarium, 
consultant/adviser, grant/research, stock, employee, travel, or royalties. Panel members were 
those listed as authors or identified as the group with primary responsibility for generating 
the publications. In line with the IOM approach,[5] an industry tie was defined as a tie to a 
pharmaceutical, diagnostic, device, or biotechnology company, but not a communications or 
medical education company. If there was any lack of clarity as to the nature of the company, 
or uncertainty if it met study criteria, a tie was not recorded. Once all industry ties were 
recorded for each panel, websites of companies with financial ties to the three highest 
proportions of panel members were searched to determine whether those companies were 
active in the specific therapeutic area. Where they appeared in disclosure sections, the 
disclosure of any ties to public agencies, non-government organizations, and publishers was 
also recorded. 
Results 
After analysing source documents,[11,12] the following drug classes, individual drugs, and 
conditions were excluded when identifying study conditions, as they were too non-specific 
or too broad, and did not map to specific conditions enabling analysis: oncologics; 
autoimmune diseases; narcotic analgesics; anti-epileptics; vaccines; hormonal contraceptives; 
immunostimulating agents; bevacizumab; oxycodone; pegfilgrastim; cancer; trauma-related 
disorders; and back problems. 
From an initial list of 16 included common conditions, for two—osteoarthritis, HIV—we 
could identify no panel that made decisions about definitions or diagnostic thresholds since 
2000 in the US context specifically. For the remaining 14 conditions, we identified the most 
recent panels that deliberated and made decisions about disease definitions, all of which 
proposed changes. For asthma and high cholesterol we identified two panels each, one 
constituted under the government funded NIH, [13,14] and one by professional societies, 
[15,16] reflecting the two main types of panels identified in this study. A single panel, the 
DSM-V Mood Disorders working group, proposed changes to two different conditions, 
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bipolar and depression, in two separate web-based publications.[17] A full list of the final 14 
conditions, 15 panels and 16 publications, key changes and rationale, analysis of panel 
decisions, and disclosed ties appears in Table 2. 
Table 2. Conditions and characteristics of the panels and publications included in the 
study. 
 
 
Among 16 publications, all authors in our study agreed that proposals in ten publications 
would tend to widen definitions (Table 3) and for one, narrow the definition. For the 
remaining five publications the impact was unclear. Rationales for the benefits of widening 
definitions or expanding diagnostic categories included: evidence about the risk of future 
adverse events for people previously considered normal (pre-hypertension); simplification 
(gastroesophageal reflux disease [GERD]); standardisation for research (rheumatoid 
arthritis); and the emergence of new evidence about biomarkers, tests, or treatments 
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(Alzheimer disease). Among 15 panels, six included mention of possible harms of proposed 
changes (Table 4), albeit briefly, with three of those including citations in that mention,[17-19] 
two citing primary studies,[18,19] and one of those citing a review of primary studies as 
well.[18] One publication referred to the potential negative consequences for those who 
would be labelled by the expanded definition,[20] and only one referred to 
overdiagnosis.[21] 
Table 3. Different ways to expand disease definitions. 
 
Table 4. Mention of possible harms of proposed changes to definitions. 
 
 
The average number of panel members was 21 (range, five to 52). Among 15 panels, 12 
included members disclosing financial ties to multiple companies, one panel disclosed ties to 
a single company only (GERD),[21] one stated that members had no relevant conflicts of 
interest (diabetes II),[22] and one had no disclosure section (high cholesterol 2002),[14] also 
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the oldest panel. For a total of 2,081 individual ties across all categories recorded in the 
study, there were 55 discrepancies, 2.6%, arising from the independent extraction, mainly 
involving one or other extractor accidentally missing or adding a specific tie, or making 
errors by entering a specific tie into an adjacent column or row in a spreadsheet. All were 
resolved by discussion. 
Among 14 panels with disclosure sections, the average proportion of members with industry 
ties was 75% (range 0%–100%) (Table 5). For members with ties, the median number of 
pharmaceutical or device companies to which they had declared ties to was seven (Table 5). 
For the nine panel publications disclosing multiple separate categories of tie, on average, 
members with industry ties were a consultant/adviser for four companies, received speaker 
fees/honoraria from two companies, and they or their institutions received research support 
from three. Twelve panels were chaired or publications led by authors with industry ties, 
most commonly to multiple companies. Among panels disclosing any ties to government 
agencies, non-government organisations, or publishers, on average around one-third of 
panel members disclosed these ties.  
Table 5. Nature and extent of disclosed ties, by panel. 
 
 
For the 12 panels for which ties were disclosed to more than one company, almost all 
companies with ties to the three highest proportions of panel members were also active in 
the market for that panel's condition, with at least one drug on the market or in the research 
pipeline (Table 6). For example, with the chronic obstructive pulmonary disease [COPD] 
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publication, Astra Zeneca, Boehringer-Ingelheim, and GSK—all companies with drugs for 
the condition—each had financial ties to 11 of 12 members, including the chair.[18] With the 
DSM-V Mood Disorders work group, Pfizer and Lilly—with drugs for depression and 
bipolar—had ties to five of the 12 members.[17] Similarly, companies marketing 
hypertension drugs—Bristol-Myers Squibb, Merck, Novartis—each had financial ties to 
eight of the 11 members of the panel which created the new diagnostic category “pre-
hypertension”.[23] 
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Table 6. Companies with highest proportions of ties, and drugs in therapeutic area. 
 
 
To evaluate any potential impact of the IOM recommendations regarding industry ties, we 
compared the panel publications released in 2012—after both IOM reports, [5,8]—to those 
released earlier. We found similar proportions of members disclosing industry ties (76% was 
the average across 2012 panels; 74% was the average across pre-2012 panels); a small 
reduction in the median number of companies to which those members disclosed ties in the 
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2012 panels (four in 2012 panels; seven pre-2012 panels); and similar proportions of panel 
publications widening definitions (four of six of 2012 publications; six of ten of pre-2012 
publications). 
Discussion 
In this cross-sectional analysis of panels making recent decisions on definitions of common 
conditions in the US context, we found most panels proposed widening definitions and most 
had a majority of members with multiple ties to pharmaceutical companies. Proposals to 
widen fell into three inter-related categories: creating new categories of “pre-disease”; 
lowering diagnostic thresholds; and proposing earlier diagnosis or different diagnostic 
methods (Table 3). In some cases a clear rationale was offered for these changes—as when 
the hypertension panel cited evidence from original studies and meta-analysis linking 
normal blood pressure with elevated risks as the reason to create “pre-hypertension”.[23] In 
other publications, including the 2007 panel proposing changes to the diagnosis of 
asthma,[13] the rational was less clear, more complex and diffuse. 
Notwithstanding the problem of under-diagnosis, a growing body of evidence suggests 
overdiagnosis may be occurring across a range of common conditions, including 
hypertension,[24] asthma,[25] attention deficit hyperactivity disorder (ADHD),[26] and 
COPD.[27] Yet less than half of the study publications mentioned potential harms of 
proposed changes to definitions, and none included a rigorous evidence-informed 
discussion of those risks or how they might be mitigated. 
In a three-part publication in 2011,[28-30] proposing new categories of “pre-clinical” 
Alzheimer disease (for research only at this stage) and “predementia”—which would clearly 
expand the population labelled—there was one short reference to the need to study the 
“ethical and practical implications” of diagnosing people at a “preclinical” stage.[30] The 
panel proposing changes to assessment and classification of COPD briefly mentioned that 
diagnostic methods “may lead to more frequent diagnosis of COPD in older adults with 
mild COPD as the normal process of aging affects lung volumes and flows”,[18] but did not 
explicitly refer to the risk of “overdiagnosis” as it had done in a previous version of its 
report.[31] Proposing changes to ADHD diagnostic criteria—in part to make the condition 
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more amenable to being a “lifespan” disorder involving adults as well as children—the 
DSM-V panel mentioned potential increases in prevalence but suggested they would be 
“negligible” (Table 4).[32] 
Among panels disclosing ties, almost all chairs had financial ties to industry, and an average 
of three-quarters of members had ties to a median of seven companies, commonly working 
as consultants, advisers and/or speakers, as well as receiving research support. Companies 
with financial relationships with the greatest proportion of panel members were marketing 
or developing drugs for the same conditions about which those members were making 
critical judgements. GSK for example, marketing top-selling products for asthma, had 
financial ties to 20 of the 24 members of the 2009 asthma panel, and all 20 were 
consultant/advisers and/or declared speaker/honoraria ties to GSK.[15] 
This study has several important limitations. First, the lack of a comparison group means it 
is impossible to draw any inference of association between frequency of industry ties and 
proposals to change disease definitions. The exclusion of common conditions too broad to 
enable a focussed analysis of single panel publications (e.g., back problems) means it may 
have missed potentially important examples of changing disease definitions and limits 
generalizability of findings. The focus on the United States—chosen explicitly because of its 
globally influential panels such as DSM-V workgroups—also limits generalizability. A 
fourth limitation is reliance solely on disclosed ties, likely leading to an underestimate of 
their extent. Finally, we note that while we tried to ensure an exhaustive and multi-layered 
search strategy, we are unaware of any established method for identifying panel 
publications that review or propose changes to disease definitions. 
Notwithstanding these limitations, the study has strong clinical, research, and policy 
relevance. Its novel focus on panels reviewing and proposing changes to common disease 
definitions or diagnostic criteria will help deepen understanding of the nature of what's 
been described as the “modern epidemic” of overdiagnosis.[2] Moreover, the group of 16 
publications includes influential articles affecting the definition of 14 common conditions 
and impacting directly on medical policy and practice around the world. 
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The study findings are consistent with and help augment the evidence-base about industry 
ties of influential medical professionals. The 2011 systematic review found 56%–87% of 
clinical guideline writers had conflicts of interest,[6] similar to our finding of 75% across 
disease-defining panels. Kung and colleagues found 71% of guideline committee chairs had 
conflicts,[9] again similar to our findings. While these proportions may reflect the level of 
ties among medical specialists more generally, they are in stark contrast to IOM 2009 and 
2011 reports calling for panels to generally exclude people with conflicts of interest.[5,8] As 
reported above, we found no change in the proportion of members disclosing ties in the 
2012 publications, after release of both IOM reports. 
At least two publications,[20,21] made reference to members believing industry ties did not 
influence their decision-making, and we make no suggestion to the contrary. Indeed our 
data do not support any inference industry ties are associated with widening definitions or 
failure to rigorously assess potential harms of that widening. With anemia in chronic kidney 
disease, a panel with a high proportion of ties raised thresholds, effectively narrowing the 
definition.[33] There will doubtless be other cases where diseases have been widened by 
panels of medical specialists without industry ties. Moreover, as Lurie and colleagues found 
in the context of drug regulation, the financial conflicts of expert advisory committees did 
not correlate significantly with their voting outcomes.[34] Medicalisation and overdiagnosis 
are driven by many factors—technological, professional, commercial, legal, and cultural.[3] 
While inferences of association or causation between industry ties and expanding disease 
definitions cannot be drawn, our findings can be considered in the context of broader 
evidence about potentially distorting biases associated with widespread industry 
sponsorship and financial ties in medical research,[35-37] education,[38] and practice,[5] and 
in relation to “key opinion leaders” who speak and consult for industry.[39] 
In 1999 Schwartz and Woloshin found changes to definitions of high blood pressure, high 
cholesterol, diabetes, and overweight would “dramatically inflate disease prevalence” and 
“ultimately label 75% of the adult U.S. population as diseased”.[40] They concluded the 
“extent to which new ‘patients’ would ultimately benefit from early detection and treatment 
of these conditions is unknown. Whether they would experience important physical or 
psychological harm is an open question.” To what extent newly created “patients” produced 
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by widening disease definitions will experience important harms remains a largely 
unanswered question, over a decade later. 
This study did not investigate the merits of the proposed changes to the conditions 
identified. However, findings that diagnostic thresholds are being lowered by panels 
dominated by those with financial ties to multiple companies that may benefit directly from 
those decisions raise questions about current processes of disease definition. While it may be 
more difficult to locate senior specialists without industry ties, two recent IOM reports have 
encouraged such a change,[5,8] and models already exist for panels free of such conflicts, 
including the NIH consensus development program.[41]  
Several unanswered questions arise from this study, which could benefit from further 
investigation. Researchers might fruitfully examine how definitions are changing over time, 
what dollar amounts are being received from industry by panel members and organisations 
that auspice them, and how panel proposals impact on potential markets of sponsors. Most 
importantly enhanced research and policy attention might be directed at designing new 
processes for reviewing disease definitions, free of financial conflicts of interest and 
informed by rigorous analysis of benefits and harms. 
 
Supplemental Table S1: Asthma Search Strategy  
 
Database: Ovid MEDLINE(R) <1946 to July Week 2 2012> 
Search Strategy: Asthma 
-------------------------------------------------------------------------------- 
1     consensus/ (3929) 
2     exp guideline/ (22675) 
3     (consensus or report or recommend* or "position paper" or statement or guidance or 
guideline*).ti. (397131) 
4     or/1-3 (407005) 
5     ((expert* or advisory or scientific or review or national or working or professional or 
governing) adj3 (panel or group or meeting or conference or committee or board or agenc* 
or body)).tw. (50995) 
6     (taskforce or "working party" or association or societ*).tw. (774846) 
7     5 or 6 (816637) 
8     4 and 7 (36140) 
9     exp *Asthma/ (80805) 
10     exp Asthma/cl, di [Classification, Diagnosis] (13608) 
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11     (asthma* and (class* or diagnos* or defin*)).tw. (21202) 
12     asthma.ti. (56667) 
13     or/9-12 (92056) 
14     8 and 13 (314) 
15     limit 14 to (english language and yr="2000 -Current") (154) 
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Summary  
• Clinical context—Concern about the late presentation of kidney disease and missed 
opportunities for earlier intervention 
• Diagnostic change—A novel framework defining and classifying “chronic kidney 
disease” (CKD) introduced in 2002 and modified in 2012, based largely on laboratory 
measurements of kidney function and damage 
• Rationale for change—Identifying chronic kidney disease early would slow 
progression towards total kidney failure and provide an opportunity to prevent 
associated illness, particularly cardiovascular disease 
• Leap of faith—Identifying, monitoring, and treating the newly described chronic 
kidney disease will improve survival and quality of life  
• Increase in disease—The new definition labels over 1 in 8 adults (around 14%) as 
having chronic kidney disease. Before 2002 the lack of a consistent definition made 
prevalence estimates unreliable, but one US study suggested a figure of 1.7% of the 
population. 
• Evidence of overdiagnosis—The combination of the large numbers now labelled as 
having chronic kidney disease with low rates of total kidney failure suggest many of 
those diagnosed will never progress to symptomatic forms of kidney disease 
• Harms from overdiagnosis—Psychological effect of a disease label and the burden and 
costs of repeated assessment, testing, and potentially unnecessary treatment 
• Limitations—Lack of prospective data evaluating the benefits and harms of testing for, 
monitoring, and treating the early stages of chronic kidney disease 
• Conclusions—Clinicians should be sceptical about the current definition of chronic 
kidney disease and cautious about labelling patients, particularly older people  
  
Preventing Overdiagnosis 
 
 
89 
 
 
In 2002 the United States Kidney Foundation launched a novel framework for defining and 
classifying chronic kidney disease.[1] The framework was widely embraced because it 
imposed order in a chaotic landscape characterised by a variety of names, including renal 
insufficiency, renal impairment, and renal failure. It has had an appreciable effect on clinical 
care worldwide through guidelines,[2] pay for performance measures,[3] and sparked 
debate on the merits of screening programmes.[4] However, it has also generated 
considerable controversy.[5-7] We examine the rationale for the framework, the varying 
responses and controversies it has provoked, and provide advice for clinicians who are 
being faced with an increasing number of people categorised as having chronic kidney 
disease. 
Changes in definition and diagnostic criteria  
Two centuries ago Bright’s description of the associations between kidney disease and 
albumin in the urine of patients with dropsy was hailed as one of the first practical modern 
aids to diagnosis. Starting with Homer Smith in the 1930s, estimates of “renal clearance” 
emerged as measures of kidney function, leading most recently to the development of 
equations using various serum biomarkers, such as creatinine or cystatin C, for estimating 
the glomerular filtration rate (GFR). 
The 2002 framework uses the term “chronic kidney disease” to include conditions that affect 
the kidney, with the potential to cause either progressive loss of kidney function or 
complications resulting from decreased kidney function. Chronic kidney disease was 
defined as the presence of kidney damage or decreased kidney function for three months or 
more, irrespective of the cause.[1] It relies largely on two laboratory measures: an estimate of 
glomerular filtration rate (eGFR) based on serum creatinine or cystatin C levels and an 
assessment of kidney damage, derived from a range of tests, most commonly increased 
albumin in the urine (albuminuria). A single threshold for eGFR, <60 ml/min/1.73 m2 
uncalibrated for age or sex, was arbitrarily adopted to define chronic kidney disease. 
Similarly, ≥3 mg albumin/mmol creatinine in a random urine sample identified albuminuria. 
Initially, the framework set out five stages of chronic kidney disease, largely based on eGFR, 
ending with total kidney failure or end stage renal disease. Modifications followed, with 
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2012 guidelines dividing stage 3 (eGFR 30-59 ml/min/1.73 m2) into 3A (30-44 ml/min/1.73 m2) 
and 3B (45-59 ml/min/1.73m2) and adding three extended categories for persistent 
albuminuria (fig 3).[8] These are in line with previous changes made in the classification 
adopted by the National Institute for Health and Care Excellence (NICE) in the UK.[2]  
Figure 3: Prevalence of chronic kidney disease in the US by 2012 classification. 
 
Data on 18  026 adults from the National Health and Nutrition Examination Survey 1999-2006. Values in cells do 
not total to values in margins because of rounding. Green=low risk (if no other markers of kidney disease, no 
CKD), yellow=moderately increased risk, orange=high risk, red=very high risk. Reproduced with permission[8] 
 
Rationale for change  
The stimulus for the 2002 framework was the absence of an agreed definition and 
classification of kidney disease and evidence that people were experiencing avoidable harm 
through late presentation of serious kidney disease, including disproportionate numbers of 
African Americans,[4] and the Australian aboriginal community.[9]  
A key rationale for the new definition arises from evidence showing decreased eGFR and 
albuminuria are associated with increased risk of death or end stage renal disease.[10] The 
CKD Prognosis Consortium, an international research group, conducted a meta-analysis of 
published data from over two million people and concluded that “measures of kidney 
function and damage are independently associated with mortality and end stage renal 
disease regardless of age across a wide range of populations.”[10] A second and related 
rationale comes from meta-analyses showing that reduced eGFR or albuminuria were 
consistently associated with cardiovascular mortality.[11, 12]  
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The assumption was made that earlier identification and treatment could slow, stop, or 
reverse progression towards end stage renal disease.[1] The 2002 guidelines stated that 
treating early chronic kidney disease is “effective in slowing the progression toward kidney 
failure,” with optimism largely directed at patients with more severe forms of specific 
kidney diseases manifested by marked proteinuria or rapidly declining eGFR.[1] A decade 
later, however, the National Kidney Foundation website stated that a suite of claims about 
benefits of early detection and treatment of generic chronic kidney disease “remains to be 
proven in appropriately powered randomized trials.”[13] Similarly, the US Preventive 
Services Task Force, which recently found there was insufficient evidence to recommend 
general population based screening, reported that although identifying and treating chronic 
kidney disease may affect outcomes for people with established specific conditions, 
including diabetes or hypertension, there were no studies on the benefits of early treatment 
in people without them.[4]  
Who developed the framework? 
The framework was drawn up and published in 2002 by the Kidney Disease Outcomes 
Quality Initiative under the auspices of the US National Kidney Foundation. The guideline 
that launched the framework was supported by a pharmaceutical company.[14] In the face 
of confusion and criticism of the potential for the framework to lead to overdiagnosis, 
specialist international meetings were held in 2004, 2006, and 2009 to discuss modifications. 
In 2012 new guidelines reaffirmed the key elements of the 2002 guidelines, with 
modifications including dividing eGFR based stage 3 into 3A and 3B subcategories and 
formally adding three extended categories for albuminuria to the diagnostic matrix.[8] Nine 
of the 16 working group members who produced the 2012 guidelines declared financial ties 
to drug or device companies, though they stated every effort was taken “to avoid any actual 
or reasonably perceived conflicts of interest.”[8] The body responsible for developing the 
guidelines has disclosed funding from a consortium of pharmaceutical or device 
manufacturers, though not for the “development of specific guidelines.”[8]  
Effect of framework on disease prevalence  
Although it has long been recognised that kidney function declines with age and differs for 
men and women (fig 4), the threshold eGFR chosen to define disease was set at 60 
ml/min/1.73 m2, about half that of the normal level of a young adult.[8] Under the 2002 
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framework anyone with an eGFR below 60 ml/min/1.73 m2 for three months or longer can 
be diagnosed as having chronic kidney disease stage 3A or greater, irrespective of their age 
or sex and even if they have no other overt signs of kidney damage, such as moderate or 
severe albuminuria.  
Figure 4. Median eGFR rates for healthy white men and women by age.  
Redrawn with permission[5]  
 
 
 
The adoption of this definition has resulted in more than 1 in 8 adults (almost 14%) in the US 
being labelled as having chronic kidney disease[8,15] and as many as 1 in 6 adults in 
Australia.[16] Before the 2002 framework, estimates of prevalence varied widely depending 
on which threshold and definition was being used. For example, one study published in 
2001, which used abnormal serum creatinine values (adjusted for sex) persisting for three 
months or more in people enrolled in a health maintenance organisation, estimated that 4.2 
million Americans (1.7%) had chronic kidney disease.[17] 
At least a third of the people who meet the new definition of chronic kidney disease are 
classified as stage 3A.[8] Most of them are older than 65 years of age, with more women than 
men, and many will have an eGFR that falls within the normal range (5th to 95th percentile) 
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for their age.[5] Around three quarters of these have no urine markers of kidney damage, 
such as albuminuria.[18]  
Response to the framework 
The chronic kidney disease framework has been adopted by groups in many countries 
including the United States, Australia,[19] and the United Kingdom.[2] One organisation has 
made substantial modifications to the framework. Kaiser Permanente in Southern California 
has adapted the framework using a formula to take age into account,[20] reducing the 
prevalence of chronic kidney disease in its insured population to about 3% compared with 
the almost 14% estimate arising from the framework definition.  
Evidence of overdiagnosis  
The use of a single threshold of an eGFR of 60 ml/min/1.73 m2 without calibrating it for age 
or sex means that around half of people aged 70 years or more are being labelled or at risk of 
being labelled as having chronic kidney disease.[21] However, Dutch researchers have 
shown that an eGFR of 60 ml/min/1.73 m2 is “within the normal reference range” for men 
over 60 years and women over 50 years and “cannot be used to define a diseased 
population.”[5]  
Advocates of the definition claim that “early detection can help prevent the progression of 
kidney disease.”[22] But while 1 in 8 adults in the US may now be labelled as having chronic 
kidney disease, only around 1 in 3000-5000 are being newly treated for end stage renal 
disease each year.[15] In a study in a Norwegian county published in 2006, which surveyed 
65 000 members of the general population with a median age of 49 less than 1% of people 
with an eGFR of 45-59 ml/min/1.73 m2 (stage 3A disease) went on to develop end stage renal 
disease after eight years of follow-up.[23] Based on this, it is estimated that thousands of 
people with stage 3A disease may need to be treated to prevent one case of end stage 
disease,[24] raising questions about opportunity costs to health systems. A systematic 
review of screening and treatment concluded that although some treatments reduced the 
risk of end stage renal disease in selected patients with chronic kidney disease, “many of 
these patients may already warrant treatment with these therapies regardless of CKD 
status.”[25] 
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Although early detection might benefit some people, by labelling so many people at low risk 
of symptoms as having chronic kidney disease, the new definition axiomatically produces 
overdiagnosis: “like a fishing trawler it captures many more innocent subjects than it 
should.”[26] The current definitions may misclassify at least 30% of elderly people as having 
stage 3 disease,[18] with those classified as stage 3A without albuminuria at highest risk of 
overdiagnosis. 
Concern among primary care physicians and specialists  
Primary care doctors have expressed concern about the framework (Inside Health, BBC 
Radio 4, 15 August 2012),[24] and a qualitative research study conducted in a representative 
group of general practitioners and practice nurses across England found nearly all had 
“reservations as to whether CKD was really a disease,” with some expressing concern about 
the medicalisation of the ageing process and the attendant potential for unintended harm.[27] 
The website of the United Kingdom National Kidney Foundation, a charitable patient 
organisation, explains that “Often CKD is only a very slight abnormality in the kidneys” and 
that “many of the elderly people with CKD may . . . have normal ageing of their 
kidneys.”[28]  
Uncertainties about what the evidence shows  
Acknowledging concern about the risk of overdiagnosis, proponents have continued to 
defend the use of an eGFR threshold of <60 ml/min/1.73 m2 to define chronic kidney disease 
by referring to the meta-analyses showing its associations with end stage renal disease and 
cardiovascular and all-cause mortality.[10-12] Although these analyses provide complex and 
important evidence, they are open to differing interpretations.[29,30] Some argue that the 
meta-analysis of data on end stage renal disease “neither supports nor refutes” the use of the 
60 ml/min/1.73 m2 threshold uncalibrated for age and sex for delineating chronic kidney 
disease.[31] 
In relation to the associations with cardiovascular disease, questions remain about the extent 
to which a diagnosis of chronic kidney disease—as currently defined—adds meaningfully to 
the traditional assessment of risk,[32, 33] and whether these associations justify current 
laboratory based thresholds to diagnose chronic kidney disease. Firstly, in terms of 
uncertainty, estimations of such associations have important limitations, including 
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establishing appropriate reference points for comparisons, problems with standardising 
measurement, and a lack of a uniform protocol across study cohorts.[11,12] Secondly, some 
studies suggest that the designation of chronic kidney disease may not meaningfully add to 
the predictive ability of traditional cardiovascular risk factors.[33-35] For example, 
Angelantonio and colleagues found the clinically relevant incremental gain provided by 
chronic kidney disease was “about a sixth that provided by history of smoking.”[33] 
Uncertainties about the reliability of laboratory measurements  
Although new estimating equations have improved the precision and reliability of eGFR 
measurements, problems with inaccuracy remain.[21] This is one reason why the framework 
requires that abnormal measurements persist for three months or more.[7] However, 
because eGFR levels can change over time, it is likely that many people would not be 
categorised as having chronic kidney disease if a longer period were required before 
diagnosis. A Norwegian study involving measurements from over 38 000 patients suggests 
that if the definition of disease required that an abnormality persists for 12 months, this 
could reduce the prevalence of stage 3 disease by 37%.[7]  
There is also uncertainty about what concentration of albumin in the urine constitutes 
clinically “meaningful” kidney damage and how levels contribute to increased risk of future 
adverse events. Moderate albuminuria (defined as a urine albumin to creatinine 
concentration ratio of 3-30 mg/mmol (30-300 mg/g) and formerly known as 
microalbuminuria) is not pathognomonic of persisting chronic kidney damage. It can be 
transitory and is affected by many extraneous factors, including high fever, vigorous 
exercise, smoking, obesity, medications, and diet.[36] A third of people who are identified as 
having kidney damage on the basis of moderate microalbuminuria may shed that label 
when re-tested up to two months later.[37]  
Potential harms from overdiagnosis 
The United States Preventive Services Task Force identified the most important potential 
harm of screening as “Patients could be falsely identified as having CKD and receive 
unnecessary treatment and diagnostic interventions.”[4] Management of early disease 
mostly consists of tight management of blood pressure, and as the task force has pointed out 
the potential benefits of identifying and treating people at risk of cardiovascular disease 
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through any screening programme for chronic kidney disease have to be weighed against 
the harms from the side effects of drugs and the risk of bringing blood pressure to 
excessively low levels.[4] In addition there is concern about the adverse effects of labelling 
healthy and asymptomatic people as having chronic kidney disease.[38,24,27] Studies of 
hypertension suggest that more disease labelling could increase psychological distress, 
absenteeism from work, and decrease quality of life.[39]  
Cost implications  
More routine reporting of kidney function since the advent of the 2002 framework has 
substantially increased specialist referrals for chronic kidney disease, with referrals up 60% 
within a single NHS trust covering a population of 560 000 people, according to a University 
of Cardiff study,[40] and up 40% in two hospitals in Brisbane, Australia.[41] In the United 
Kingdom general practitioners have been asked to form registers of those with chronic 
kidney disease and monitor people. An analysis of the cost and benefits of moving to 
reporting eGFR in routine blood analyses by den Hartog and colleagues found a far higher 
number of patients falsely diagnosed with chronic kidney disease and that “any small 
benefit in cost effectiveness was offset by potential adverse consequences of incorrectly 
diagnosing CKD.”[42]  
How to do better 
It is not clear that the current markers of early renal dysfunction, either eGFR or 
microalbuminuria, are useful in identifying those patients who are at most risk of 
symptomatic renal disease. Further research is needed to better identify which patients are 
at greatest risk of a modifiable form of chronic kidney disease that without intervention 
would progress to symptomatic advanced disease. Until better methods are available, we 
suggest that clinicians consider the age of the patient and the trajectory of eGFR or urinary 
albumin test results, and acknowledge to patients that at the moment it is uncertain whether 
mildly reduced renal function in the absence of other risk factors should be treated or not 
(see box 3). If a patient is found to have reduced renal function on a single test, the current 
guidance to confirm the result with another test soon after the first and that another test 
should be conducted after three months, should be followed.  
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Conclusions  
The benefits, harms, and costs of testing, monitoring, and treating the increased number of 
people being identified as having chronic kidney disease need to be established by 
prospective studies. Meanwhile the risk of overdiagnosis warrants greater professional 
scrutiny and more public awareness. Clinicians should be careful not to apply disease labels 
to the many older people whose eGFR falls within the definition of chronic kidney disease 
but who are at very low risk of developing clinical problems. The fact that Kaiser 
Permanente explicitly attempted to avoid labelling “low risk elderly” people and adopted a 
higher threshold reinforces the argument for reviewing the 2012 framework. A review 
should be conducted by a panel with broad representation from specialty and primary care, 
population health, patient organisations, and civil society with minimal conflicts of interest. 
It is in everyone’s interest to find the best way to maximise prevention of kidney disease and 
its consequences while minimising the risks and cost of overdiagnosis. 
Box 3. Suggestions for clinicians  
Be informed about the controversy and debate over methods used to define chronic kidney 
disease  
Share uncertainty about appropriateness of diagnostic thresholds and reliability of 
measurements with patients 
Look for other changes that support the diagnosis—for example, is there evidence of 
anaemia, abnormal urinalysis results, or abnormalities on renal ultrasonography? 
Be aware of the variability in measures of kidney function (eGFR and albuminuria) and the 
need to repeat the test to confirm reduced renal function 
Don’t routinely use the label chronic kidney disease for people aged 65 years and older with 
eGFR stage 3A and no albuminuria 
Older people with stable but modestly reduced eGFR (45-59 ml/min/1.73 m2) are unlikely to 
have a high risk of future adverse events unless they have persistent overt albuminuria  
 
This article is part of a series on overdiagnosis looking at the risks and harms to patients of expanding 
definitions of disease and increasing use of new diagnostic technologies. 
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Abstract 
 
Background 
Despite evidence about the "modern epidemic" of overdiagnosis, and expanding disease 
definitions which medicalise more people, data are lacking on public views about these 
issues. Our objective was to measure public perceptions about overdiagnosis, and views 
about financial ties of panels setting disease definitions. 
Methods and Findings 
We conducted a 15 minute Computer Assisted Telephone Interview with a randomly 
selected community sample of 500 Australians in January 2014. We iteratively developed 
and piloted a questionnaire, with a convenience sample(n=20), then with participants 
recruited by a research company(n=20). Questions included: whether respondents had been 
informed about overdiagnosis; opinions on informing people; views about financial ties 
among panels writing disease definitions. 
Our sample was generally representative, but included a higher proportion of females and 
seniors, typical of similar surveys. American Association for Public Opinion Research 
response rate was 20% and cooperation rate, 44%. Only 10% (95% CI 8%-13%) of people 
reported ever being told about overdiagnosis by a doctor. 18% (95% CI 11%-28%) of men 
who reported having prostate cancer screening, and 10% (95% CI 6%-15%) of women who 
reported having mammography said they were told about overdiagnosis. 93% (95% CI 90%-
95%) agreed along with screening benefits, people should be informed about overdiagnosis. 
On panels setting disease definitions, 78% (95% CI 74%-82%) felt ties to pharmaceutical 
companies inappropriate, and 91% (95% CI 82%-100%) believed panels should have a 
minority or no members with ties. Limitations included questionnaire novelty and 
complexity.  
Conclusions 
A small minority of Australians surveyed, including those reporting being screened for 
prostate or breast cancer, reported being informed of overdiagnosis; most believed people 
should be informed; and a majority felt it inappropriate doctors with ties to pharmaceutical 
companies write disease definitions. Results suggest strategies to better inform people about 
overdiagnosis, and review disease definition processes, have significant public sympathy. 
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Introduction 
The “modern epidemic” of overdiagnosis is now recognised as an important risk to 
health,[1,2] with evidence-based efforts underway to combat it.[3] Overdiagnosis occurs 
when someone is diagnosed with a disease that would not have harmed them,[2] often as a 
result of undergoing screening, and evidence is emerging that many people are 
overdiagnosed and labelled unnecessarily across a range of conditions.[4] An inquiry in the 
United Kingdom estimated 19% of the breast cancers detected during mammography 
screening may be overdiagnosed,[5] and the United States Preventive Services Task Force 
recently noted there is “convincing evidence that PSA-based screening leads to substantial 
overdiagnosis of prostate tumors”, with estimates ranging from 17% to 50%.[6]  
While there is on-going scientific discussion about the best methods for measuring 
overdiagnosis, and debates about strategies for reducing avoidable overdiagnosis without 
increasing under-diagnosis, there is now official recognition of the need for greater 
awareness of the problem. As a working group convened under the auspices of the National 
Cancer Institute has observed, “Physicians, patients, and the general public must recognize 
that overdiagnosis is common and occurs more frequently with cancer screening”.[7]  
Screening programmes are one of many causes of overdiagnosis including technological 
changes enabling detection of ever-smaller abnormalities, commercial interests seeking 
wider markets, the medicalisation of risk and cultural enthusiasm for early detection.[2] 
Overdiagnosis can also be seen as one aspect of much broader processes of 
biomedicalization.[8] “In the biomedicalization era” wrote sociologists Clarke and 
colleagues “what is perhaps most radical is the biomedicalization of health itself”, an era 
when “it is no longer necessary to manifest symptoms to be considered ill or ‘at risk’”.[8] 
Armstrong has also described the inexorable rise of “surveillance medicine”, which 
reconstructs the nature of disease to become “less the illness per se but rather the semi-
pathological pre-illness at-risk state.”[9] More recently, in a series in The BMJ, researchers are 
investigating how  expanding disease definitions which label more people with milder 
symptoms or at lower risks are increasing the potential for overdiagnosis, with examples 
including thyroid cancer,[10], gestational diabetes,[11] and pulmonary embolism.[12]   
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A 2013 study of the guideline panels which recently changed definitions of 14 common 
conditions found a majority widened those definitions - including creating pre-
hypertension, expanding the diagnosis of myocardial infarction, and lowering diagnostic 
thresholds for Attention Deficit Hyperactivity Disorder.[13] In addition panel publications 
did not generally report potential harms of these changes, including risks of overdiagnosis, 
and among panels which made disclosures, 75% of members had multiple ties to 
pharmaceutical companies benefiting directly from any increase in populations classified as 
patients. This finding of extensive conflicts of interest among medical professionals who 
define human disease is in stark contrast to recommendations from the Institute of Medicine 
that guideline panels should wherever possible exclude members with conflicts.[14]  
While overdiagnosis and expanding disease definitions are recognised as important and 
related problems, data on public awareness and views about them are extremely limited. In 
2004, Schwartz and colleagues found widespread enthusiasm for cancer screening, largely 
unmodified by awareness of potential harms.[15] More recently Hersch and colleagues 
published focus group data on Australian women’s views on overdiagnosis of breast cancer, 
finding high enthusiasm for screening and minimal awareness of overdiagnosis, but also a 
demand for information about the topic.[16] In 2013 an on-line survey of 317 people invited 
to cancer screening found under 10% were informed by their doctor about the risk of 
overdiagnosis and overtreatment, and 80% expressed a desire to be informed about these 
risks.[17] To our knowledge, no previous survey has asked the general community about 
perceptions and views on overdiagnosis. And while there is data on public views about 
different aspects of industry-health professional relationships,[18,19] no study has sought 
community views specifically about ties of panels which change disease definitions.  
We aimed to measure the general community’s awareness and perceptions about 
overdiagnosis and views about financial ties of panels which set disease definitions and 
diagnostic thresholds. Notwithstanding important limitations outlined below, we believe 
our results will help inform attempts to better communicate about overdiagnosis.  
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Methods 
We conducted a national Computer Assisted Telephone Interview (CATI) survey with 500 
members of the Australian community aged 18 years and older, using a randomly selected 
dual frame sample - including land-line and mobile phones - during January and February 
2014.  The survey questionnaire included items about awareness of overdiagnosis, 
experience of being informed about overdiagnosis during screening, enthusiasm for genetic 
screening, and attitudes to financial ties of expert panel members who change disease 
definitions. It also collected demographic information on age, gender, employment, 
education, and cancer history. Questions were iteratively developed jointly by all authors, 
based on published and unpublished findings including from focus groups on views about 
overdiagnosis with 50 women of diverse age and educational background,[16] a qualitative 
study on patient attitudes,[20] and the 2004 survey of attitudes towards screening.[15]   
Draft items were piloted initially by three authors (RM, BN, JH) with a convenience sample 
of 20 adults. Then 20 pilot telephone interviews were conducted by an experienced social 
research company, the Social Research Centre, which subsequently conducted 500 
interviews.  
The survey sample size of 500 was chosen as appropriately powered so that the confidence 
interval around the proportion responding affirmatively would be approximately 4% either 
side of the observed proportion for the expected responses to key questions on awareness of 
overdiagnosis (expected response around 20%), enthusiasm for screening (expected 
response around 80%), and belief people should be made aware of risks (expected response 
around 80%).  
A dual frame random digit dialling sample design was employed with a 50:50 split between 
landline and mobile samples. After calling the randomly selected telephone numbers, 
interviewers asked to speak with the person in the household aged 18 years or over who had 
the last birthday (landlines) or confirmed if the person answering was over 18 years 
(mobiles). A slightly modified approach was adopted after approximately 400 interviews, in 
order to target more difficult to reach demographic groups, notably males and young adults. 
Rather than asking for the person with the last birthday, the modified screening approach 
requested to speak with the youngest adult male. Once a potential interview was 
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established, interviewers provided information about the research purpose and process, and 
obtained informed consent.(see Ethics Statement below)  Answer options included yes/no 
answers, and Likert type scales to offer more options for intensity of response.  
The survey took approximately 15 minutes to complete. Key questionnaire questions and 
the brief explanation of overdiagnosis offered to participants after the question on 
unprompted awareness are listed in Box 4. Other questions are available at Appendix 1. An 
open-ended item and a separate section on concern and treatment preferences relating to 
ductal carcinoma in situ terminology are being separately analysed and reported elsewhere.  
At the questionnaire conclusion, participants were asked if they would like to participate in 
a follow-up qualitative interview about similar topics, and if so, provide name and contact 
details. 
Box 4. Survey Questions 
 
Survey Question Response Format 
On awareness and opinions about overdiagnosis  
 
Have you seen or heard the term ‘overdiagnosis’ before today? 
 
Yes 
No 
Don’t know 
A generally accepted view is that overdiagnosis happens 
when people are diagnosed with a disease that would never 
have harmed them. This could be due to the condition being 
so slow developing or them displaying only very minor 
symptoms.  
Given this explanation, have you seen or heard the term 
or concept of ‘overdiagnosis’? 
 
 
 
Yes 
No  
Don’t Know 
 
Has a doctor ever told you that healthy people can be over-
diagnosed as a result of being screened or tested for a disease?  
Yes 
No 
Don’t Know 
 
[For those who reported being screened for prostate or breast 
cancer]:  Were you told about the risk of overdiagnosis? 
Yes 
No 
Don’t Know 
 
Do you think routine screening tests for healthy people are 
almost always a good idea? 
Yes 
No 
Don’t Know 
When healthy people are considering having a screening test - 
along with being told about the potential benefits of the 
screening test –  do you agree or disagree that they 
should be informed about the potential risk of 
overdiagnosis?  
7 point Likert scale: 
Completely Agree  
to 
Completely Disagree 
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On enthusiasm for genetic screening 
 
 
Imagine that there was a genetic screening test which could 
analyse your genes and identify all the diseases you may 
ever get, for which some had effective treatments and 
some did not. Would you be likely or unlikely to have 
that screening test? 
7 point Likert scale: 
Completely Likely 
To 
Completely Unlikely 
 
Imagine now that the results of the genetic screening test were 
often uncertain, and the predictions could be wrong. Would 
you be likely or unlikely then to have that screening test? 
7 point Likert scale: 
Completely Likely 
To 
Completely Unlikely 
 
On expert disease panel ties to pharmaceutical companies 
 
From time to time, doctors who specialise in a particular 
disease will come together to discuss the characteristics of that 
disease, to decide who should be diagnosed with it and who 
requires treatment for it. These are called panels and currently 
some doctors on these panels have financial ties with 
pharmaceutical companies who market drugs for that disease 
and some do not. 
Is it appropriate or inappropriate for doctors who have 
financial ties with pharmaceutical companies to be members of 
these panels? 
 
 
 
7 point Likert scale: 
Completely 
Appropriate to 
Completely 
Inappropriate  
Ideally, what proportion of the panel should be made up of 
doctors with financial ties to pharmaceutical companies who 
market drugs for that disease? 
None 
A minority 
A majority 
 
 
There is debate in the survey literature about different ways to calculate outcome rates, with 
a key question being to what extent households that could not be contacted or screened are 
included in the denominator. To assess our sampling strategy we calculated the response 
rate and cooperation rate as per recommendations and formulae from the American 
Association for Public Opinion Research.[21] The AAPOR response rate includes in its 
denominator estimations of the proportion of cases of unknown eligibility which is actually 
eligible, and calculations involve all households including those where no contact at all was 
made. The AAPOR cooperation rate excludes un-contacted households, and calculates the 
proportion of those contacted who cooperated. 
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No weighting was applied to primary results. For adjusted results, a two-stage weighting 
process was used where-by a pre-weight to adjust for the overlapping sample was 
calculated for people with and without a mobile phone. People have varying chances of 
selection in a dual-frame sample and those with a landline and mobile phone have multiple 
chances of selection. After these pre-weights were calculated, post-stratification weights 
were created using rim weighting to adjust weighted proportions to comply with 
population proportions from four benchmarks obtained from the Australian Bureau of 
Statistics for gender, age, location and education.[22,23] All results were analyzed 
descriptively using IBM SPSS Statistics 22, using proportions and confidence intervals. Chi-
square tests of association were used to determine the strength of association between 
demographic variables and four key questions. Variables significant at the 5% level in chi-
square analyses were fitted in multivariable models. 
Ethics Statement  
Ethics approval was granted by the Bond University Human Research Ethics Committee, 
BUHREC, whose comments helped refine questionnaire text. (Approval #RO1765) 
Participants were assured responses would be anonymous and not recorded, and in order to 
maximise informed consent, a Participant Information Sheet was developed and made 
available to be read on request, and posted on accessible websites. The information sheet 
and the process for seeking informed consent were explicitly approved by BUHREC. 
Interviewers underwent a tailored training session in preparation for the survey, covering 
topics including sensitive subject matter training and strategies for handling distressed 
respondents.  
Results  
The random sample selection process commenced with 4,268 numbers available, from which 
4,156 landline and mobile calls were initiated, and 3,307 eligible numbers identified. Contact 
was made with 1,282 numbers from which 500 completed interviews were achieved, 251 
from the landline sample and 249 from the mobile phone sample, in addition to the 20 pilot 
interviews, and 8 mid-survey terminated interviews(Figure 5). The response rate was 20.4% 
(AAPOR, RR3) and the cooperation rate 43.8% (AAPOR, COOP3).  
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The sample was generally representative, but included a higher proportion of women and 
older adults than the general Australian community, as is typical with telephone based 
health surveys, and slightly higher levels of education(Table 7). All proportions reported 
here are unadjusted, and both adjusted and unadjusted results are available in Table 8, 
demonstrating generally minimal impact of adjustment.  
Figure 5. Participant recruitment for Computer Assisted Telephone Interview survey of 
500 Australians 
 
 
 
*Ineligible participants included: persons under age 18 years; those with a medical condition rendering them 
physically unable to complete the interview; people with language difficulties; respondent away for duration of 
fieldwork; people claiming to have done survey or named person not known. 
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Table 7: Characteristics of survey respondents 
 
Characteristic No. of Survey Respondents n=500 
(%) 
Age, y   
    18-29 76 (15.2)  *(21.4) 
    30-49 139 (27.8) *(36.5) 
    50-69 209 (41.8)  *(29.5) 
    ≥70 76 (15.2)   *(12.7) 
Sex  
    Men 218 (43.6)  *(49.4)  
    Women 282 (56.4) *(50.6) 
Education **  
    <High school 74 (14.8)     *(26.9) 
    High school graduate 169 (33.8)  *(38.7) 
    Bachelor degree/advanced diploma 168 (33.6) *(26.5) 
    >Bachelor degree  89 (17.8)   *(7.7) 
Employment   
     Employed  298 (59.6)  
     Unemployed 20 (4) 
     Not working***   182 (36.4) 
Cancer diagnosis   
     Yes 70 (14.0) 
     No 430 (86.0) 
*Australian population data from the Australian Bureau of Statistics 2011 Census; ** High school normally 
completed at age 17;*** Not in labour force (e.g. student, retired) 
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Table 8: Main results of national community survey on overdiagnosis 
*Adjustment involved two-step, rim weighting as described in Methods; due to rounding some rows do not add to 100%; calculation of Confidence Intervals includes 
continuity correction
 
 
 
 
On overdiagnosis 
Unadjusted 
  
Adjusted* 
 
Yes/Agree No/Disagree Don’t know/ 
neither/refused 
Yes/Agree No/Disagree Don’t know/ 
neither/refused 
n(%) (95%CI) n(%) (95%CI) n(%) (95 %CI) % (95%CI) % (95%CI) % (95% CI) 
Seen or heard term ‘overdiagnosis’ 
before? 
313(62.6)  (58.2-
66.8) 
181(36.2)  (32.0-
40.6) 
6(1.2)  (0.5-2.7) 57.4  (52.9-
61.8) 
41.1 (36.7-
45.4) 
1.5  (0.8-3.3) 
Doctor ever told you about 
overdiagnosis? 
52(10.4)  (7.9-13.5) 443(88.6)  (85.4-
91.2) 
5(1.0) (0.4-2.5) 9.7  (7.2-12.6) 89.5 (86.3-
91.9) 
0.8  (0.3-2.2) 
If screened for prostate cancer, told 
of overdiagnosis? 
16(18.2)  (11.1-
28.1) 
71(80.7) (70.6-
88.0) 
1(1.1) (0.1-7.1) 15.8 (9.2-26.3) 83.1 (72.4-
89.9) 
1.1 (0.1-7.6) 
If screened for breast cancer, told of 
overdiagnosis? 
18(9.7) (6.0-15.1) 162(87.1) (81.2-
91.4) 
6(3.2) (1.3-7.2) 10.8 (6.5-17.3) 86.4 (79.5-
91.3) 
2.9 (0.9-7.3) 
Think routine screening almost 
always good idea? 
382(76.4)   (72.4-
80.0) 
85(17.0)  (13.9-
20.7) 
33(6.6
) 
(4.7-9.2) 79.0 (75.1-
82.4) 
15.1 (12.1-
18.5) 
6.0 (4-8.3) 
Should people be informed about 
risk of overdiagnosis? 
465(93.0)  (90.3-95) 18(3.6)  (2.2-5.7) 17(3.4
) 
(2.1-5.5) 93.4 (90.8-
95.4) 
3.5 (2.4-6) 3.0  (1.9-5.3) 
On genetic screening Likely Unlikely Don’t know/ 
neither 
Likely Unlikely Don’t know/ 
neither 
Likely or unlikely to have genetic 
screening test? 
243(48.6)  (44.2-
53.1) 
226(45.2)  (40.8-
49.7) 
31(6.2
) 
(4.3-8.8) 51.0 (46.5-
55.5) 
42.5 (38.2-
47.1) 
6.5 (4.7-9.2) 
If results uncertain, likely or 
unlikely to have test? 
142(28.4) (24.5-
32.6) 
335(67.0) (62.7-
71.1) 
23(4.6
)  
(3-6.9) 31.0 (27.2-
35.5) 
64.0 (59.6-
68.2) 
4.8 (3.2-7.2) 
On financial ties of disease-
defining panels 
Appropriate Inappropriate Don’t know/ 
neither/refused 
Appropriate Inappropriate Don’t know/ 
neither/refused 
Appropriate or inappropriate for 
doctors with ties to pharmaceutical 
companies to be panel members? 
71(14.2)  (11.3-
17.6) 
391(78.2)  (74.3-
81.7) 
38(7.6
) 
(5.5 -10.4)  16.2 (13-19.6) 75.6 (71.6-
79.3) 
8.1  (5.8-10.8) 
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Of all participants, 63% (95% CI 58%-67%) said they had heard or seen the word 
overdiagnosis before, although following a brief explanation of the term to all participants 
(Box 4) the number fell to 50% (95% CI 45%-54%).  Only 10% of people said they had ever 
been told by a doctor that overdiagnosis was a risk of being screened or tested, (95% CI 8%-
13%).  Only 18% of men who reported having had prostate cancer screening (95% CI 11%-
28%) and 10% of women who reported having had a mammogram (95% CI 6%-15%) said 
they were told about the risk of overdiagnosis. 76 % of participants (95% CI 72%-80%) 
agreed screening tests were almost always a good idea and 93% (95% CI 90%-95%) agreed 
(88% completely or mostly agreed) that along with the benefits of screening, people should 
be informed about the risk of overdiagnosis(Figure 6). 
 
Figure 6. Community views about availability of information on overdiagnosis 
 
 
Asked about enthusiasm for a genetic screening test, the community was split almost 
equally, with 49% likely to have a screening test, (95% CI 44%-53%) and 45% unlikely,(95% 
CI 41%-50%). When asked to imagine the results of genetic screening tests were often 
uncertain and predictions potentially wrong, enthusiasm waned dramatically, with 28% 
likely, (95% CI 25%-33%) and 67% unlikely, (95% CI 63%-71%) to undergo tests.  
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In response to questions about panels which set disease definitions, 78% (95% CI 74%-82%) 
felt it inappropriate (72% completely or mostly inappropriate) for members to have financial 
ties to pharmaceutical companies (Figure 7). Asked what proportion of panel members 
would ideally have financial ties to pharmaceutical companies, 55% (95% CI 50%-59%) said 
there should be no panel members with ties, 36% (95% CI 32%-40%) said a minority - less 
than 50%, and 5% (95% CI 3%-7%) said a majority - 50% or more. At the conclusion of the 
survey, 81% of all participants volunteered to take part in a qualitative follow-up study. The 
number of refusals to answer questions was negligible.  
 
Figure 7. Community views about financial ties of panel members who set disease 
definitions 
 
 
For four key questions - unprompted awareness of overdiagnosis, whether participants had 
been informed about overdiagnosis, merits of routine information about overdiagnosis, and 
appropriateness of financial ties for disease panels - we looked for associations with 5 key 
demographics: age, gender, employment, education and cancer history. For gender and 
employment, we found no significant associations. Responses to unprompted awareness of 
the term overdiagnosis had significant associations with age, education status and cancer 
history. After re-coding multiple categories for age into two categories above and below the 
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median age, and removing “don’t knows” and refusals,  among those aged 53 and younger, 
57% said yes they had heard or seen the term, while for those older than 53 years, 71% said 
yes, (chi-square 9.7, p=0.002). For those with a history of cancer, 76% said yes they had heard 
or seen the term, and for those without 61% said yes (chi-square 5.5, p=0.019).  After re-
coding the highest level of education into two categories, among those with education up to 
and including year 12(~age 17), 51% said they were aware of the term, while for those with a 
post-year 12 education the figure was 68%, (chi-square 12, p=0.001). The only other 
significant association also involved education levels: those with higher levels were slightly 
more likely to report a doctor had informed them about overdiagnosis (13% vs 6%; chi 
square 5.0, p=0.025).   
The only key outcome that had more than one significant association with a demographic 
variable was the question about having heard of the term ‘overdiagnosis’. Therefore, age 
(above and below the median age), educational level (above and equal to or below year 12 
attainment) and history of cancer diagnosis were used as predictors in multivariable logistic 
regression. All were significant. The adjusted odds ratio for reporting having heard of 
overdiagnosis was 1.8 for the older age group (p=0.003, 95% CI 1.2 to 2.7), 2.2 for educational 
level above year 12 (p=0.001, 95% CI 1.5 to 3.4) and 1.9 for those with a history of cancer 
diagnosis (p=0.048, 95% CI 1.0 to 3.4).   
Discussion     
Our community survey found a large majority of adults reporting they had not been 
informed about the risk of overdiagnosis attached to screening tests, and a large majority 
expressing the view that along with screening benefits, people should be informed of the 
risk of overdiagnosis. Despite strong evidence overdiagnosis is a significant risk of prostate 
cancer screening,[6] 81% of men who reported being screened said they had not been told; 
among women who reported having breast cancer screening, where overdiagnosis is also 
now an established risk,[5] 87% said they hadn’t been informed. A third of respondents said 
they had not seen or heard of the term before, with those who were older, more highly 
educated and with a history of cancer more likely to say they had.  
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Over two-thirds of Australians surveyed felt it was completely or mostly inappropriate for 
doctors with financial ties to pharmaceutical companies to serve on panels which set disease 
definitions. Moreover, when asked how these panels should ideally be constituted, just over 
half of all participants said they should have no doctors with financial ties. 
Against a background of concern widespread promotion of genetic screening could produce 
new vectors for overdiagnosis,[24] we found public enthusiasm might be modified if people 
were informed the results of screening tests could be uncertain or potentially wrong. Given 
the propensity of media coverage to over-promote benefits and minimise harms,[25] our 
findings suggest routine provision of information about the limitations and potential harms 
of screening tests may be desirable.  
Our study has several important limitations. As part of the survey methodology we 
axiomatically relied solely on unverified self-reports.  While previous data suggests 
telephone survey self-reports of screening are reliable indicators of actual behaviour,[26] 
some of the large majority who reported not being informed about overdiagnosis may in 
fact have been informed. Secondly, because this is a new area of inquiry, our questionnaire 
has not been used before, apart from the question on enthusiasm for screening taken with 
minor modification from a previously published national survey.[15] While new items were 
rigorously piloted by the research team and social research company using a multi-stage 
pilot process with 40 adults, and explicit efforts were made  to ensure questions were not 
leading, we cannot exclude the possibility some responses may be influenced by the 
questions. A third limitation arises from the complexity of the material, though there was a 
strong focus on comprehensibility and clarity in questionnaire development and interviewer 
training.  
A final limitation arises from the AAPOR response rate of 20.4% and cooperation rate of 
43.8%. While modest, these rates are common and considered satisfactory for community 
surveys of this type. In 2012 the highly regarded Pew Research Centre stated its standard 
telephone surveys were achieving an AAPOR response rate of 9%, and cooperation rate of 
14%, and that the 9% response rate was similar to that achieved by other major survey 
organisations.[27] With the outcome rates achieved there is a possibility of systematically 
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different responses between respondents and non-respondents, though this possibility is 
lessened by the general representativeness of sample respondents. 
Alongside limitations, the study has important strengths. In the context of growing evidence 
about overdiagnosis this is to our knowledge the first national telephone survey to assess 
how the general community reports being informed about the topic, finding both a deficit of 
information and a desire for it. Secondly, we gathered rare and novel data on community 
attitudes about the timely question of who should most appropriately be setting diagnostic 
criteria which determine the nature and extent of human pathology. And finally, our 
random sample was generally representative of the Australian community, achieved in part 
as a result of our dual frame method, reaching both landline-users and the fast growing 
demographic of mobile-only users, now estimated to be more than 20% of phone users in 
Australia,[28] and 38% in the United States.[29] Moreover, generally negligible differences 
between adjusted and unadjusted results strengthen representativeness and generalizability, 
and potential applicability to other nations with similar demographics.  
There is extremely limited data on public awareness about overdiagnosis. A small on-line 
survey limited to individuals who had been invited to undergo cancer screening - reported 
briefly as a research letter in 2013 - found only 9.5% reported they’d been informed by a 
physician about the risk of overdiagnosis and overtreatment, and 80% felt people should be 
routinely informed of such screening harms.[17] Similarly our survey found only 10% of 
women who reported undergoing breast screening said they were told of these harms, and 
just 18% of men who reported having prostate screening, while 88% completely or mostly 
agreed people should be informed about the risk of overdiagnosis, echoing findings from a 
2002 survey of around 650 Australian women, which found over 90% wanted to receive 
information about false results or mammogram side effects[30]. This strong community 
desire for information about harms is set against a backdrop of widespread enthusiasm for 
screening. In 2004 Schwartz and colleagues found 87% agreed routine cancer screening was 
almost always a good idea,[15] while 76% agreed with a similar proposition in our survey a 
decade later.  
There are mixed findings on public attitudes to financial ties between health professionals 
and industry. Some studies suggest trial participants want information about investigator 
Preventing Overdiagnosis  
 
119 
 
financial ties, but are not deterred by them,[18] while other studies find concern is strongest 
where the tie brings direct benefits, such as the professional being paid research recruitment 
fees.[19] To our knowledge, no previous study has investigated public opinions about the 
pharmaceutical company ties of panels which set disease definitions.  Our findings of strong 
public antipathy to these ties is significant and timely: in tune with Institute of Medicine 
recommendations to minimise and eliminate them,[14] but in contrast to current reality, 
where many panel members have such ties.[13]  
In light of the limitations of this telephone survey, and the complexity of the material 
covered, caution in interpretation is appropriate. In 2014 researchers in the United Kingdom 
reported that even written information about overdiagnosis and mammography was not 
well understood.[31] However, despite the complexity, at the completion of our survey, 
around 400 of the 500 participants, ultimately shared personal details and agreed to take 
part in a follow-up qualitative research project, underscoring not only a positive survey 
experience, but suggesting a public hunger to learn more about overdiagnosis and related 
issues. While increasing numbers of research projects are underway worldwide 
investigating the nature and extent of overdiagnosis, these findings, notwithstanding 
limitations, point to the need to find ways to better communicate with the community about 
the problem. Not least to facilitate more informed decision making, but more broadly, as 
Clarke suggests,[8] to enable “greater democratic participation” in shaping the future of 
relationships between people and their health care.  
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Abstract  
 
Objective 
Against a backdrop of growing evidence and concern about the risk of overdiagnosis 
associated with some screening activities, and recognition of the need to better inform the 
public about it, we aimed to ask what the Australian community understood overdiagnosis 
to mean.  
Design, setting and participants 
Content analysis of verbatim responses from a randomly sampled community survey of 500 
Australian adults, between January and February 2014. Data were analysed independently 
by two researchers.  
Main Outcome Measures 
Analysis of themes arising from community responses to open-ended questions about the 
meaning of overdiagnosis.   
Results 
The sample was broadly representative of the Australian population. The American 
Association for Public Opinion Research response rate was 20% and cooperation rate, 44%.  
40% of respondents thought overdiagnosis meant exaggerating a condition that was there, 
diagnosing something that was not there, or too much diagnosis. 24% described 
overdiagnosis as overprescribing, overtesting, or overtreatment. Only 3% considered 
overdiagnosis meant doctors gained financially. No respondents mentioned screening in 
conjunction with overdiagnosis, and over 10% of people were unable to give an answer. 
Conclusions 
Around half the community surveyed had an approximate understanding of overdiagnosis, 
although no-one identified it as a screening risk and a quarter equated it with overuse.  
Strategies to inform people about the risk of overdiagnosis associated with screening and 
other diagnostic tests, in clinical and public health settings, could build on a nascent 
understanding of the nature of the problem.  
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Strengths and limitations of this study  
• This is the first study to ask the general community about the meaning of 
overdiagnosis, a problem attracting growing research attention 
• Our survey sample was generally representative of the Australian community 
• Findings offer a unique and rich dataset of public understanding, to help inform 
strategies to communicate better about overdiagnosis and overuse 
• Limitations arise from the modest response and cooperation rates, though similar 
rates are now common with telephone surveys 
• Another limitation arises because survey participants had little time to reflect on the 
meaning of overdiagnosis before responding             
 
Introduction 
Overdiagnosis occurs when a person is diagnosed with a disease that would not have 
harmed them, and evidence is emerging the problem is associated with a range of 
conditions.[1] There are a number of drivers of overdiagnosis including the medicalization 
of risk,[2] improvements in diagnostic technology which identify ever-smaller 
“abnormalities”, widening disease definitions, and cultural enthusiasm for early 
detection.[3] Appearing in the medical literature as early as the 1970s, the complex and 
counter-intuitive concept is attracting increasing research attention, as part of wider interest 
in preventing avoidable medical excess, manifested in initiatives including JAMA Internal 
Medicine’s Less is More,[4] Choosing Wisely,[5] and The BMJ’s Too Much Medicine series on 
expanding disease definitions and the risk of overdiagnosis.[6] To our knowledge however 
there are no data on what the community understands overdiagnosis to mean.  
While scientific debate about the nature and extent of overdiagnosis continues, evidence is 
most well advanced in the field of cancer screening. After assessing all available evidence, 
an independent panel in 2012 estimated 19% of breast cancers detected during 
mammography screening may be overdiagnosed: defined as detection of cancers that don’t 
progress to be symptomatic and “would never have been found were it not for the screening 
test.”[7] In the same year the United States Preventive Services Task Force pointed to 
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“convincing evidence that PSA-based screening leads to substantial overdiagnosis of 
prostate tumors”, with estimates ranging from 17% to 50%.[8] 
This evidence has contributed to recognition of the need for greater professional and public 
awareness of the problem. In 2013 a working group convened under the auspices of the 
United States National Cancer Institute stated, “Physicians, patients, and the general public 
must recognize that overdiagnosis is common and occurs more frequently with cancer 
screening.”[9] In late 2014, the science and technology committee of the United Kingdom 
parliament produced a report calling for routine communication of the benefits and risks of 
screening programs.[10] In November 2014, a report from the Academy of Medical Royal 
Colleges signalled a “cultural shift” away from unnecessary medical care,[11] underscoring 
the need for new clinical approaches including “de-prescribing” strategies designed to 
confront inappropriate poly-pharmacy.[12] In order to inform on-going scientific and policy 
debates about how to effectively communicate about overdiagnosis and related overuse in 
clinical and public health settings, we aimed to discover what the community currently 
understood overdiagnosis to mean.  
Methods 
We conducted a Computer Assisted Telephone Interview (CATI) survey of randomly 
selected adult Australians to explore understanding of overdiagnosis. The survey recruited 
500 Australians aged 18 years and older using a randomly selected dual frame sample, 
including landlines and mobile phones.  As per formulae from the American Association for 
Public Opinion Research (AAPOR),[13] we calculated the AAPOR response rate - which 
includes in its denominator estimations of the proportion of cases of unknown eligibility 
which is actually eligible, and calculations involve all households including those where no 
contact at all was made - and the AAPOR cooperation rate - which excludes un-contacted 
households, and calculates the proportion of those contacted who cooperated. 
A survey questionnaire was developed iteratively and piloted with a convenience sample of 
20 adult Australians and then through an experienced social research company, The Social 
Research Centre, with an additional 20 recruited participants. Ethics approval was granted 
by the Bond University Human Research Ethics Committee, BUHREC, (Approval #RO1765). 
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Participants were assured responses would be anonymous and not recorded, and in order to 
maximise informed consent, a Participant Information Sheet was developed and made 
available to be read on request, and posted on accessible websites. The information sheet 
and the process for seeking informed consent were explicitly approved by BUHREC. The 
final CATI survey lasted for an average of 15 minutes and was conducted by The Social 
Research Centre between January and February 2014. 
Following an initial question asking “Have you seen or heard the term ‘overdiagnosis’ 
before today?”, participants who said yes were then asked “What do you understand the 
term overdiagnosis to mean?” and if they said no or “don’t know” they were asked, “What 
do you think the term ‘overdiagnosis’ means?” Responses were transcribed verbatim.  
Quantitative elements of the survey are being analysed and reported separately from this 
qualitative analysis of participants’ verbatim responses.  
Upon completion of the survey, we used content analysis of the verbatim responses to 
identify and code emergent themes that captured the diverse understanding of 
overdiagnosis.[14] Two authors (RM, BN) independently reviewed the verbatim responses 
from the 500 participants, and identified salient themes. To ensure rigour of the analysis, we 
used constant comparison methods,[15,16] to look for similarities and differences in the 
themes across responses. The two sets of independently identified major themes were 
documented and discussed with co-authors (JD, JH, KM, AB) and an initial coding 
framework of themes was developed and then pilot tested, by independent double coding of 
50 of the verbatim responses by RM and BN. By comparing and reviewing the pilot data, 
and with more discussion with the experienced qualitative researcher on our research team 
(KM), the final coding framework was then developed. For final coding, the 500 verbatim 
responses were randomized, and two authors (RM, BN) independently coded 300 responses 
each, including 100 responses which were double coded, resulting in agreement in over 80% 
of cases in assigning responses to themes.  A single response could be coded to more than 
one theme.  
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Results 
Of 4,156 landline and mobile calls initiated, 3,307 eligible numbers were identified and 
contact made with 1,282 numbers from which 500 completed interviews, plus 20 pilots, were 
achieved.(Figure 5) The response rate was 20.4% (AAPOR, RR3) and the cooperation rate 
(people who completed the survey, as a proportion of those who completed, plus those who 
refused) 43.8% (AAPOR, COOP3).The sample was generally representative, but included a 
higher proportion of women and older adults than the general Australian community, as is 
typical with telephone based health surveys, and slightly higher levels of education(Table 7).  
 
Figure 5. Participant recruitment for Computer Assisted Telephone Interview survey of 
500 Australians 
 
 
 
*Ineligible participants included: persons under age 18 years; those with a medical condition rendering them 
physically unable to complete the interview; people with language difficulties; respondent away for duration of 
fieldwork; people claiming to have done survey or named person not known 
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Table 7: Characteristics of survey respondents 
 
Characteristic No. of Survey Respondents n=500 
(%) 
Age, y   
    18-29 76 (15.2)  *(21.4) 
    30-49 139 (27.8) *(36.5) 
    50-69 209 (41.8)  *(29.5) 
    ≥70 76 (15.2)   *(12.7) 
Sex  
    Men 218 (43.6)  *(49.4)  
    Women 282 (56.4) *(50.6) 
Education   
    <High school 74 (14.8)     *(26.9) 
    High school graduate 169 (33.8)  *(38.7) 
    Bachelor degree/advanced diploma 168 (33.6) *(26.5) 
    >Bachelor degree  89 (17.8)   *(7.7) 
Employment   
     Employed  298 (59.6)  
     Unemployed 20 (4) 
     Not working   182 (36.4) 
Cancer diagnosis   
     Yes 70 (14.0) 
     No 430 (86.0) 
*Australian population data from the Australian Bureau of Statistics 2011 Census  
 
Of 500 participants, 433 offered a response to the question about the meaning of the term 
overdiagnosis. After independent content analysis of themes by RM and BN, for 9 major 
themes there was clear agreement between the two authors on the nature of the theme. 
Following discussion with co-authors, and piloting of the coding framework, a final list of 10 
themes were agreed upon. Following independent double coding of 100 responses, in 82 
cases there was agreement on the theme/s a response was coded to, including 5 cases where 
one or other coder assigned the response to an additional theme as well. All discrepancies 
were resolved by discussion.  
The final ten themes and their accompanying explanations are listed in Table 9. These ten 
themes were then divided into three categories described as: 1) approximate understanding 
of overdiagnosis; 2) overuse; and 3) other.  The most prevalent theme of the responses was 
“exaggerating something that is there”, which included responses suggesting overdiagnosis 
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meant “diagnosing a condition to be more serious/severe than what it actually is; 
overmedicalising; overcomplicating.” 22% of responses were coded as fitting into this theme, 
exemplified by the comment, “Someone's condition has been made out to be worse than what it 
is.”(Table 10) Responses in this theme revolved around ideas that diagnostic labels made 
problems seem more severe than what they were, causing unnecessary fear or worry.(see 
more examples of all themes in Table 11) Another example of a comment in this theme was: 
“When a patient presents with symptoms and the doctor diagnoses it as something more serious than 
it is, for example, when a boisterous child is diagnosed with ADHD when they just have a lot of 
energy.” ADHD was the most commonly mentioned condition, appearing in 8 responses.  
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Table 9: Coding framework for analysis of responses to “What do you think overdiagnosis means?”  
 
 
 
Theme Explanation of theme 
  
Overdiagnosis   
Exaggerating something that is there diagnosing a condition to be more serious/severe than what it actually is; overmedicalising; overcomplicating 
Diagnosing something that is not there diagnosing a condition that the person does not actually have/does not exist 
Too much diagnosis/too many diagnoses doctors making a diagnosis more frequently than what is needed/people being diagnosed with too many 
conditions 
  
Overuse  
Overprescribing prescribing too many medications - more than is needed 
Overtreatment unnecessary medical interventions and services provided, including referrals; overservicing 
Overtesting a doctor performing or a person having too many unnecessary tests to get a diagnosis 
  
Others  
Doctors looking too much into things doctors looking too hard, too much or too often for a problem to diagnose 
Patients/people driving it   patients/people who search for too much unnecessary medical information or are unusually  anxious or 
worried about their health 
Wrong diagnosis   wrongly diagnosed with a condition (with no suggestion of exaggerating something) 
Doctors financial gain as a driver doctors whose ultimate goal is to make money or cover themselves for financial or litigation reasons 
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Table 10: What do you think overdiagnosis means?: response theme, example, and frequency  
 
 
*does not add to 100% as some responses coded to more than 1 theme 
 
 
 
 
 
Theme Example of comment  Number  (% of 
500)* 
Overdiagnosis     
Exaggerating something that’s there Someone's condition has been made out to be worse than what it is 112 22 
Diagnosing something not there  Sort of pre-empting a potential disease when there isn't one 48 10 
Too much/too many diagnoses I take it to mean something like ADHD, where previously it hadn't been diagnosed and now 
it is and suddenly people find it everywhere 
45 9 
Overuse    
Overprescribing A doctor is handing out medication willy nilly 69 14 
Overtreatment Over servicing or providing greater service than is essential for the correct diagnosis 26 5 
Overtesting Where too many tests are done, particularly with prostate cancer 33 7 
Others    
Doctors looking too much Looking too far into a problem 21 4 
Patients driving it People get on the internet and diagnosing themselves with things they don't have 22 4 
Wrong diagnosis That they haven't diagnosed you correctly or they have given you the wrong diagnosis 20 4 
Doctors’ financial gain   They want to make more cost for patients and make more money or they sometimes go 
further to cover themselves. 
17 3 
Non-responses    
Did not respond at all  67 13 
Miscellaneous/don’t know/unsure  61 12 
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Table 11. What do you think overdiagnosis means?  Additional examples of responses 
Exaggerating something that is there 
I'm guessing it means a mountain made out of a mole hill 
Making diseases more severe than they are 
When a patient presents with symptoms and the doctor diagnoses it as something more serious than it is, for example, when a boisterous child is 
diagnosed with ADHD when they just have a lot of energy 
Someone's condition has been made out to be worse than what it is 
Maybe reading too much into symptoms 
Something that's not really serious making it sound as though it is really  bad 
They over diagnose what's going on with a person and they scare them more than they need to 
It might mean that they've given a diagnosis that you're far worse off than you really are 
When you’re diagnosed with something but it’s not as life threatening as its being explained to be 
Diagnosing something that is not there 
When they assign diseases to people who aren't ill. 
Diagnosing a disease some one doesn't have. 
Doctor seeing things that aren't there. 
There is so many different ailments around and now there are so many different medications now it’s possible that doctors are describing things that 
aren't there. 
Too much diagnosis/too many diagnoses 
When there are more people given a label than you would expect to be the case 
For example cholesterol, they just use a level in the blood and if you are over the level you have that and they lower the level so everyone has it. 
I take it to mean something like ADHD, where previously it hadn't been diagnosed and now it is and suddenly people find it everywhere 
Overprescribing 
Too much medication. 
Doctors trying to give out drugs that don't need to be taken to cure an ailment. 
You are being given too much medication when you don't need it. 
Overtreatment 
If you have an illness where there are too many treatments for it. 
Over servicing of a patient’s needs. 
Overtesting 
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Doctors sending people for too many tests. 
I think they send you off to have this test or that test and it's all a bit unnecessary. 
Doctors looking too much 
When a doctor is looking for too many things. 
Patients driving it   
If you go on the internet and you're looking at things you're just taking the information but it's probably the wrong information. 
Wrong diagnosis 
The doctor wrongly diagnoses. 
Doctors’ gain 
Generally speaking it's a doctor who is milking the system to get more funds. 
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Related to the “exaggeration” theme was the theme described as “diagnosing something not 
there”, which included responses which defined overdiagnosis as “diagnosing a condition 
that the person does not actually have/does not exist”  and exemplified  by the comment  
“Sort of pre-empting a potential disease when there isn't one.” This theme occurred in 10% of 
responses. Also related was the theme “too much or too many diagnoses”, explained as 
“doctors making a diagnosis more frequently than what is needed/people being diagnosed 
with too many conditions”. This theme was exemplified by the response, “For example 
cholesterol, they just use a level in the blood and if you are over the level you have that and they lower 
the level so everyone has it”, and this occurred in 9 % of responses. While none of the three 
related themes corresponds exactly with the current definitions of overdiagnosis being 
debated within the scientific community, they can be seen to approximate an understanding 
of the problem of an unnecessary and unhelpful diagnosis.  
The second most common set of themes related to overuse of interventions, occurring in 24% 
of responses.  The theme of “overprescribing” - which was described as “prescribing too 
many medications/more than is needed” - ran through 14% of responses, exemplified by the 
comment, “A doctor is handing out medication willy nilly.”  This theme related closely to 
“overtreatment” - defined as “unnecessary medical interventions and services provided, 
including referrals; overservicing.” The overtreatment theme was exemplified by the 
comment, “Over servicing or providing greater service than is essential for the correct diagnosis” 
and occurred in 5% of responses.  The theme “overtesting” - defined as “a doctor performing 
or a person having too many unnecessary tests to get a diagnosis” - was exemplified by the 
comment “Where too many tests are done, particularly with prostate cancer” and occurred in 7% 
of responses. 
Relatively small numbers of people made responses coded into themes including “doctors 
looking too much“,(4%) “patients driving it”,(4%) “wrong diagnosis”,(4%) and “doctors’ 
financial gain.”(3%) Around 13% of participants failed to respond, and for another 12% their 
responses were unable to be categorised into the final 10 themes, because for example a 
participant answered by saying “probably  overdiagnosis”. No responses mentioned screening.  
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Discussion  
 Our survey of 500 Australian adults found almost half of participants thought the term 
overdiagnosis meant exaggerating a problem that exists, diagnosing something that is not 
there, or deploying too many diagnoses, and another quarter equate the term with some 
form of overuse, including overprescribing, overtesting or overtreating. A significant 
minority offered either no response, or a response unable to be categorised. Only a tiny 
proportion gave responses which made mention of doctors’ financial gain, and notably no 
respondent mentioned the association between overdiagnosis and screening.   
This study has several limitations. First, the brevity of some participant responses made 
coding into themes more difficult for answers where comprehensibility was in doubt and 
roughly one in ten responses were unable to be categorised into our final 10 themes. Second, 
the open-ended question to participants about the meaning of overdiagnosis happened at 
the very start of the survey, enabling valuable analysis of unprompted understanding of the 
term, but not giving participants much time to reflect or think through responses. A third 
limitation arises from the AAPOR response rate of 20.4% and cooperation rate of 43.8%. 
While modest, these rates are however now common and satisfactory for community 
surveys of this type. In 2012 the well regarded Pew Research Centre stated its standard 
telephone surveys were achieving AAPOR response rates of 9%, and cooperation rates of 
14%, and that the 9% response rate was similar to that achieved by other major survey 
organisations.[17] With the rates achieved in our survey there is a possibility of 
systematically different responses between respondents and non-respondents, though this 
possibility is lessened by the general representativeness of sample respondents. 
Study strengths include the strong level of agreement on themes in the initial independent 
coding of the 500 responses, pointing to a thematic coherence in the community’s response, 
and notwithstanding demographic variations between our random sample and population 
data, the study’s 500 Australian adults were generally representative. Most importantly, to 
our knowledge this is the first time internationally that general community members have 
been asked what they understand overdiagnosis to mean, with responses providing a 
unique dataset. Other data on public understanding or views about overdiagnosis are 
extremely limited. A quantitative survey by Schwartz and colleagues in 2004 found 
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widespread enthusiasm for screening, unmodified by awareness of potential harms,[18] 
while a qualitative study published in 2013 involving focus groups with 50 Australian 
women aged 40-79 found few had heard of overdiagnosis, though there was a desire to 
know more.[19] In 2014 researchers found brief written information about overdiagnosis 
and mammography, of the sort currently sent to women in the United Kingdom, was 
incompletely understood and may not be enough to facilitate informed choice.[20]   
At a time when the scientific community is still debating the definition of overdiagnosis, it 
makes little sense to judge the accuracy of community comprehension. Instead, we interpret 
the results to suggest that while many people grasp the basic idea overdiagnosis means too 
many unnecessary diagnoses, many others failed to offer even an approximate 
understanding. For clinicians attempting to explain to their patients the counter-intuitive 
concepts like the risk of overdiagnosis or the value of choosing not to test or to reduce or 
stop medication for instance,[11,12] our results point to an encouraging though limited 
reservoir of community recognition of the potential dangers of excess. Clinicians may also 
take heart from how very few respondents identified doctors’ financial gain as relevant to 
the meaning of overdiagnosis. Our finding that almost one in four respondents associated 
overdiagnosis with overuse suggest overdiagnosis might be best communicated about not in 
isolation, but within a wider context of its potential harms, including overuse. And finally, 
we believe the failure to associate overdiagnosis with screening should be interpreted as a 
strong signal to policy-makers to introduce more routine communication about potential 
benefits and harms into screening programs.   
While there are ongoing and complex debates about how to define and measure 
overdiagnosis, and resulting disagreements over its magnitude and extent, there is a 
growing consensus around the need to communicate better with the community about the 
problem, particularly as a risk of screening. Our findings offer a rich dataset of lay 
understanding to researchers and policy makers, to help inform development of effective 
communication strategies. Notwithstanding the complexity of the issues, the community 
responses provide some refreshingly simple and clear insights - such as suggesting the 
meaning of overdiagnosis might be akin to “a mountain made out of a molehill” - reinforcing 
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the need to intimately involve community members in developing and evaluating future 
communication strategies.   
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Chapter 7     Using Evidence to Combat Overdiagnosis and 
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Summary Points 
• Overdiagnosis and related overtreatment are increasingly recognised as major 
problems. 
• “Positive” average results from trials of treatments can mask situations where many 
participants at low risk of disease may receive no benefit. 
• The evaluation of diagnostic tests usually involves assessing how well tests detect 
presence versus absence of a certain disease—rather than how well they detect 
clinically meaningful stages of disease. 
• Changes to disease definitions typically do not involve evaluation of potential harms 
of overdiagnosis, and are often conducted by heavily conflicted panels. 
• We offer suggestions for improving the way evidence is produced, analysed, and 
interpreted, to help combat overdiagnosis and related overtreatment. These include 
routine consideration of overdiagnosis and related overtreatment in studies of tests 
and treatments, and clearer stratification by baseline risk to identify treatment 
thresholds where benefits are likely to outweigh harms. 
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While a large part of the world's population faces the problems of underdiagnosis and 
undertreatment, it is apparent that a “modern epidemic” of overdiagnosis afflicts high-
income countries,[1] with tangible human and financial costs of the unnecessary 
management of overdiagnosed diseases.[2,3] While there is ongoing debate about how to 
best describe the problem, narrowly defined, overdiagnosis occurs when increasingly 
sensitive tests identify abnormalities that are indolent, non-progressive, or regressive and 
that, if left untreated, will not cause symptoms or shorten an individual's life. Such 
overdiagnosis leads to overtreatment when these “pseudo-diseases” are conventionally 
managed and treated as if they were real abnormalities; because these findings have a 
benign prognosis, treatment can only do harm. More broadly defined, overdiagnosis 
happens when a diagnostic label is applied to people with mild symptoms or at very low 
risk of future illness, for whom the label and subsequent treatment may do more harm than 
good.[3] 
Among the drivers of overdiagnosis are technological developments producing ever more 
sensitive imaging and biomarker tests, and changing disease and treatment thresholds that 
medicalize more people.[4] For example, detection of indolent breast lesions is now 
recognised as an established risk of mammography screening [5]; widened definitions of 
chronic kidney disease label many asymptomatic seniors as diseased [6]; lowered thresholds 
increase concerns about overdiagnosis of attention deficit hyperactivity disorder [7]; and 
more sensitive imaging methods are causing the treatment of large numbers of potentially 
benign pulmonary emboli.[8] 
It's important to note there is a complex interrelationship between overdiagnosis and 
overtreatment—which can occur for many reasons other than overdiagnosis. If we consider 
the narrow definition of overdiagnosis—where someone is diagnosed with a “disease” that 
will not progress or harm them—overdiagnosis generally leads to overtreatment. Writing 
about overdiagnosis in 1998, Black described the cycle of increasingly sensitive tests causing 
more “pseudo-disease” to be diagnosed and conventionally treated.[9] Because prognosis of 
“pseudo-disease” is generally benign, there is a perception that patients do well on 
treatment, reinforcing belief in the value of treatment to the widened patient pool, and in 
turn fuelling further overtreatment.[9] In other situations, inappropriate overtreatment can 
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occur where there is a legitimate clinical diagnosis, and in some circumstances a degree of 
overtreatment may be warranted, for instance, the early use of parenteral antibiotics in 
someone suspected of having bacterial meningitis. 
Considering the broader definition of overdiagnosis—involving the medicalisation of people 
with mild problems or at very low risk of disease—it becomes more difficult to define what 
constitutes subsequent overtreatment. Those judgements will depend on a complex mix of 
evidence about individual risk, prognosis, and treatment benefit–harm calculations, 
combined with the personal values and preferences inherent in any decision-making. 
Cognisant of this complex context, this essay explores how the production, analysis, and 
interpretation of evidence—whether from individual studies or systematic reviews—might 
be improved to better inform those judgements, and to better understand and combat the 
challenges of overdiagnosis and related overtreatment. 
Average Therapeutic Trial Results Can Mislead 
It's widely recognised that average treatment effects estimated by systematic reviews of 
primary therapeutic trials don't really apply to any single patient, and an average benefit can 
mask both positive and negative effects in different patient subgroups. This leads to 
treatment of patients who don't benefit, and may suffer harms. Almost two decades ago, 
advocates of the then emerging evidence-based approach stressed the importance of a 
nuanced application of evidence from primary trials and systematic reviews for individuals, 
taking into account a person's absolute risk of an outcome and the need to weigh up 
potential benefits and harms.[10] 
More recently Kent and colleagues cited examples where positive clinical trial results 
masked a lack of meaningful benefit for those at lower risks of illness, including trials 
involving statins, anticoagulant therapies, and some common surgical procedures.[11] The 
authors argued that this problem of trials masking the “heterogeneity of treatment effects” 
can result in guidelines that promote overtreatment, as well as undertreatment, and they 
recommended estimation of treatment effects after stratifying trial participants according to 
baseline risk. 
Preventing Overdiagnosis  
145 
 
Similarly, in a presentation to the inaugural Preventing Overdiagnosis Conference in 2013, 
Llewelyn re-analysed trial data involving medication for diabetic microalbuminuria and 
identified subsets of trial participants according to their specific disease stage, finding that 
many people were likely being treated without benefit.[12] The hope is that better 
stratification of people by disease stage, or baseline risk of relevant outcomes, will enable 
better identification of who will benefit and who will be harmed by an intervention, 
potentially informing the development of more appropriate diagnostic cut-points and 
treatment thresholds, ultimately reducing overdiagnosis and overtreatment. 
We Need More Nuanced Evaluation of Tests, Too 
Just as with the average treatment effects of therapeutics, the average accuracy of a test does 
not apply to everyone.[13] Moreover, disease is often not simply “present” or “absent”, but 
rather exists on a continuous scale.[14] Hence, assessing a diagnostic test is more complex 
than simply knowing its average sensitivity and specificity or how well it detects the 
presence or absence of a disease.[13] There is a need to know how well diagnostic tests 
detect subsets of clinically meaningful, as opposed to non-meaningful, abnormalities or 
disease stages. In other words, it's important to diagnose or identify the spectrum of 
individuals for whom a disease label and associated intervention will do more good than 
harm. 
A more sophisticated approach is particularly needed when assessing newer, highly 
sensitive tests—often more costly and burdensome to perform—that can identify earlier, 
milder, or indolent abnormalities or disease stages. For example, computed tomography 
pulmonary angiography has led to a dramatic increase in detection of small “sub-segmental” 
pulmonary emboli, of uncertain clinical significance, with emerging debate over whether 
many people are being treated unnecessarily with anticoagulants.[8] As a result, pulmonary 
embolism has been described as a “model for the modern phenomenon of overdiagnosis”.[1] 
The Benefits and Harms of Expanding Disease Definitions 
A recent investigation of panels that change disease definitions found that while lowering 
diagnostic thresholds and widening definitions are common, few panels reported on the 
potential harms of expanding the numbers of people who qualify for a diagnosis.[4] Among 
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panels that had made recent changes to the definitions of common conditions—such as 
hypertension, attention deficit hyperactivity disorder, and myocardial infarction—the study 
also found widespread conflicts of interest. For panel publications that included disclosure 
sections, around 75% of panel members disclosed multiple financial ties to pharmaceutical 
companies active in the relevant therapeutic area. 
Without doubt there are many cases where lower diagnostic thresholds and earlier 
diagnosis and treatment of disease or risk factors can improve health outcomes. For example, 
early diagnosis of hypertension helps precipitate preventive lifestyle changes or medication 
use. However, increasing medicalization may bring harms as well as benefits, as many 
others have highlighted in debates about “disease mongering”.[15] When, for example, 
conditions such as restless legs syndrome or female sexual dysfunction are constructed and 
promoted as being widespread and severe,[15] there are legitimate concerns that diagnosing 
and treating those with mild problems may do them more harm than good. 
Improving the Evidence Base to Combat Overdiagnosis and 
Overtreatment 
As a matter of urgency, the potential for overdiagnosis and related overtreatment should be 
routinely considered for inclusion in the introduction and discussion sections of reports of 
studies of therapies, studies of diagnostic test accuracy, systematic reviews of those studies, 
clinical guidelines, and changes to disease definitions (Box 5). Second, there is a clear need 
for more research—both original studies and reviews of studies—into the nature and extent 
of overdiagnosis and related overtreatment within specific conditions—as, for example, has 
occurred with studies on the risks associated with mammography.[5] Third, the potential 
harms associated with new treatments and tests, or expanded disease definitions, demand 
much greater attention in primary studies and reviews. 
Box 5. Summary of Suggestions for Improving the Evidence Base to Combat 
Overdiagnosis and Related Overtreatment 
1. Routine consideration of overdiagnosis and related overtreatment in the introduction and 
discussion sections of primary studies and systematic review articles about tests and 
treatments 
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2. More condition-specific studies and reviews on the risk of overdiagnosis and related 
overtreatment—e.g., diagnosis of pulmonary embolism 
3. More rigorous routine evaluation of potential harms of treatments, tests, and changes to 
disease definitions 
4. In studies and reviews of studies of therapies, clearer stratification by baseline risk, to 
better identify treatment thresholds where benefits are likely to outweigh harms 
5. In studies and reviews of studies of test accuracy, more clarity about which target 
condition or spectrum of a disease is being considered, with a shift from a dichotomous 
“disease/no disease” frame to a “spectrum of disease severity” frame, and a linking of 
test accuracy to consequences for treatment and patient outcomes 
6. Panels that review and change disease definitions that are free of conflicts, and routinely 
consider evidence for potential harms as well as potential benefits of the changes they 
propose 
For evaluation of treatments, more clarity is required about the specific definitions of 
diseases being treated in primary treatment studies and subsequent systematic reviews. As 
per the recommendations of Kent and colleagues,[11] clearer stratification of groups at 
varying degrees of baseline risk or disease stage is needed, to better identify treatment 
thresholds at which the harms of treatment start to outweigh benefits. Sometimes this will 
require re-analysis of large (e.g., pooled individual participant) datasets, underscoring the 
need for access to raw data from trials. 
For primary studies and reviews of studies of diagnostic test accuracy, there is a need to 
make explicit exactly which stages or spectrum of a target disease is being considered—also 
referred to as the “target condition”.[14] Where possible, it may be desirable to shift the 
paradigm from a dichotomous frame—disease presence versus absence—to thinking about a 
spectrum of disease severity. Moreover, when diagnostic studies show improved detection 
(or exclusion) of specific disease stages, researchers should try to link the consequences of 
such improved diagnostic accuracy to subsequent treatment decisions. Ideally, the 
consequences of such changed treatment decisions for patient outcomes might also be 
addressed.[16] Such elaborations to conventional diagnostic test accuracy studies would 
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help identify at what diagnostic disease spectrum thresholds subsequent treatments will do 
more good than harm. 
And, finally, the need to improve the process of disease definition—with awareness of the 
dangers of overdiagnosis and overtreatment—is being increasingly accepted, with 
international organisations, including the Guidelines International Network, currently 
looking to develop new guidance. While a detailed debate will ensue in coming years, we 
believe several key principles might underpin the reform of how disease definitions are 
changed: panel members should be free of financial and reputational conflicts of interest; 
strong evidence, ideally from randomised trial data, should demonstrate that the use of new 
criteria will meaningfully reduce mortality and/or morbidity; and potential benefits and 
potential harms of labelling and treatment using the new criteria should be explicitly 
investigated and reported. 
Conclusions 
We offer these suggestions as part of the wider scientific debate underway on how to safely 
and fairly wind back the harms of too much medicine.[17] We are hopeful that a heightened 
attention to the dangers of overdiagnosis and related overtreatment may lead to an 
enhanced evidence base on these topics. This, in turn, will help produce fairer, more rational, 
and less wasteful health care systems, built on a reformed process of disease definition that 
offers diagnostic labels and medical interventions only to those likely to benefit from them. 
 
Acknowledgments 
The genesis of this article was a special session on overdiagnosis at the 21st Cochrane 
Colloquium, held in 2013 in Quebec City, Canada. 
Author Contributions 
Wrote the first draft of the manuscript: RM. Contributed to the writing of the manuscript: 
RM DH KM. ICMJE criteria for authorship read and met: RM DH KM. Agree with 
manuscript results and conclusions: RM DH KM. 
 
Preventing Overdiagnosis  
149 
 
 
References 
1. Hoffman JR, Cooper RJ. Overdiagnosis of disease: a modern epidemic. Arch Intern 
Med. 2012;172: 1123–1124. doi: 10.1001/archinternmed.2012.3319  
2. Berwick D, Hackbarth A. Eliminating waste in US health care. JAMA. 2012;307:1513–
1516. doi: 10.1001/jama.2012.362  
3. Welch G, Schwartz L, Woloshin S. Overdiagnosed: making people sick in the pursuit 
of health. Boston: Beacon Press; 2011.   
4. Moynihan RN, Cooke GP, Doust JA, Bero L, Hill S, Glasziou P. Expanding disease 
definitions in guidelines and expert panel ties to industry: a cross-sectional study of 
common conditions in the United States. PLoS Med. 2013;10:e1001500. 
doi:10.1371/journal.pmed.1001500  
5. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast 
cancer screening: an independent review. Lancet. 2012;380:1778–1786. 
doi:10.1016/S0140-6736(12)61611-0.  
6. Moynihan R, Glassock R, Doust J. Chronic kidney disease controversy: how 
expanding definitions are unnecessarily labelling many people as diseased. BMJ. 
2013;347: f4298. doi:10.1136/bmj.f4298  
7. Thomas R, Mitchell G, Batstra L. Attention-deficit/hyperactivity disorder: are we 
helping or harming? BMJ. 2013;347: f6172. doi:10.1136/bmj.f6172  
8. Wiener RS, Schwartz LM, Woloshin S. Time trends in pulmonary embolism in the 
United States: evidence of overdiagnosis. Arch Intern Med. 2011;171: 831–837. 
doi:10.1001/archinternmed.2011.178  
9. Black W. Advances in radiology and the real versus apparent effects of early 
diagnosis. Eur J Radiol. 1998;27:116–122. doi: 10.1016/s0720-048x(97)00160-5  
10. Glasziou P, Irwig L. An evidence based approach to individualising treatment. BMJ. 
1995;311:1356–1359. doi: 10.1136/bmj.311.7016.1356  
11. Kent DM, Rothwell PM, Ioannidis JPA, Altman DG, Hayward RA. Assessing and 
reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 
2010;11:85. doi:10.1186/1745-6215-11-85  
12. Llewelyn DEH. Analysis of clinical trial data by using evidence based triage reduces 
overdiagnosis [abstract]. Preventing Overdiagnosis Conference; 10–12 September 
2013; Hanover, New Hampshire, United States.  
13. Moons KGM, van Es GA, Deckers JW, Habbema JD, Grobbee DE. Limitations of 
sensitivity, specificity, likelihood ratio, and bayes' theorem in assessing diagnostic 
probabilities: a clinical example. Epidemiology. 1997;8:12–17. doi:10.1097/00001648-
199701000-00002  
14. Lord SJ, Staub LP, Bossuyt PMM, Irwig LM. Target practice: choosing target 
conditions for test accuracy studies that are relevant to clinical practice. BMJ. 
2011;343:d4684. doi:10.1136/bmj.d4684.  
15. PLoS Medicine disease mongering collection. 2006. [webpage] Available at 
http://www.ploscollections.org/article/b
rowse/issue/info%3Adoi%2F10.1371%2Fissue.pcol.v07.i02. Accessed 30 April 2014.  
16. Koffijberg H, van Zaane B, Moons KGM. From accuracy to patient outcome and cost-
effectiveness evaluations of diagnostic tests and biomarkers: an exemplary modelling 
study. BMC Med Res Methodol. 2013;13:12. doi:10.1186/1471-2288-13-12  
Preventing Overdiagnosis  
150 
 
17. Glasziou P, Moynihan R, Richards T, Godlee F. Too much medicine: too little care. 
BMJ. 2013; 347:f4247. doi:10.1136/bmj.f4247  
 
  
Preventing Overdiagnosis  
151 
 
 
 
Chapter 8         Discussion 
 
 
   Ray Moynihan 
 
  
Preventing Overdiagnosis  
152 
 
Summary 
 
This final chapter offers a summary of the thesis findings, explores their limitations and 
strengths within the context of the wider literature, outlines implications and makes some 
suggestions for future research and policy responses to help prevent overdiagnosis or 
ameliorate its impacts.   
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Summary of findings   
The initial scoping of the overdiagnosis literature found considerable research evidence of 
varying quality about the problem of overdiagnosis, across many conditions.[1] The 
evidence was most extensive and developed in relation to the risk of overdiagnosis 
associated with cancer and cancer screening, including for example breast,[2] prostate,[3] 
and thyroid cancers.[4] The overview, which arose from the scoping and appears as chapter 
2, also described differing but related pathways that can lead a person to be overdiagnosed, 
including via screening, via expanded disease definitions and via the detection of 
“incidentalomas”. In addition the overview explored a range of inter-related causes of the 
problem: technological change, commercial forces and cultural enthusiasm for early 
detection.  
The cross-sectional study of the expert guideline panels operating across 14 common 
conditions featured in chapter 3, found that over the past decade when panels reviewed 
disease definitions, they often proposed changes which would increase the proportions of 
the population diagnosed, by creating pre-diseases, by lowering diagnostic thresholds or by 
changing diagnostic assessment processes to enable earlier or increased detection of 
disease.[5] Among the 16 publications from expert panels analysed, coverage of the potential 
harms of proposals to change definitions was generally brief and cursory, and none reported 
on any investigation of the potential for overdiagnosis arising from panel proposals.   
The study reported in chapter 3 also found widespread and direct financial conflicts of 
interest among these highly influential panels which set the boundaries defining human 
diseases and medical conditions. These findings are in direct contrast to repeated 
recommendations from the Institute of Medicine,[6,7], IOM, to wherever possible, constitute 
guideline panels without members with financial ties, in part to restore public trust in 
guidelines. For the 14 publications which included disclosure sections, 75% of panel 
members disclosed multiple financial ties to a median of seven pharmaceutical or device 
manufacturers. Ties included working as speakers, consultants, advisers or researchers. In 
addition 12 of 14 panels were chaired by people disclosing multiple financial ties.  
The study also found that companies to which guideline panel members were most 
commonly tied were all selling or developing medications for the specific conditions and 
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diseases on which those same panel members were deliberating.  For example companies 
marketing hypertension drugs—Bristol-Myers Squibb, Merck, Novartis—each had financial 
ties to eight of the eleven members of the panel that created the new diagnostic category pre-
hypertension. In another example 57% of the panel that described “pre-dementia” disclosed 
ties to a median of five companies each. Eli Lilly - a company developing a drug in the area - 
had financial ties to almost one third of panel members.  In order to assess how the quantum 
of conflicts was affected by repeated recommendations in IOM reports, we assessed disease-
defining panels which published before and after 2012. Post 2012 we found a decrease in the 
median number of companies to which members had ties, from seven to four, but no 
difference in the high proportion of panel members reporting conflicts. 
The 2013 examination of the definition of chronic kidney disease, CKD, reported in chapter 4, 
found an intense and on-going controversy within the scientific literature, dating back to the 
inception of the framework which launched the new disease definition in 2002.[8] A key 
criticism of the CKD definition, and a concern repeatedly expressed in the literature, is that 
it does not take into account age as a factor when assessing and categorizing kidney function, 
and as a result the very broad definition of CKD unnecessarily medicalises and 
overdiagnoses many older people. Yet in the face of on-going criticism and concern, the 
organisations and experts which launched the new disease framework have consistently 
defended their decisions and diagnostic thresholds, with only minor modification, arguing 
that thresholds for diagnosis are based on meaningful increases in the risks of future adverse 
events. Emblematic of a much wider problem, risks are portrayed as diseases:  in this case a 
risk for heart disease is effectively described as “chronic kidney disease.” As reported in 
chapter 4, an important proportion of the experts who created and have consistently 
defended the controversial definition have disclosed financial ties to pharmaceutical or 
device manufacturers, and the organisations which have auspiced and promoted the new 
definition have relied heavily on funding from a consortia of pharmaceutical companies.    
The 2014 national community survey reported in chapter 5 had a number of key findings.[9] 
Only a small minority, 10%, (95% CI 8%-13%) of respondents reported that they had been 
informed about the risk of overdiagnosis by a doctor. For those who reported being screened, 
only 18%, (95% CI 11%-28%) of those screened for prostate cancer, and 10% (95% CI 6%-
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15%), for breast cancer, reported being informed of the risk of overdiagnosis, despite that 
risk being well established in the medical literature.  A large majority, 93%, (95% CI 90%-
95%) agreed that along with screening benefits, people should be informed about the risk of 
overdiagnosis. The number of people likely to take a hypothetical genetic screening test, 49% 
(95% CI 44%-53%) waned significantly to 28%, (95% CI 25%-33%) when participants were 
told disease predictions could be uncertain and inaccurate.  In relation to public opinions 
about expert panels which define disease, a majority, 78%, (95% CI 74%-82%) felt it 
inappropriate that panel members have financial ties to pharmaceutical companies, echoing 
recommendations from IOM reports.[6,7] 
The qualitative analysis of responses to the open-ended survey question - “what do you 
think the term overdiagnosis means?” - is reported in chapter 6.[10] Following independent 
analysis by two investigators of the themes emerging from responses, the study found 40% 
thought overdiagnosis meant exaggerating a condition, diagnosing something that was not 
there, or too much diagnosis.  24% of respondents thought overdiagnosis meant 
overprescribing, overtesting or overtreating. No respondent associated overdiagnosis with 
screening.  
Limitations and strengths in context of wider literature  
There are important limitations attached to each of these research projects, as identified 
explicitly in the preceding chapters. The overview published as a result of the initial scoping 
of the literature on overdiagnosis was not a systematic review: the literature covered many 
conditions, many different study designs and was extremely heterogeneous. In chapter 3, 
the study of expert disease panels had no “control” group of panels which made no changes 
to definitions, so no claims are made about causal factors determining decisions to expand 
definitions. In particular no findings are made that there is a causal link between panel 
member financial ties and decisions to widen disease definitions. An additional limitation 
was that the study did not investigate the nature or proportion of non-financial ties, also 
known as intellectual or reputational conflicts, and the influence these may have on the 
guideline decisions regarding disease definitions.  
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For the case study involving examination of the controversy over chronic kidney disease, 
there are no randomised controlled trial data which enables estimates of the extent of 
overdiagnosis, as is the case with some cancer screening programmes. Unlike the situation 
for cancer screening, for many of the non-cancer conditions where there is concern that 
definitions have been inappropriately widened, current evidence would suggest the 
existence of a risk of overdiagnosis, rather than being able to reliably estimate and quantify 
the magnitude of that risk. 
For the national community survey of Australians, as outlined in chapter 5, an important 
limitation arises from the modest response rates, though concern about the possibility of 
systematically different responses from those unable to be contacted is mitigated to some 
extent by the general representativeness of the survey’s random sample. The use of 7-item 
Likert scales can also present difficulties in relation to a participant’s ability to discriminate 
between two items – for example “mostly likely- somewhat likely” – though, as Table 8 
shows, all similar responses were combined in our main analysis. (e.g. all “likely” were 
combined and all “unlikely” were combined) An important limitation of the qualitative 
analysis of responses to the open-ended questions is that survey participants only had 
limited time to think through their answer before responding.  
Along with limitations, there are a number of important strengths of the thesis research 
projects. The results of the initial scoping offered a concise and accessible summary of the 
evidence and overview of the problem of overdiagnosis. The resulting article has since been 
well-cited, attracted much public attention via media coverage,[11] and helped raised the 
profile of the problem globally.  The article also helped launch two important global projects 
which have run in parallel with the thesis, the Preventing Overdiagnosis international 
scientific conferences,[12] and the series in The BMJ on expanding disease definitions.[13] 
Both projects arose in part from the initial scoping of the literature for this thesis, which 
identified a need for an annual international scientific meeting where the emerging science 
of overdiagnosis could be shared, and a need to focus more research attention on the 
problem of expanding disease definitions and the subsequent risks of overdiagnosis. 
Informed by many different research studies, the initial scoping and overview is strongly 
indebted to the 2011 book, Overdiagnosed: making people sick in the pursuit of health,[14] written 
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by clinician-researchers based at Dartmouth college in the United States, who have all 
contributed much to the evidence-base, and helped raise public and professional awareness 
of the problem.    
Key strengths of the expert panel cross-sectional study were novelty and timeliness: this was 
the first study to systematically investigate panels which review and change common 
disease definitions in order to analyse their decisions and their financial conflicts of interest.  
Previously Schwartz and Woloshin had looked at proposed changes to four selected 
conditions, and analysed implications for disease prevalence,[15] and many other authors 
have investigated the conflicts of interest of guideline panels.[16,17] None however have 
investigated the specific subset of panels whose deliberations have implications for disease 
definition or diagnostic thresholds. To my knowledge, our study was the first to bring these 
differing strands of inquiry together in a systematic way, in order to bring more scientific 
scrutiny to this lesser-investigated pathway to overdiagnosis: expanding disease definitions. 
Notwithstanding important limitations, the findings of widespread financial ties involving 
the vast majority of panel members, including chairs, in direct contrast to IOM 
recommendations for more independence, raise questions about the legitimacy of panel 
proposals which widen definitions and directly benefit companies to which panel members 
are tied. The results reinforce calls for reform of the way guideline panels are constituted,[18]  
and disease definitions are changed.  
While the cross-sectional study of expert guideline panels provided a snapshot at a certain 
point in time across many conditions, the strength of the examination of the chronic kidney 
disease case study was that it looked back over the past decade of debate about 
overdiagnosis within the literature around a single condition. Where the cross-sectional 
study found extensive financial ties at a given point of time, the case study found that over 
time organisations funded by industry and experts with financial ties to industry, repeatedly 
worked to defend controversial decisions against sustained scientific criticism and concern 
about overdiagnosis. Again, the findings do not establish a causal link between industry ties 
and particular positions, but the appearance of major conflicts of interest, in direct contrast 
to professional recommendations, are evident.  
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In the context of growing calls for better communication about the problem of 
overdiagnosis,[19] and greater public awareness of the harms as well as benefits of 
screening,[20] the national survey was the first time the general community has been asked 
explicitly about overdiagnosis, how well they were informed, and what their views were on 
providing such information. In line with a small internet-based study in the United States by 
Wegwarth and Gigerenzer, which focussing more narrowly only on those invited for 
screening,[21] our community telephone survey of landline and mobile-only users found 
few survey participants reported being informed about overdiagnosis, including those who 
reported being screened for prostate or breast cancer. Another survey from Waller and 
colleagues in the United Kingdom,[22] found that the overdiagnosis information being 
provided to women about breast cancer screening was not well understood and was not 
enough for informed consent, underscoring the challenge of communicating complex and 
often counter-intuitive information.  
Against a backdrop of growing use of molecular diagnostics and direct-to-consumer 
marketing of genetic testing, our general community survey found public enthusiasm for 
genetic screening may well be modified significantly by information about uncertainties and 
potential harms associated with such tests. And for the first time the survey sought views on 
the financial ties of panels which set disease definitions - finding considerable agreement 
between participant opinion and recommendations of the IOM.[6,7] The strength of the 
qualitative analysis of community understanding of the term overdiagnosis, is that it helps 
bring the community voice into the debate about the problem, although that wider 
conversation is only just beginning.  
Caveats and cautions  
Before moving to discuss the way evidence is already informing action, and the implications 
of the thesis findings, a few important caveats and cautions are warranted. Given that 
research in overdiagnosis is axiomatically about investigating the potential harms of medical 
interventions, in attempting to reduce these harms it would seem critically important to be 
cognisant of trying to minimise any unintended adverse consequences. In recognition of this, 
it follows that the evidence establishing the problem of overdiagnosis is not overstated, and 
that its limitations are clearly articulated.  
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Even with cancer screening, where the science is most well-advanced and numerical 
estimates of the extent of overdiagnosis appear regularly in the literature, sometimes 
derived from randomised trials or systematic reviews, there are vigorous debates about 
methodology, and wide variations in numerical estimates. For non-cancer conditions, while 
numerical estimates do appear, as featured in the overview on chapter 2, the evidence-base 
is not as well developed.  
Importantly, strong arguments appear in the overdiagnosis literature that some degree of 
overdiagnosis is inevitable, particularly in screening programmes, [23] and that winding 
back the risk of overdiagnosis may come at the risk of increasing underdiagnosis. Any 
strategies to combat overdiagnosis must be cognisant of this risk, focussing on identifying 
that proportion of overdiagnosis that is avoidable and preventable. A related caution arises 
because much of the evidence for overdiagnosis comes from population-based analysis, 
rather than the direct experience of harm to individual people. For example, while there is 
now convincing evidence overdiagnosis is a risk of breast cancer screening, and many 
women will be diagnosed with cancers that would never have harmed them, it is almost 
impossible to identify an individual woman who has been overdiagnosed. However, while 
it is important to acknowledge the fact that some degree of overdiagnosis is inevitable, and 
that it is hard to identify overdiagnosed individuals, this is not a justification for nihilism in 
the face of the problem and should not deter the development of a range of potential 
mitigation strategies.   
Evidence-informing action 
There is a variety of research already underway internationally describing the problem, 
exploring its causes, and developing potential responses, both generally and condition-
specific, as evidenced by both a small but burgeoning literature and the many contributions 
to the Preventing Overdiagnosis conferences at Dartmouth in 2013, Oxford University in 2014, 
and the forthcoming event to be held at the National Cancer Institute in Washington DC in 
September 2015.[12] 
In the move from research to response, there are now several examples where the science on 
overdiagnosis is motivating evidence-based evaluation of mitigation strategies. For example, 
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as a result of evidence suggesting potentially widespread overdiagnosis of pulmonary 
embolism,[24] an observational study is now underway to evaluate whether it is possible to 
reduce unnecessary diagnosis and treatment of some small and potentially benign clots.[25]  
In the field of cancer, leading researcher-clinicians are responding to the problem of 
overdiagnosis by suggesting a suite of possible solutions,[26] including more 
communication about the problem, changes to terminology that removes the word cancer 
from early abnormalities with a generally benign natural history, and where appropriate, 
the evaluation of observational registries, and watch and wait strategies.  In some cases, 
evidence about potential or actual harm from overdiagnosis has contributed to official 
recommendations against screening programmes, for example, for chronic kidney disease[27] 
and prostate cancer.[28] In some places health systems and health sectors are prioritising 
overdiagnosis, as in Quebec, Canada, where the professional medical association has 
brought many stakeholders together to try to develop a province-wide action plan to combat 
it.[29]  Communicating about overdiagnosis is also receiving more research attention, with 
randomised trials evaluating the best ways to present information to people,[30] and 
surveys investigating how well the emerging information provision is informing people.[22] 
Implications and recommendations arising from the thesis   
While there is existing evidence of varying quality across many conditions, and more 
research projects underway, the potential size and significance of the problem suggests a 
clear need for more research into the nature of overdiagnosis, its causes, consequences, and 
solutions. As discussed below in more detail, four key implications and recommendations 
arise from the findings of this thesis:  
• Synthesis and aggregation of overdiagnosis evidence into an accessible repository 
• More investigation of expanding disease definitions and their impacts on 
overdiagnosis 
• Reform of the process of disease definition 
• New international research collaborations to understand and combat overdiagnosis   
 
Synthesis and aggregation of evidence into overdiagnosis repository 
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With the growing research evidence and interest in overdiagnosis, there is an urgent need 
for an accessible synthesis and aggregation of the evidence, condition by condition, available 
for the public, professionals and policy makers. Such an overdiagnosis repository could 
contain: information about research methods; estimates of the magnitude of the risk of 
overdiagnosis for each condition where evidence exists; estimates of costs and opportunity 
costs; estimates of the burden of overdiagnosis-related harms; key limitations around the 
evidence; and strategies for mitigating risk of unnecessary diagnoses, ranging from 
adjusting policy levers that can discourage unnecessary diagnoses, to creating aids for 
shared decision making in the clinical setting.   
Currently information and evidence about overdiagnosis is available in a highly fragmented 
way, chiefly in articles published across a wide spectrum of journals and conditions. 
Similarly the experiences of organisations around the world which are adopting policy or 
practice changes designed to address overdiagnosis are not easily available to others seeking 
to learn from them. Undertaking the suggested aggregation and synthesis of current 
evidence would also reveal important gaps in the existing literature and point to future 
research projects.  In addition, it could lead to the development of “tool kits” for health 
managers, and clearly articulated policy processes for policy-makers interested in 
preventing overdiagnosis.  
More investigation of expanding disease definitions and impacts on overdiagnosis 
The most important implication for research arising from this thesis is that, alongside the 
growing investigation of the risk of overdiagnosis associated with cancer screening, more 
research attention is required to investigate the risk of overdiagnosis caused by the way 
disease definitions and diagnostic procedures are widening the proportions of populations 
labelled as diseased. We need to know much more about how and why the definitions of 
common conditions are changing, and how and why expert panels are proposing changes to 
those definitions.  While the study of multiple conditions will allow identification of general 
patterns, specific investigations of how and why particular disease definitions have changed 
over time will also enable more informed and constructive responses to the problem of 
inappropriately widened conditions, including “pre-diseases” which label increasing 
proportions of the healthy populations..  Most significantly, research is required to 
investigate the implications of these expanding definitions for labelling people as suffering 
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from “diseases” or “conditions” that will never cause them harm, for whom a diagnosis and 
subsequent treatment will axiomatically do more harm than good.  
Research in this field needs to precisely examine the way threshold changes impact on the 
benefit-harm ratios for those labelled and subsequently treated, and to investigate examples 
of conditions where raising thresholds[31] may be appropriate. The series currently 
appearing in The BMJ on expanding disease definitions and the risk of overdiagnosis -  
which has covered a range of common conditions including pulmonary embolism,[24] 
attention deficit hyperactivity disorder,[32]  and gestational diabetes[33] - is contributing to 
a greater awareness of the problem, but more research in required on optimum methods for 
measuring non-cancer overdiagnosis, and the precise nature and extent of the problem 
across specific conditions, in order to inform effective responses in terms of practice and 
policy change.    
Reform the process of disease definition: independent, representative, evidence-based 
As to potential policy solutions, a key implication arising from this thesis is the need for 
major reform of the process of disease definition. It is inappropriate and indefensible that 
expert panels dominated by those with multiple direct financial relationships with 
interested companies are lowering thresholds and labelling growing populations of 
“patients” among the previous healthy. Similarly it is inappropriate that there is currently 
no routine investigation of the risk of overdiagnosis and related overtreatment when disease 
definitions are being reviewed and changed. Notwithstanding the limitations associated 
with the thesis findings, reform of both panel constitution and their processes are indicated. 
In line with IOM recommendations, derived from solid independent assessment of the large 
body of evidence about conflicts of interest, and echoed in findings arising from the thesis 
research, panels which define human disease will likely serve the public interest far better if 
they were more independent from vested interests, more broadly representative, and are 
informed by the best evidence about the potential harms as well as the potential benefits of 
their decisions, as outlined in the essay published with colleagues in PLOS Medicine, which 
appears as chapter 7 of this thesis.[34] 
To inform policy reform, research projects which  investigate new ways to review disease 
definitions or diagnostic thresholds could focus on specific conditions where controversy 
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around expanded definitions is high, and potential for overdiagnosis is significant, 
including for example chronic kidney disease, gestational diabetes, or pre-dementia. 
Templates for more independent evidence-informed and broadly representative expert 
panels already exist, notably the current series of Pathways to Prevention conferences 
hosted by the National Institutes of Health ,[35], NIH, and the former series of NIH 
consensus conferences,[36] which explicitly used a three-step process: a panel was 
assembled with professional and public representatives who were free of reputational and 
financial conflicts of interest; the panel was informed by systematic literature reviews; and 
testimony was sought from (potentially conflicted) researchers and clinicians active in the 
area.  
New multi-national research collaborations on overdiagnosis   
In order to undertake the proposed research agenda and inform policy reforms outlined 
above, new international research alliances or collaborations will be required, affording the 
chance to strategically and systematically address the multi-facetted problem of 
overdiagnosis.  Such collaborations would ideally involve consumer/citizen organisations, 
have a patient-centred and shared-decision making focus, and as far as possible be 
independent from professional and commercial groups with interests in maximising the size 
of patient populations.   
A number of collaborative efforts arising from the Preventing Overdiagnosis scientific 
conferences are already underway to refine overdiagnosis definitions, research methods and 
optimum communication strategies. More innovative international alliances and 
collaborations of researchers, clinicians and consumers may well emerge from the 
conferences.  Others are also advocating similar multinational collaborations to better 
understand and address overdiagnosis.[37] Such collaborative efforts could draw on, or 
work with existing international collaborative efforts including the Cochrane Collaboration 
and its review groups, and the many centres and networks specialising in evidence-based 
approaches globally. In order to understand and address the many causes and consequences 
of overdiagnosis in healthcare, greater cooperation and collaboration will be essential.  
Conclusions  
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The increasing recognition of the need to address overdiagnosis[19] is part of a wider 
awareness of the need to try and wind back the harms of too much medicine, in order that 
healthcare resources might be spent where they are most needed.  Many initiatives have 
been launched in recent years to tackle the problem of excess, by a range of leading medical 
journals, professional and consumer groups and not-for-profit foundations, including Less is 
More,[38] Choosing Wisely,[39] Too Much Medicine,[13] the Right Care Alliance,[40]  and 
Preventing Overdiagnosis.[12] In Europe, as Brodersen and colleagues describe, the 
emerging movement within primary care for “quaternary prevention” is similarly focussing 
on helping steer people away from medicalisation, diagnosis, testing and treatment likely to 
cause them more harm than good.[41] The movement is gaining increasing support as a way 
to combat the dangers of iatrogenic harm,[42] and is related to other moves within general 
practice organisations to re-think guidelines in ways that prevent unnecessary diagnoses 
and overtreatment.[43] In addition, as climate change mitigation becomes a reality, moves to 
avoid waste and overuse in medicine will be increasingly be seen as one of the paths 
towards a more sustainable and less-polluting healthcare system, as identified in a report in 
late 2014 from the Academy of Royal Medical Colleges in the United Kingdom: “Reducing 
waste in the clinical domain has a triple imperative; it improves value, lowers costs and 
reduces CO2 emissions.”[44] While all these initiatives are related by a desire to prevent 
harm and waste, the differentiation of scientific research specifically on overdiagnosis will 
continue.  
A key challenge in responding to medical excess is the wide range of powerful forces 
driving it, be they technological, commercial, professional, personal or cultural. Commonly 
with the best of intentions medicine has long promoted the benefits of early detection, and 
championed the value of diagnosing and treating disease, without a commensurate 
enthusiasm for the rigorous evaluation of potential harms. The science of evaluation 
continues to live in the shadows of the science of innovation. Yet as new molecular 
diagnostics and genetic testing move increasingly from the lab into the clinic, as advanced 
imagining enables the detection of ever-tinier abnormalities, and as the proliferating self-
monitoring health technologies becomes embedded in the marketplace as symbols of 
consumer empowerment, a new wave of overdiagnosis and the over-medicalisation of 
marginal risk is virtually inevitable, potentially bringing much more harm and wasting 
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resources that could be far better spent preventing and treating genuine illness. A necessary, 
though not sufficient, condition for meeting that challenge, will be an enhanced evidence-
based assessment of the risks of overdiagnosis, and the aggregation, synthesis  and 
dissemination of that evidence to inform personal, public, professional and policy responses.   
The scientific debate about overdiagnosis is a debate grounded in evidence. As the evidence-
based approach has grown in strength over recent decades, the many tools of its critical 
scrutiny have been aimed not just at treatments, but at diagnostic tests, including screening 
tests that target the healthy, where the risk of overdiagnosis is axiomatically greatest. What 
started with speculation has in many cases moved through evaluation and ultimately grown 
into convincing evidence of a public health problem, notwithstanding important debates 
around methods and uncertainties around estimates. Understandably, evidence suggesting 
iconic, popular and well-funded public screening programmes may be causing much 
unnecessary diagnosis and treatment, has not always been quickly or warmly welcomed. 
As flagged in the introduction, ironically, the success of evidence-based scrutiny has helped 
precipitate something of a crisis in the evidence-based approach.[45] Increasingly rigorous 
and unbiased evaluation and analysis have helped expose how benefits of tests and 
treatments are generally overplayed and harms, including overdiagnosis, generally played 
down in much evidence, and how vested interests can distort and corrupt evidence, in 
everything from marketing to guidelines. Paradoxically the evidence “brand” has been 
debased as evidence has been hijacked, and proponents of evidence-based medicine are now 
calling for a rebirth of the approach.[45] 
Writing in The BMJ in 2014 the Evidence-Based Medicine Renaissance Group flagged a 
number of proposed actions highly relevant to the findings and implications arising from 
this thesis.  Among recommendations from the group were specific calls for policy-makers 
to resist “evidence” generated by vested interests, for independent funders to play a much 
bigger role in producing, synthesising and disseminating evidence, and for the medical 
research agenda to generate evidence on “how to prevent harm from overdiagnosis.”[45]  
Developing new ways to define human disease, much freer of vested interests, more 
independently funded and more cognisant of the risk of overdiagnosis, will surely be a key 
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feature of any such renaissance, reducing iatrogenic harm and helping redirect health 
resources to where they are genuinely needed.  
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Appendix 1. 
 
 
 
 
 
 
 
Bond University 
“Medical Overdiagnosis” 
 
16 January, 2014 
Questionnaire version 8 (including pilot changes) 
 
 
[PROGRAMMER NOTE: 
• Use standard SMS list 
• Use standard RR1 list] 
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*INTRODUCTION & SCREENING 
 
*(PHONE ANSWERER) 
INTRO1: Good (morning/afternoon/evening) my name is (…) and I am calling from the Social 
Research Centre on behalf of Bond and Sydney Universities. 
 
We’re doing a short survey across Australia about community views on the way doctors diagnose 
diseases.  This is an emerging issue and the results will help researchers find better ways for 
doctors to communicate about the risks and benefits of medical tests and treatments. 
 
1. Continue  
 
*(LANDLINE) 
INTRO2a: We would like to speak to the person in your household who is aged 18 years or over and 
who had the LAST birthday? Would that be you? 
 
 [REINTRODUCE IF NECESSARY:  Good (morning/afternoon/evening) my name is (…) and I 
am calling from the Social Research Centre on behalf of Bond and Sydney Universities. We’re 
doing a short survey across Australia about community views on the way doctors diagnose diseases.  
This is an emerging issue and the results will help researchers find better ways for doctors to 
communicate about the risks and benefits of medical tests and treatments.] 
 
1. Yes (continue) 
2. Not a good time: appointment (MAKE APPOINTMENT) 
3. Household refusal (GO TO RR1) 
4. Language difficulty (NO follow up) (GO TO TERM2) 
5. Wants more information before participating (GO TO INFO1) 
6. No one aged 18+ in household (GO TO TERM1) 
7. Queried about how telephone number was obtained (GO TO TEL_LAND) 
 
*(MOBILE) 
INTRO2b. Can I ask whether you are aged 18 years or over? 
 
1. Yes (continue) 
2. Not a good time: appointment (GO TO MOB1) 
3. Mobile answerer refusal (GO TO RR1) 
4. Language difficulty (NO follow up) (GO TO TERM2) 
5. Wants more information before participating (GO TO INFO1) 
6. Under 18 years of age (GO TO TERM1) 
7. Queried about how telephone number was obtained (GO TO TEL_MOB) 
8. Queried why mobile was called (GO TO TINFO_MOB) 
 
*(IF INTRO2a=5 OR INTRO2b=5 – MORE INFO REQUIRED) 
INFO1. You can find more information online from the Social Research Centre website 
(www.srcentre.com.au, on the ‘participants’ tab under ‘current surveys’. This includes links to 
the Bond University and the University of Sydney websites.) 
 
1. Make appointment [PROGRAMMER NOTE: IF MOBILE GO TO MOB1, ELSE MAKE 
APPOINTMENT] 
2. (Wants info but NO INTERNET) (COLLECT MAILING DETAILS THEN IF MOBILE GO TO 
MOB1, ELSE MAKE APPOINTMENT; SET UP GETDET!] 
 
*(QUERIED HOW LANDLINE NUMBER WAS OBTAINED) 
TEL_LAND Your telephone number has been chosen at random from all possible telephone 
numbers.  We find that this is the best way to obtain a representative sample of people across 
Australia. 
 
1. Snap back to previous question 
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*(QUERIED HOW MOBILE NUMBER WAS OBTAINED) 
TEL_MOB Your mobile number was randomly generated by a computer.  We’re calling mobile 
phones as well as landlines so we can get a representative sample of people across Australia. 
 
1. Snap back to previous question 
*(QUERIED WHY MOBILE WAS CALLED) 
TINFO_MOB One of the issues currently facing telephone survey researchers in Australia is the 
increasing proportion of households without a landline telephone. We are calling mobile phones 
as well as landlines so we can get a representative sample of people across Australia.  
 
1. Snap back to previous question 
 
*(MOBILE SAMPLE)  
MOB2. May I just check whether or not it is safe for you to take this call at the moment?  If not, I am 
happy to call you back when it is more convenient for you. 
 
1. Safe to take call  
2. Not safe to take call  
3. Respondent refusal (GO TO RR1) 
 
*(MOBILE SAMPLE) 
MOB1.  Just so I know your time zone, can you tell me which state you‘re in? 
 
1. NSW 
2. VIC 
3. QLD 
4. SA 
5. WA 
6. TAS 
7. NT 
8. ACT 
9. (Refused) 
 
*PROGRAMMER NOTE – WRITE STATE / TERRITORY TO SAMPLE RECORD 
 
[PREMOBAPPT IF INTRO2b=2 OR 5, OR MOB2=2 CONTINUE (mob appointment), ELSE GO TO 
INTRO3a] 
 
*(MOBILE SAMPLE NEEDING APPOINTMENT) 
MOB_APPT Do you want me to call you back on this number or would you prefer I call back on 
another phone? 
  
1. This number (TYPE STOP, MAKE APPOINTMENT) 
2. Another number (TYPE STOP, MAKE APPOINTMENT, RECORD ALT NUMBER) 
3. Respondent refusal (GO TO RR1) 
 
*(ALL) 
INTRO3a: Thank you. Now, I’m just going to run some details past you about the study…. 
 
1. Continue 
2. Not a good time (MAKE APPOINTMENT) 
3. Respondent refusal (GO TO RR1) 
4. Language difficulty (NO follow up) (GO TO TERM2) 
5. More info “go to www.srcentre.com.au, on the ‘participants’ tab under ‘current surveys’. 
This includes links to the Bond University and the University of Sydney websites.” (MAKE 
APPOINTMENT) 
6.  (Wants info but NO INTERNET: collect details to mail info sheet) (MAKE APPOINTMENT) 
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*(ALL) 
INTRO3b:   
The survey has been approved by the Bond University Ethics Committees and participation is 
completely voluntary. You can choose not to answer any question or to cease the survey at any 
time. Your phone number was selected randomly, your answers will remain completely 
anonymous and we will not be recording this phone call. It will only take around 15 minutes to 
complete. 
 
Would you like more information or would you be willing to participate in this important study?  
 
[INTERVIEWER NOTE: If more information requested, read the abridged Participant 
Information Sheet. If potential participant doesn’t want to be read information, offer to provide 
website details and arrange an appointment.] 
 
1. Continue 
2. Not a good time (MAKE APPOINTMENT) 
3. Respondent refusal (GO TO RR1) 
4. More info “go to www.srcentre.com.au, on the ‘participants’ tab under ‘current surveys’. 
This includes links to the Bond University and the University of Sydney websites.” (MAKE 
APPOINTMENT) 
5. (NO INTERNET ACCESS: arrange to send information sheet) (MAKE APPOINTMENT) 
 
*(ALL) 
MON: This call may be monitored for training and quality purposes but will NOT be recorded. Is that 
OK? 
 
1. Monitor 
2. Do not monitor 
 
*(ALL) 
S1a. Thank you. Now, before we begin the survey, would you mind telling me your age? 
1. (Record number in years) [RANGE 18 to 105] 
2. (Refused) (GO TO S1b) 
 
*(IF S1a=2 – Refused age) 
S1b.  Could you please tell me which of the following age groups you are in? 
 
1. 18-29  
2. 30-49  
3. 50-69 
4. 70 and over 
5. (Refused) 
 
*(ALL) 
S2.  As we are talking about the way doctors diagnose diseases and medical treatments which 
affect men and women differently would you mind confirming your gender? 
 
 [IF NECESSARY: we need to ask this question of everyone to make sure we ask people the 
right questions throughout the survey] 
 [INTERVIEWER NOTE: If ‘refuse’ or ‘other’, allocate at your discretion]  
 
1. Male 
2. Female 
 
*(ALL) 
S3. What is the post code of the area in which you live? 
 
1. (Record post code ____) [RANGE: 800 to 9999] 
2. (Don’t know)(Specify suburb) 
3. (Refused) 
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[PROGRAMMER NOTE: DERIVE ‘STATE’ WHERE RESPONDENT CAN PROVIDE POSTCODE; IF 
NO ELIGIBLE POSTCODE PROVIDED ALLOCATE TO ‘OTHER’ STATE] 
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*SECTION A: GENERAL KNOWLEDGE ABOUT OVERDIAGNOSIS 
 
Just to start our survey… 
 
*(ALL) 
A1. Have you seen or heard the term ‘overdiagnosis’ before today? 
 
 [IF NECESSARY: We are discussing overdiagnosis of medical illnesses, diseases and 
conditions]. 
1. Yes  
2. No 
3. (Don’t know) 
4. (Refused) 
 
[PRE A2 IF A1=1 use A2i ELSE use A2ii] 
*(ALL) 
A2i. What do you understand the term ‘overdiagnosis’ to mean? 
A2ii. What do you think the term ‘overdiagnosis’ means? 
  
[IF NECESSARY: We are discussing overdiagnosis of medical illnesses, diseases and 
conditions]. 
 
1. Response Given (Specify) *(PROGRAMMER NOTE: Set up as full verbatim)  
2. (Don’t know / can’t say) 
3. (Refused)  
 
*(ALL) 
A3.  A generally accepted view is that overdiagnosis happens when people are diagnosed with a 
disease that would never have harmed them. This could be due to the condition being so slow 
developing or them displaying only very minor symptoms.  
 
Given this explanation, have you seen or heard the term or concept of ‘overdiagnosis’? 
 
[IF NECESSARY: For example sometimes people are diagnosed with cancer, but that cancer 
would be so slow growing it would not cause them any harm in their lifetime, or a person with 
very mild problems may be diagnosed with a mental disorder such as ADHD.  
We are discussing overdiagnosis of medical illnesses, diseases and conditions]. 
 
1. Yes  
2. No 
3. (Don’t know) 
4. (Refused) 
 
*(ALL) 
A4. Has a doctor ever told you that healthy people can be over-diagnosed as a result of being 
screened or tested for a disease?  
 
1. Yes  
2. No  
3. (Don’t know) 
4. (Refused) 
 
*(ALL) 
A5.  Routine screening means testing healthy people to find signs of diseases such as cancer. 
 
Do you think routine screening tests for healthy people are almost always a good idea? 
 
1. Yes  
2. No 
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3. (Don’t know) 
4. (Refused) 
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*(ALL) 
A6.  Do you agree or disagree that routine screening tests for healthy people are important for their 
health? 
 
PROBE: IS THAT COMPLETELY, MOSTLY OR SLIGHTLY AGREE / DISAGREE? 
 
(RESPONSE FRAME) (DO NOT READ OUT) 
1. Completely agree 
2. Mostly agree 
3. Slightly agree 
4. (Neither agree nor disagree) 
5. Slightly disagree 
6. Mostly disagree 
7. Completely disagree 
8. (Don’t know / Can’t say) 
9. (REFUSED) 
 
*(ALL) 
A7.  When healthy people are considering having a screening test - along with being told about the 
potential benefits of the screening test – do you agree or disagree that they should be informed 
about the potential risk of overdiagnosis?  
 
[IF NECESSARY: For example a screening test for prostate or breast cancer, chronic kidney 
disease or other diseases and illnesses]. 
 
 
PROBE: IS THAT COMPLETELY, MOSTLY OR SLIGHTLY AGREE / DISAGREE? 
 
(RESPONSE FRAME) (DO NOT READ OUT) 
1. Completely agree 
2. Mostly agree 
3. Slightly agree 
4. (Neither agree nor disagree) 
5. Slightly disagree 
6. Mostly disagree 
7. Completely disagree 
8. (Don’t know / Can’t say) 
9. (REFUSED) 
 
 
*(ALL) 
TS1_Section A  
  
Preventing Overdiagnosis  
181 
 
*SECTION B: SCREENING EXPERIENCES  
  
*(ALL) 
B0. I will now ask you a few brief questions about your experiences with medical screening tests.  
 
[PREB1a: IF S2=2 (female) GO TO PREB2; ELSE CONTINUE] 
 
*(S2=1 – Males only) 
B1a  Have you ever had a screening test, sometimes called a PSA test before for prostate cancer?  
 
1. Yes 
2. No (GO TO B3) 
3. (Don’t know) (GO TO B3) 
4. (Refused)  (GO TO B3) 
 
*(B1a=1 – had screening test) 
B1b. Were you told about the risk of overdiagnosis (of this test)?  
[IF NECESSARY: In other words, were you told by a doctor, GP, or the person who offered or 
administered the test that you may be diagnosed and treated for a cancer that would never 
have caused you any harm in your lifetime?] 
 
1. Yes I was told 
2. No I wasn’t told 
3. (Don’t know) 
4. (Refused)  
 
[PREB2: IF S2=1 (male) GO TO B3; ELSE CONTINUE] 
 
*(S2=1 – Females only) 
B2a  Have you ever had a mammogram to screen for breast cancer? 
 
 [IF NECESSARY: “We are interested in finding out if women have had a screening test when 
they didn’t have any problem in their breast, such as a lump, as opposed to having a 
‘diagnostic’ mammogram, where there was a problem being investigated.]   
 
1. Yes 
2. No (GO TO B3) 
3. (Don’t know) (GO TO B3) 
4. (Refused) (GO TO B3) 
 
*(B2a=1 – had screening test) 
B2b.  Were you told about the risk of overdiagnosis (of this test)?  
[IF NECESSARY: In other words, were you told by a doctor, GP, or the person who offered or 
administered the test that you may be diagnosed and treated for a cancer that would never 
have caused you any harm in your lifetime?] 
 
1. Yes I was told 
2. No I wasn’t told 
3. (Don’t know) 
4. (Refused) 
 
*(ALL) 
B3.  Have you ever had a genetic screening test? 
[IF NECESSARY: A genetic screening test, or DNA testing, seeks to identify inherited diseases 
or diseases passed on through blood relations]  
 
1. Yes 
2. No 
3. (Don’t know) 
4. (Refused) 
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*(ALL) 
TS2_Section B   
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*SECTION C: INTEREST IN GENETIC SCREENING  
 
*(ALL)  
C1. Imagine that there was a genetic screening test which could analyse your genes and identify all 
the diseases you may ever get, for which some had effective treatments and some did not. 
Would you be likely or unlikely to have that screening test? 
 
PROBE: IS THAT COMPLETELY, MOSTLY OR SOMEWHAT LIKELY / UNLIKELY? 
 
(RESPONSE FRAME) 
1. Completely likely 
2. Mostly likely  
3. Somewhat likely 
4. (Neither likely nor unlikely) 
5. Somewhat unlikely 
6. Mostly unlikely 
7. Completely unlikely 
8. (Don’t know) 
9. (Refused) 
 
*(ALL) 
C2. Imagine now that the results of the genetic screening test were often uncertain, and the 
predictions could be wrong. Would you be likely or unlikely then to have that screening test? 
 
PROBE: IS THAT COMPLETELY, MOSTLY OR SOMEWHAT LIKELY / UNLIKELY? 
 
(RESPONSE FRAME) 
1. Completely likely 
2. Mostly likely  
3. Somewhat likely 
4. (Neither likely nor unlikely) 
5. Somewhat unlikely 
6. Mostly unlikely 
7. Completely unlikely 
8. (Don’t know) 
9. (Refused) 
 
 
*(ALL) 
TS3_Section C 
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*SECTION D: BREAST SCREENING (MALES VS FEMALES) 
*(ALL) 
D0.  In this next section I’m going to describe a particular scenario about screening for cancer, 
then ask you some questions about that scenario. Sometimes people can find these 
questions personal or sensitive. If you are unsure how to answer or do not want to answer 
any question please let me know and I will move on. 
 
[PROGRAMMER NOTE: create dummy variable to randomly assign males and females to relevant 
Option 1 and Option 2. Each respondent to respond to one scenario.] 
 
*(ALL) [PROGRAMMER NOTE: All respondents need to be assigned a code at RAND; minimum of 
100 respondents per code] 
RAND: “Random assignment of males and females to Option 1 and Option 2” 
1. S2=2 + random assignment (Female, Option 1)  
2. S2=2 + random assignment (Female, Option 2)  
3. S2=1 + random assignment (Male, Option 3)  
4. S2=1 + random assignment (Male, Option 4)  
 
[PRED1: IF RAND=1, CONTINUE. ELSE GO TO PRED5] 
 
*(RAND=1 – Female, Option 1) 
D1.  Breast screening (mammograms) detects abnormal changes of cells in the breast as well as 
finding breast cancers.  In some women these abnormal cells can progress to invasive cancer 
and in others they do not. It’s estimated that if left untreated about one-third may progress to 
breast cancer over 10 years or more.  That means that for about two-thirds of women these 
abnormal cells may not become cancer.  
 
Imagine you had an abnormal breast screen and follow-up tests showed that there were 
abnormal cells found in your breast.  
 
How concerned would you be about your result? Would you say… 
 
[IF NECESSARY: ‘Invasive’ cancer means potentially life threatening.] 
 
(RESPONSE FRAME) (READ OUT) 
1. Extremely concerned 
2. Moderately concerned 
3. (Neither concerned nor unconcerned) 
4. Not really concerned 
5. Not concerned at all 
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
 
*(RAND=1 – Female, Option 1) 
D2.  Abnormal breast cells are usually treated by surgery, radiation or drugs as in the case of breast 
cancer.  Another approach is called watchful waiting, where doctors closely monitor the 
abnormal breast cells with regular mammograms and only treat if cells become more abnormal.   
 
If research shows that watchful waiting is a safe and effective option, how do you think you 
would prefer to manage these abnormal cells?  Would you say… 
 
[IF NECESSARY: If people want more information on exactly what watchful waiting would entail 
- say, that’s what research would determine.] 
 
(RESPONSE FRAME) (READ OUT) 
1. Definitely prefer treatment  
2. Probably prefer treatment 
3. (Prefer to do nothing) 
4. Probably prefer watchful waiting (close monitoring by doctors) 
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5. Definitely prefer watchful waiting (close monitoring by doctors)  
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
*(RAND=1 – Female, Option 1) 
D3.  Thinking again about the previous scenario, if these abnormal cells in your breast were instead 
called pre-invasive breast cancer cells (rather than abnormal cells), would you be more 
concerned or less concerned about your screening test result? 
 
(RESPONSE FRAME) 
1. More concerned 
2. (No difference) 
3. Less concerned 
4. (Don’t know) 
5. (Refused) 
6. (Respondent does not understand terminology / issues)  (GO TO TS4) 
 
*(RAND=1 – Female, Option 1) 
D4.  And if research shows that watchful waiting is a safe and effective option, how do you think you 
would prefer to manage these pre-invasive breast cancer cells? Would you say… 
 
(RESPONSE FRAME) (READ OUT) 
1. Definitely prefer treatment  
2. Probably prefer treatment 
3. (Prefer to do nothing) 
4. Probably prefer watchful waiting (close monitoring by doctors) 
5. Definitely prefer watchful waiting (close monitoring by doctors)  
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
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[PRED5: IF RAND=2, CONTINUE. ELSE GO TO PRED9] 
 
*(RAND=2 – Female, Option 2) 
D5. Breast screening (mammograms) detects pre-invasive breast cancer cells in the breast as well 
as finding breast cancers.  In some women these pre-invasive breast cancer cells can progress 
to invasive cancer and in others they do not.  It’s estimated that if left untreated about one-third 
may progress to breast cancer over 10 years or more.  That means that for about two-thirds of 
women these pre-invasive breast cancer cells may not become cancer. 
 
Imagine you had a breast screen and follow-up tests showed that there were pre-invasive 
breast cancer cells found in your breast.  
 
How concerned would you be about your result? Would you say… 
 
[IF NECESSARY: ‘Invasive’ cancer means potentially life threatening.] 
 
(RESPONSE FRAME) (READ OUT) 
1. Extremely concerned 
2. Moderately concerned 
3. (Neither concerned nor unconcerned) 
4. Not really concerned 
5. Not concerned at all 
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
 
*(RAND=2 – Female, Option 2) 
D6.  Pre-invasive breast cancer cells are usually treated by surgery, radiation or drugs as in the 
case of breast cancer.  Another approach is called watchful waiting, where doctors closely 
monitor the pre-invasive breast cancer cells with regular mammograms and only treat if cells 
become more invasive.   
 
If research shows that watchful waiting is a safe and effective option, how do you think you 
would prefer to manage these pre-invasive breast cancer cells? Would you say… 
 
[IF NECESSARY: If people want more information on exactly what watchful waiting would entail 
- say, that’s what research would determine.] 
 
(RESPONSE FRAME) (READ OUT) 
1. Definitely prefer treatment  
2. Probably prefer treatment 
3. (Prefer to do nothing) 
4. Probably prefer watchful waiting (close monitoring by doctors) 
5. Definitely prefer watchful waiting (close monitoring by doctors)  
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
 
*(RAND=2 – Female, Option 2) 
D7.  Thinking again about the previous scenario, if these pre-invasive breast cancer cells were 
instead called abnormal cells (rather than pre-invasive cells), would you be more concerned or 
less concerned about your screening test result? 
 
(RESPONSE FRAME) 
1. More concerned 
2. (No difference) 
3. Less concerned 
4. (Don’t know) 
5. (Refused) 
6. (Respondent does not understand terminology / issues)  (GO TO TS4) 
Preventing Overdiagnosis  
187 
 
 
  
Preventing Overdiagnosis  
188 
 
*(RAND=2 – Female, Option 2) 
D8.  And if research shows that watchful waiting is a safe and effective option, how do you think you 
would prefer to manage these abnormal cells? Would you say… 
 
(RESPONSE FRAME) (READ OUT) 
1. Definitely prefer treatment  
2. Probably prefer treatment 
3. (Prefer to do nothing) 
4. Probably prefer watchful waiting (close monitoring by doctors) 
5. Definitely prefer watchful waiting (close monitoring by doctors)  
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
 
 
[PRED9: IF RAND=3, CONTINUE. ELSE GO TO PRED13] 
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*(RAND=3 – Male, Option 3) 
D9. Breast screening (mammograms) detects abnormal changes of the cells in the breast as well 
as finding breast cancers.  In some women these abnormal cells can progress to invasive 
cancer and in others they do not.  It’s estimated that if left untreated about one-third may 
progress to breast cancer over 10 years or more.  That means that for about two-thirds of 
women these abnormal cells may not become cancer. 
 
Imagine your wife, daughter, mother or close female friend had an abnormal breast screen and 
follow-up tests showed that there were abnormal cells found in her breast.  
 
How concerned would you be about her result? Would you say… 
 
[IF NECESSARY: ‘Invasive’ cancer means potentially life threatening.] 
  
(RESPONSE FRAME) (READ OUT) 
1. Extremely concerned 
2. Moderately concerned 
3. (Neither concerned nor unconcerned) 
4. Not really concerned 
5. Not concerned at all 
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
 
*(RAND=3 – Male, Option 3) 
D10.  Abnormal breast cells are usually treated by surgery, radiation or drugs as in the case of breast 
cancer.  Another approach is called watchful waiting, where doctors closely monitor the 
abnormal breast cells with regular mammograms and only treat if cells become more abnormal.   
 
If research shows that watchful waiting is a safe and effective option, how do you think you 
would prefer she manage these abnormal cells? Would you say… 
 
[IF NECESSARY: If people want more information on exactly what watchful waiting would entail 
- say, that’s what research would determine.] 
 
(RESPONSE FRAME) (READ OUT) 
1. Definitely prefer treatment  
2. Probably prefer treatment 
3. (Prefer to do nothing) 
4. Probably prefer watchful waiting (close monitoring by doctors) 
5. Definitely prefer watchful waiting (close monitoring by doctors)  
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
 
*(RAND=3 – Male, Option 3) 
D11.  Thinking again about the previous scenario and the same person, if these abnormal breast 
cells were now called pre-invasive breast cancer cells (rather than abnormal cells), would you 
be more concerned or less concerned about her screening test result? 
 
(RESPONSE FRAME) 
1. More concerned 
2. (No difference) 
3. Less concerned 
4. (Don’t know) 
5. (Refused) 
6. (Respondent does not understand terminology / issues)  (GO TO TS4) 
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*(RAND=3 – Male, Option 3) 
D12.  And if research shows that watchful waiting is a safe and effective option, how do you think you 
would prefer your wife, daughter, mother or close female friend manage these pre-invasive 
breast cancer cells? Would you say… 
 
(RESPONSE FRAME) (READ OUT) 
1. Definitely prefer treatment  
2. Probably prefer treatment 
3. (Prefer to do nothing) 
4. Probably prefer watchful waiting (close monitoring by doctors) 
5. Definitely prefer watchful waiting (close monitoring by doctors)  
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
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[PRED13: IF RAND=4, CONTINUE. ELSE GO TO TS4_SECTION D] 
 
*(RAND=4 – Male, Option 4) 
D13.  Breast screening (mammograms) detects pre-invasive breast cancer cells in the breast as well 
as finding breast cancers.  In some women these pre-invasive breast cancer cells can progress 
to invasive cancer and in others they do not. It’s estimated that if left untreated about one-third 
may progress to breast cancer over 10 years or more.  That means that for about two-thirds of 
women these pre-invasive breast cancer cells may not become cancer  
 
Imagine your wife, daughter, mother or close female friend had a breast screen and follow-up 
tests showed that there were pre-invasive breast cancer cells found in her breast.  
 
How concerned would you be about her result? Would you say… 
 
[IF NECESSARY: ‘Invasive’ cancer means potentially life threatening.] 
  
(RESPONSE FRAME) (READ OUT) 
1. Extremely concerned 
2. Moderately concerned 
3. (Neither concerned nor unconcerned) 
4. Not really concerned 
5. Not concerned at all 
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
 
*(RAND=4 – Male, Option 4) 
D14. Pre-invasive breast cancer cells are usually treated by surgery, radiation or drugs as in the 
case of breast cancer.  Another approach is called watchful waiting, where doctors closely 
monitor the pre-invasive breast cancer cells with regular mammograms and only treat if cells 
become more invasive.   
 
If research shows that watchful waiting is a safe and effective option, how do you think you 
would prefer she manage these pre-invasive breast cancer cells? Would you say… 
 
[IF NECESSARY: If people want more information on exactly what watchful waiting would entail 
- say, that’s what research would determine.] 
 
(RESPONSE FRAME) (READ OUT) 
1. Definitely prefer treatment  
2. Probably prefer treatment 
3. (Prefer to do nothing) 
4. Probably prefer watchful waiting (close monitoring by doctors) 
5. Definitely prefer watchful waiting (close monitoring by doctors)  
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
 
*(RAND=4 – Male, Option 4) 
D15.  Thinking again about the previous question and the same person, if these pre-invasive breast 
cancer cells were now called abnormal cells (rather than pre-invasive cells), would you be more 
concerned or less concerned about her screening test result? 
 
(RESPONSE FRAME) 
1. More concerned 
2. (No difference) 
3. Less concerned 
4. (Don’t know) 
5. (Refused) 
6. (Respondent does not understand terminology / issues)  (GO TO TS4) 
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*(RAND=4 – Male, Option 4) 
D16.  And if research shows that watchful waiting is a safe and effective option, how do you think you 
would prefer your wife, daughter, mother or close female friend manage these abnormal cells? 
Would you say… 
 
(RESPONSE FRAME) (READ OUT) 
1. Definitely prefer treatment  
2. Probably prefer treatment 
3. (Prefer to do nothing) 
4. Probably prefer watchful waiting (close monitoring by doctors) 
5. Definitely prefer watchful waiting (close monitoring by doctors)  
6. (Don’t know) 
7. (Refused) 
8. (Respondent does not understand terminology / issues)  (GO TO TS4) 
 
*(ALL) 
TS4_Section D 
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*SECTION E: DISEASE DEFINITION 
 
*(ALL) 
E0.  Next, I’d like to ask you a couple of questions about the way diseases are defined.  
 
1. Continue 
 
*(ALL) 
E1.  From time to time, doctors who specialise in a particular disease will come together to discuss 
the characteristics of that disease, to decide who should be diagnosed with it and who requires 
treatment for it. These are called panels and currently some doctors on these panels HAVE 
financial ties with pharmaceutical companies who market drugs for that disease and some DO 
NOT. 
 
Is it appropriate or inappropriate for doctors who HAVE financial ties with pharmaceutical 
companies to be members of these panels? 
 
PROBE: IS THAT COMPLETELY, MOSTLY OR SLIGHTLY APPROPRIATE / INAPPROPRIATE? 
 
(IF NECESSARY: Financial ties mean do paid work such as being a speaker or a consultant) 
 
(RESPONSE FRAME) (DO NOT READ OUT) 
1. Completely appropriate 
2. Mostly appropriate  
3. Slightly appropriate 
4. (Neither appropriate nor inappropriate) 
5. Slightly inappropriate 
6. Mostly inappropriate 
7. Completely inappropriate 
8. (Don’t know) 
9. (Refused)   
 
*(ALL) 
E2.  Sometimes, these panels decide to change the definition of a disease in a way that means 
larger or smaller numbers of people may be treated for it. A recent study found on average, 
roughly three-quarters of doctors on these panels had financial ties with the pharmaceutical 
companies selling medicines for the same diseases.  
 
Based on this knowledge, how appropriate or inappropriate is it for doctors with financial ties to 
pharmaceutical companies who market drugs for that disease to be on these panels? 
 
PROBE: IS THAT COMPLETELY, MOSTLY OR SLIGHTLY APPROPRIATE / INAPPROPRIATE? 
 
(RESPONSE FRAME) 
1. Completely appropriate 
2. Mostly appropriate  
3. Slightly appropriate 
4. (Neither appropriate nor inappropriate) 
5. Slightly inappropriate 
6. Mostly inappropriate 
7. Completely inappropriate 
8. (Don’t know) 
9. (Refused) 
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*(ALL) 
E3.  Ideally, what proportion of the panel should be made up of doctors with financial ties to 
pharmaceutical companies who market drugs for that disease? 
 
(READ OUT) 
1. None (0%) 
2. A minority - less than 50% 
3. A majority - 50% or more 
4. (Don’t care) 
5. (Don’t know) 
6. (Refused)  
 
*(ALL) 
TS5_Section E  
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*SECTION F: EXPERIENCE WITH CANCER 
*(ALL) 
F0.  We’re almost finished. Now I’m going to ask you a few brief questions about your experiences 
with cancer and cancer screening. Sometimes people can find these questions quite personal 
or sensitive. If you prefer not to answer any question, please let me know and I will move on. 
 
1. Continue 
 
[PREF1:  
IF B1a=1 DISPLAY “have had a PSA test to screen for prostate cancer” 
IF B1a=2 DISPLAY “have NOT had a PSA test to screen for prostate cancer” 
IF B1a=3 DISPLAY “didn’t know if you had been screened for prostate cancer” 
IF B1a=4 DISPLAY “would prefer not to say if you had been screened for prostate cancer” 
IF B2a=1 DISPLAY “have had a mammogram to screen for breast cancer” 
IF B2a=2 DISPLAY “have NOT had a mammogram to screen for breast cancer” 
IF B1a=3 DISPLAY “didn’t know if you had been screened for breast cancer” 
IF B1a=4 DISPLAY “would prefer not to say if you had been screened for breast cancer”] 
 
*(ALL) 
F1.  Earlier you mentioned that you < have had a PSA test to screen for prostate cancer / have NOT 
had a PSA test to screen for prostate cancer / didn’t know if you had been screened for 
prostate cancer / would prefer not to say if you had been screened for prostate cancer / have 
had a mammogram to screen for breast cancer / have NOT had a mammogram to screen for 
breast cancer / didn’t know if you had been screened for breast cancer / would prefer not to say 
if you had been screened for breast cancer>.   
 
 Have you been screened for other forms of cancer? 
  
1. Yes 
2. No 
3. (Don’t know) 
4. (Refused) 
 
*(ALL) 
F2a.  Have you ever been diagnosed with cancer?  
 
1. Yes 
2. No (GO TO F3a) 
3. (Don’t know) (GO TO F3a) 
4. (Refused) (GO TO F3a) 
 
*(IF F2a=1 – has been diagnosed with cancer) 
F2b.  What type of cancer? 
 
 (ACCEPT MULTIPLES) (DO NOT READ OUT UNLESS REQUIRED) 
1. Bowel 
2. Breast 
3. Cervical 
4. Lung 
5. Lymphoma 
6. Melanoma 
7. Prostate 
8. Response Given (Specify) *(PROGRAMMER NOTE: Set up as full verbatim)  
9. (Don’t know) 
10. (Refused) 
 
*(ALL) 
F3a. Have any of your immediate family, that is your parents, siblings or children, ever been 
diagnosed with cancer?  
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1. Yes 
2. No (GO TO TS6_Section F) 
3. (Don’t know) (GO TO TS6_Section F) 
4. (Refused) (GO TO TS6_Section F) 
 
*(IF F3a=1 – has a family history of cancer) 
F3b.  What’s their relationship to you?  
 
 (SELECT MULTIPLE) 
1. Mother 
2. Father 
3. Sister 
4. Brother 
5. Daughter 
6. Son 
7. (Don’t know / can’t say)  
8. (Refused)  
 
*(IF F3a=1 – has a family history of cancer) 
F3c.  What type or types of cancer were they diagnosed with?  
 
 (ACCEPT MULTIPLES) (DO NOT READ OUT UNLESS REQUIRED) 
1. Bowel 
2. Breast 
3. Cervical 
4. Lung 
5. Lymphoma 
6. Melanoma 
7. Prostate 
8. Response Given (Specify) *(PROGRAMMER NOTE: Set up as full verbatim)  
9. (Don’t know) 
10. (Refused) 
 
*(ALL) 
TS6_Section F 
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*SECTION G: DEMOGRAPHICS 
 
*(ALL) 
G0.  Now I would like to ask you a few demographic questions to make sure we speak with a good 
cross-section of the community. Again, I’d like to assure you that everything you tell me today is 
anonymous. 
 
*(ALL) 
G1.  Are you of Aboriginal and/or Torres Strait Islander origin? 
 
1. Yes 
2. No 
 
*(ALL) 
G2.  What is the main language you speak at home?  
 
1. English 
2. Other (specify________) 
 
*(ALL) 
G5. What is your employment status? 
  
1. Permanent or on-going 
2. Casual/temporary (with no paid sick or annual leave)  
3. Fixed-term contract   
4. Self-employed 
5. (On paid leave: e.g. maternity leave)  
6. Unemployed (e.g. looking or not looking for work)  
7. Not working / not in the labour force (e.g. student, home duties, retired)  
 
*(ALL) 
G6.  Are you now or have you ever worked as a health professional? This includes Doctors, 
Specialists, Nurses or Pharmacists. 
1. Yes 
2. No 
 
*(ALL) 
G7. What is the highest level of education that you have completed? 
(INTERVIEWER NOTE: Prompt if year 12 or below: Have you completed TAFE, trade or 
apprenticeship qualifications?) 
 
(RESPONSE FRAME]) 
 
1. Postgraduate Degree 
2. Graduate Diploma/Graduate Certificate 
3. Bachelor Degree 
4. Advanced Diploma/Diploma 
5. Certificate III/IV 
6. Certificate I/II 
7. Certificate not further defined 
8. Year 12 
9. Year 11 
10. Year 10 or below 
11. Level not determined 
98. (Don’t know) 
99. (Refused) 
 
*(ALL) 
TS7_Section G  
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*SECTION H: DUAL FRAME WEIGHTING 
 
[PRESMP1 IF SAMPLE=LANDLINE CONTINUE, ELSE GO TO PRESMP3] 
 
*(LANDLINE SAMPLE) 
SMP1. How many residential phone numbers do you have in your household, not including lines 
dedicated to faxes, modems or business phone numbers?  Do not include mobile phones.  
 
(IF NECESSARY: How many individual LANDLINE numbers are there at your house that you 
can use to make and receive telephone calls?) 
 
1. Number of lines given (Specify________) RECORD WHOLE NUMBER  (ALLOWABLE RANGE 1 TO 
99) *(DISPLAY “UNLIKELY RESPONSE” IF = >3) 
2. Don’t know/ Not stated (PROGRAMMER NOTE: RECORD IN DATA AS 999) 
3. Refused  (PROGRAMMER NOTE: RECORD IN DATA AS 888) 
 
*(LANDLINE SAMPLE) 
SMP2 Do you also have a working mobile phone? 
 
1. Yes  (GO TO SMP5) 
2. No  (GO TO SMP5) 
3. (Don’t know)  (GO TO SMP5) 
4. (Refused)  (GO TO SMP5) 
 
[PRESMP3 IF SAMPLE=MOBILE CONTINUE, ELSE GO TO SMP5] 
 
*(MOBILE SAMPLE) 
SMP3  Is there at least one working fixed line telephone inside your home that is used for making and 
receiving calls? 
 
1. Yes 
2. No (GO TO SMP5) 
3. (Don’t know) (GO TO SMP5) 
4. (Refused) (GO TO SMP5) 
 
*(SMP3=1 - MOBILE SAMPLE, HAS AT LEAST ONE WORKING FIXED LINE IN HOUSEHOLD) 
SMP4  How many residential phone numbers do you have in your household, not including lines 
dedicated to faxes, modems or business phone numbers.  Do not include mobile phones.  
 
(IF NECESSARY: How many individual LANDLINE numbers are there at your house that you 
can use to make and receive telephone calls?) 
 
1. Number of lines given (Specify________) RECORD WHOLE NUMBER  (ALLOWABLE 
RANGE 1 TO 99) *(DISPLAY “UNLIKELY RESPONSE” IF = >3) 
2. Don’t know/ Not stated (PROGRAMMER NOTE: RECORD IN DATA AS 999) 
3. Refused  (PROGRAMMER NOTE: RECORD IN DATA AS 888) 
 
*(ALL) 
SMP5 And how many people in your household are aged 18 years or over? 
 
1. One 
2. Two or more (Specify) [ALLOWABLE RANGE 2-6] 
3. (Don’t know) 
4. (Refused) 
 
*(ALL) 
TELDUM (COMPUTE TELEPHONE STATUS) 
1. Mobile only (SMP3=2,3,4) 
2. Landline only (SMP2=2,3,4) 
3. Dual user (SMP2=1 or SMP3=1) 
Preventing Overdiagnosis  
199 
 
*CLOSE & RECONTACT 
 
*(ALL) 
CLOSE0: This brings us to the end of the survey questions. Just before we finish...  
 
1. Continue 
 
*(ALL) 
REC1. The University of Sydney are planning to conduct another telephone survey, with similar 
questions to the ones you answered today, within the next 12 months. Would you be interested 
in being a potential participant in this future study?  
 
(IF NECESSARY: Saying “yes” at this stage means you may be invited, but you will not be obliged 
to participate) 
 
1. Yes (GO TO REC2) 
2. No (GO TO END1a) 
 
*(REC1=1 – agrees to recontact) 
REC2.  And can I confirm that you consent to the Social Research Centre passing your contact 
details (name and telephone phone number) and survey responses to Sydney University so 
that they will be able to contact you for the future study? 
 
(IF NECESSARY: All of your information will be sent securely to the University of Sydney 
researchers and used for research purposes only. Survey responses would need to be passed 
on to the University of Sydney to enable re-contact based on views and experiences)  
 
1. Yes (GO TO REC3name) 
2. No (GO TO END1a) 
 
*(REC2=1 – Agrees to recontact & to passing of details and responses) 
REC3name Can you please tell me your name? 
 
1. (Specify_______) 
 
REC3telnum. Is this the phone number you’d like the researchers to contact you on? (If no: can you 
please tell me a preferred phone number?)  
 
1. Yes 
2. No – ENTER NEW TELNUM (INCLUDE AREA CODE) 
 
RECaltnum As this survey will be conducted sometime over the next 12 months, do you have an 
alternative number you could give us (such as a mobile phone), just in case we can’t reach you 
on this phone number? 
 
1. Yes – ENTER ALTERNATE NUM (INCLUDE AREA CODE) 
2. No  
 
*(ALL) 
END1a.  And finally, is overdiagnosis something you would like to know more about? 
1. Yes (GO TO END1B) 
2. No (GO TO END2) 
3. (Don’t know) (GO TO END2) 
4. (Refused) (GO TO END2) 
  
*(IF End1a=1 – Yes would like to know more) 
END1b. You can find more information on the not-for-profit website ‘Preventing Overdiagnosis’, at 
www.preventingoverdiagnosis.net)  
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1. Continue 
 
*(ALL) 
END2. Thank you for your involvement in this survey. All of the information you provided today will be 
kept secure and only used for research purposes. 
 
Just in case you missed it my name is (…) and this survey was conducted on behalf of Bond 
and Sydney Universities. If you have any questions there is a phone number I can give you if 
you like….. 
 
1. Wants contact details (GO TO END3) 
2. Does not want contact details (GO TO CLOSE1) 
 
*(END2=1 - WANTS CONTACT DETAILS) 
END3.  
 
Questions about who is conducting the survey and how your telephone number was obtained: 
The Social Research Centre, Phone: 1800 023 040 
 
Questions concerning the manner in which this research is being conducted -  Bond University 
Human Research Ethics Committee, c/o Bond University Office of Research Services. Bond 
University, Gold Coast, 4229 Phone: +61 7 5595 4194 Fax: +61 7 5595 1120 Email: 
buhrec@bond.edu.au  
 
If you have any queries or would like to be informed about the summary of research findings, 
please contact: Jenny Doust (Principal Investigator) Centre for Research in Evidence-Based 
Practice, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, 
Australia, 4229, Phone: 07 5595 5518; Email: jdoust@bond.edu.au 
 
Cancer Council National Helpline:131120 
 
*(ALL) 
CLOSE1. Thank you very much for your time.   
 
*(ALL) 
TS8_CLOSE  
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*TERMINATION SCRIPTS 
 
TERM1. Thank you anyway but we need to speak with people who are aged 18 years and over.  
 
TERM2. Thank you for your time. 
 
ALLTERM 
Code Definition Description SUR category 
1  Completed interview Interview 
2 INTRO2a=3 Household refusal  Refusal 
3 INTRO2a=4 Language other than English Screen out 
4 INTRO2a=6 No one aged 18+ in household Screen out 
5 INTRO2b=3 Mobile answerer refusal Refusal 
6 INTRO2b=4 Language other than English Screen out 
7 INTRO2b=6 Under 18 years Screen out 
8 MOB2=3 Respondent refusal Refusal 
9 MOB_APPT=3 Respondent refusal Refusal 
10 INTRO3a=3 Respondent refusal Refusal 
11 INTRO3a=4 Language other than English Screen out 
12 INTRO3b=3 Respondent refusal Refusal 
13 All other Midway termination Refusals 
 
 
 
